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The Acute Respiratory Distress Syndrome (ARDS) is a devastating clinical disorder 
characterised by excessive inflammation in the alveolar compartment resulting in 
oedema of the airspaces due to loss of integrity in the alveolar epithelial-endothelial 
barrier. ARDS is associated with high mortality rates and there are currently no 
effective pharmacological therapies available. Human Mesenchymal Stromal Cells 
(hMSCs) are a promising candidate therapy which are currently being investigated in 
clinical trials for ARDS. However their mechanisms of effects in lung injury are not 
fully elucidated. A fuller understanding of these mechanisms may highlight novel 
therapeutic targets, identify potency assays to inform hMSC donor selection or 
biomarkers to assess their efficacy in clinical samples. The alveolar macrophage (AM) 
is key to orchestrating the inflammatory response in lung injury highlighting the AM 
as an ideal therapeutic target. hMSCs are known for their immunomodulatory capacity 
and so it was hypothesised that hMSCs could modulate human macrophage function 
to adopt a more anti-inflammatory phenotype. The aims of this project were to 
investigate the effect of hMSCs on human macrophage phenotype and function and to 
determine the mechanisms of these effects. hMSCs were able to promote an anti-
inflammatory (M2-like) macrophage phenotype in lipopolysaccharide or ARDS 
patient bronchoalveolar lavage fluid-treated human macrophages. This phenotype was 
characterised by a dampened inflammatory cytokine secretory profile, increased 
expression of the classical M2 macrophage marker CD206 and enhanced phagocytic 
capacity. Blocking hMSC-derived extracellular vesicle (EV) uptake by human 
macrophages using anti-CD44 antibody reversed these effects. Moreover, the adoptive 
transfer of murine AMs which had been pre-treated with hMSC-derived EVs was 
protective in endotoxin-induced lung injury in vivo highlighting the AM as a key 
cellular mediator of hMSC beneficial effects. A proportion of hMSC-EVs were found 
to contain mitochondria which were transferred to human macrophages in vitro 
facilitating hMSCs modulatory effects through the enhancement of macrophage 
mitochondrial oxidative phosphorylation. These data report a novel mechanism by 




Presentations and publications 
Original article publications                                                                                                
Megan Jackson, Thomas Morrison, Declan Doherty, Daniel McAuley, Michael 
Matthay, Adrien Kissenpfennig, Cecilia O’Kane and Anna Krasnodembskaya. 
Mitochondrial Transfer via Tunneling Nanotubes (TNT) is an Important Mechanism 
by which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the in vitro 
and in vivo Models of ARDS. Stem Cells, 29 April 2016, 34 (8): 2210-2223.  
 
Review publications 
Thomas Morrison, Daniel McAuley, Anna Krasnodembskaya. Mesenchymal Stromal 
Cells for Treatment of the Acute Respiratory Distress Syndrome: The Beginning of 




Thomas Morrison, Megan Jackson, Adrien Kissenpfennig, Cecilia O’Kane, Daniel 
McAuley and Anna Krasnodembskaya. S63 - Human Mesenchymal Stromal Cell 
regulation of human macrophages in in vitro models of the Acute Respiratory Distress 
Syndrome. Thorax, 2015, 70: Suppl 3 A38. 
 
 
Publications in preparation 
Thomas Morrison, Megan Jackson, Daniel McAuley, Michael Matthay, Adrien 
Kissenpfennig, Cecilia O’Kane and Anna Krasnodembskaya. Mitochondrial Transfer 
through Mesenchymal Stromal Cell-derived Microvesicles Modulates Macrophage 
Polarisation and Function by Promoting Oxidative Phosphorylation in in vitro and in 
vivo models of ARDS. In preparation for submission to the American Journal of 







Oral/Poster presentations at national/international conferences 
Title: Human Mesenchymal Stromal Cell Regulation of Macrophage Populations in 
in vitro Models of the Acute Respiratory Distress Syndrome.  
 
 Oral presentation, British Thoracic Society, London UK, December 2015. 
 Poster presentation, 3rd International ARDS Conference, Belfast UK, August 
2015. 
 Poster presentation, Stem Cells, Cell Therapies and Bioengineering in Lung 
Biology and Lung Disease Conference, Vermont USA, July 2015. 
 Poster presentation, 3rd Annual REMERGE Symposium, Belfast UK, June 2015. 
 Poster presentation, 2nd Annual REMERGE symposium, Belfast UK, July 2014. 
 Poster presentation, Irish Society for Immunology, Dublin Ireland, September 
2014. 



















ADP   Adenosine diphosphate      
AFC   Alveolar fluid clearance      
AM   Alveolar macrophage       
Ang-1   Angiopoietin-1      
AP-1   Activator protein-1       
ARDS   Acute respiratory distress syndrome       
ATG5   Autophagy-related gene 5 
ATP   Adenosine triphosphate      
BAL   Bronchoalveolar lavage 
BALF   Bronchoalveolar lavage fluid      
BCA   Bicinchoninic acid assay      
BMDMC  Bone marrow-derived mononuclear cell 
cAMP   Cyclic adenosine monophosphate     
CD40, 80 etc.  Cluster of differentiation      
cIAP   Cellular inhibitor of apoptosis 
CM   Culture medium       
COPD   Chronic obstructive pulmonary disease 
COX1,2  Cyclooxygenase-1, 2       
CREB   cAMP response element-binding protein    
DAMP   Danger-associated molecular patterns 
DGCR8  DiGeorge critical region 8      
ECM   Extracellular matrix       
E. coli   Escherichia coli       
ELISA   Enzyme-linked immunosorbent assay    
ECSIT Evolutionarily conserved signalling intermediate in Toll 
pathways 
ENaC   Epithelial sodium channel      
ESC   Embryonic stem cells       
 XIII 
 
EtBr   Ethidium bromide 
EVs   Extracellular vesicles       
FCCP   Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone  
FGF   Fibroblast growth factor 
FOXO3  Forkhead box O3  
G-CSF   Granulocyte colony-stimulating factor    
GM-CSF  Granulocyte macrophage colony-stimulating factor   
GVHD   Graft versus host disease      
HA   Hyaluronic acid       
HIF   Hypoxia-inducible factor      
HIV   Human immunodeficiency virus     
HLA   Human leukocyte antigen      
HSCT   Haematopoietic stem cell transplant     
ICAM-1  Intercellular adhesion molecule-1 
ICU   Intensive care unit       
IDO   Indoleamine 2,3-dioxygenase 
IL-6, 8, 10 etc. Interleukin        
IL-1ra   IL-1 receptor antagonist     
IFNγ   Interferon gamma       
IM   Interstitial macrophages      
IN   Intranasal/intranasally 
iNOS   Inducible nitric oxide synthase     
IP   Intraperitoneal/intraperitoneally 
IPF   Idiopathic pulmonary fibrosis 
IRAK   Interleukin-1 receptor-associated kinase 1 
IRF   Interferon regulatory factor      
Jmjd3   Jumonji domain containing-3     
KGF   Keratinocyte growth factor      
KLF4   Krüppel-like factor 4       
 XIV 
 
K. pneumoniae Klebsiella pneumoniae 
LAMP1   Lysosome-associated membrane protein 1 
LCoR   ligand-dependent nuclear receptor corepressor   
LDH   Lactate dehydrogenase 
LFA-1   Leukocyte function-associated antigen-1    
LIF   Leukaemia inhibitory factor 
LL-37   Human cathelicidin protein      
LPS   Lipopolysaccharide       
MCP   Monocyte chemoattractant protein     
MDA-5  Melanoma differentiation-associated gene 5 
MDM   Monocyte-derived macrophage     
MFI   Median fluorescence intensity     
MHC   Major histocompatibility complex      
MIP   Macrophage inflammatory protein     
MMP   Matrix metalloproteinase 
MSC   Mesenchymal stromal cell      
M. tuberculosis Mycobacterium tuberculosis 
MVs   Microvesicles        
MyD88  Myeloid differentiation factor 88 
NADPH  Nicotinamide adenine dinucleotide phosphate   
NETs   Neutrophil extracellular traps      
NF-κB   Nuclear factor-kappa B          
NIBTS   Northern Ireland Blood Transfusion Service    
NIH   National Institute of Health      
NK cell  Natural killer cell       
N-PCP-III   N-terminal peptide for type III procollagen    
NRF   Nuclear respiratory factors      
OCR   Oxygen consumption rate 
P. aeruginosa  Pseudomonas aeruginosa      
 XV 
 
PAF   Platelet-activating factor 
PAMP   Pathogen-associated molecular pattern 
P. carinii  Pneumocystis carinii       
PEEP   Positive end-expiratory pressure     
PGC-1β  PPARγ-coactivator-1β 
PGE2   Prostaglandin E2       
PI3K   Phosphoinositide-3-kinase 
Poly(I:C)  polyriboinosinic:polyribocytidylic acid    
PPARγ  Peroxisome proliferator-activated receptor-γ    
PS   Penicillin-streptomycin      
Rac1   Ras-related C3 botulinum toxin substrate 1 
RANTES  Regulated on activation, normal T cell expressed and secreted 
RBPJ Recombination signal binding protein for immunoglobulin 
kappa J region 
RIG-1 Retinoic acid-inducible gene-1 
Rip1 Receptor interacting protein 1 
RISC RNA-induced silencing complex     
ROS Reactive oxygen species      
RPMI Roswell Park Memorial Institute     
RT-PCR Real time polymerase chain reaction     
S. aureus Staphylococcus aureus 
SD Standard deviation 
SDF-1   Stromal cell-derived factor-1      
SLE   Systemic lupus erythematosus  
SOCS   Suppressor of cytokine signalling     
Sox9   SRY-related high mobility group-Box gene 9 
S. pneumoniae  Streptococcus pneumoniae      
STAT   Signal transducer and activator of transcription   
sTNFR  Soluble tumour necrosis factor receptor 
 XVI 
 
S. typhimurium Salmonella typhimurium 
TAM   Tumour-associated macrophage 
TFEB   Transcription factor EB 
TGFβ   Transforming growth factor beta     
TLR   Toll-like receptor       
TNFα   Tumour necrosis factor alpha      
TNFAIP3  Tumour necrosis factor alpha-induced protein 3 
TNT   Tunneling nanotubule       
TRAF6  TNF receptor-associated factor 6     
TSG6   TNF stimulated gene protein-6     
V-CAM  Vascular cell adhesion molecule     
VE-cadherin  Vascular endothelial-cadherin     
VEGF   Vascular endothelial growth factor  
Chapter 1  Introduction 
1 
 






















Chapter 1  Introduction 
2 
 
1.1 Acute Respiratory Distress Syndrome (ARDS)  
1.1.1 ARDS definition and epidemiology  
ARDS is a clinical disorder with a range of aetiologies that incites a powerful 
inflammatory response. Extensive damage to the alveolar spaces in the distal lung 
leads to the development of hypoxia and pulmonary oedema(1). Originally described 
by Ashbaugh et al in 1967 as the “acute onset of tachypnoea, hypoxemia, and loss of 
compliance”(2), ARDS has been the subject of extensive research by basic scientists 
and clinicians alike. Currently, diagnosis requires that symptoms develop within seven 
days of the insult, bilateral lung infiltrates must be evident through chest imaging and 
that hydrostatic oedema and cardiac failure are not solely responsible(3). Mortality 
rates vary from 25-40% and are dependent on the severity of the condition(3-6). These 
statistics have improved with time; a reflection on improvements in supportive care 
and particularly the mitigation of ventilator-induced lung injury (VILI) through the 
use of low-volume mechanical ventilation(4, 7, 8). An effective pharmacological 
treatment has not yet been identified(9). Translation of efficacy in preclinical models 
to benefit in patients with ARDS has proven difficult(10-14). Stratified medicine aimed 
at identifying risk factors to inform tailored therapy for certain patient groups is 
developing interest(15). For example, prone positioning in severe ARDS reduced 
mortality at 28 and 90 days(16). Prone positioning also seems to benefit patients with 
severe hypoxemia(17). A heterogeneous patient population and complex 
pathophysiology makes identification of novel therapies for ARDS very difficult. 
There is greater promise in putative therapies which target many elements of ARDS 
pathophysiology. 
 
1.1.2 ARDS pathophysiology 
ARDS affects the bronchoalveolar compartment of the lung. The alveoli themselves 
are made up of epithelial cells and are surrounded by the endothelia of the pulmonary 
microvasculature. The alveolar macrophage (AM) resides in the airspaces and is the 
resident immune cell of the lung. After insult, such as infection or trauma, an 
inflammatory cascade begins with the AM. Nuclear Factor-kappa B (NF-κB), a key 
inflammatory transcription factor, is activated in the AMs of patients with ARDS with 
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subsequent secretion of the pro-inflammatory cytokines interleukin-6 (IL-6) and IL-
8(18, 19). The inflammatory cascade, and in particular IL-8 production, recruits 
neutrophils from the peripheral blood which propagate the inflammation and cause 
further damage. Notably the survival of neutrophils in ARDS patients is prolonged by 
alveolar granulocyte and granulocyte/macrophage colony-stimulating factors (G-CSF 
and GM-CSF) which further facilitates these harmful effects(20). 
 
These events result in the death of alveolar and distal epithelial cells, which is 
mediated by neutrophil-derived soluble Fas ligand(21, 22). Neutrophils also produce 
Neutrophil Extracellular Traps (NETs) which constitutes an important antimicrobial 
function but are also associated with epithelial and endothelial cell cytotoxicity(23). 
Pulmonary microvasculature permeability is strongly associated with the robustness 
of endothelial adherens junctions. A major component of these junctions is Vascular 
Endothelial-cadherin (VE-cadherin) whose phosphorylation dictates the extent of 
permeability and leukocyte extravasation(24). VE-cadherin is destabilised by Tumour 
Necrosis Factor alpha (TNFα), another pro-inflammatory cytokine produced by 
macrophages(25-27). The resultant loss of integrity of the alveolar barrier allows a 
protein-rich exudate from the blood to enter the airspaces thereby hindering gas 
exchange(1). Alveolar Fluid Clearance (AFC), the active process of pumping fluid out 
of the airspaces, is impeded in patients of ARDS(28). The hallmark features of the 
alveolar compartment during ARDS are depicted in Figure 1.1.2. Following lung 
injury, there are two primary outcomes; regeneration or fibrosis. In regeneration, 
remaining type II pneumocytes of the alveolar epithelium proliferate and differentiate 
into type I pneumocytes restoring the epithelial barrier(29). Whilst it is believed that 
these type II cells are primarily responsible for repopulating injured alveolar 
epithelium, there is evidence of progenitor cells found in more proximal regions of the 
lung which could also contribute(30). Should the injury persist and regeneration be 
hindered then fibrosis will occur. Fibrosis involves excessive collagen deposition by 
mesenchymal cells forming fibrous tissue in place of the injured alveolus(31, 32). The 
fibrotic response has been demonstrated in the early stages of ARDS with the detection 
of elevated levels of N-terminal peptide for type III procollagen (N-PCP-III) in patient 
bronchoalveolar lavage fluid (BALF) and serum compared to control patients. This 
study also observes higher N-PCP-III levels in non-survivors compared to survivors 
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of ARDS(33). The mechanisms determining whether or not a patient follows the path 
of regeneration and recovery are not fully understood but there are likely many 
elements involved including risk factors such as age, gender, ethnicity and disease 
severity(34-36). 
Figure 1.1.2: The alveolar compartment in health vs. ARDS 
Ware, L.B. and Matthay, M.A., 2000(1) 
 
1.2 Mesenchymal Stromal Cells (MSCs) 
1.2.1 Introduction 
MSCs are a heterogeneous cell population found in many adult tissues including bone 
marrow, skin, adipose tissue, placenta and skeletal muscle(37-39). MSCs may 
differentiate into a variety of specialised cell phenotypes and have great potential in 
regenerative medicine applications(40-42). Currently MSCs are characterised using the 
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criteria proposed by the International Society for Cellular Therapy in 2006. This 
position statement dictates that MSCs must be plastic adherent, express mesenchymal 
markers including CD73, CD90 and CD105 but not haematopoietic markers such as 
CD14, CD34 and CD45 and finally that they have the capacity to differentiate into 
osteoblasts, chondroblasts and adipocytes in vitro(43). MSCs possess a number of 
qualities which are greatly advantageous for therapeutic application. Donor tissue and 
organ mismatching and subsequent rejection is a major limitation in transplantation 
medicine. Some evidence would suggest that MSCs have limited immunogenicity and 
that allogeneic administration is well tolerated(44, 45).  
 
In homeostasis MSCs lack major histocompatibility complex (MHC) class II 
expression but this is induced by interferon gamma (IFNγ) treatment. MSCs do not 
express cluster of differentiation (CD) 40, 80 or 86, each of which are co-stimulatory 
molecules involved in T cell activation, contributing to recipient tolerance to 
allogeneic donation of MSCs(46). The extent of immunogenicity of MSCs is a topic of 
controversy; there are reports that MSCs elicit immune responses in non-matched 
hosts(47, 48). These inconsistencies could be explained by differences in the source of 
MSCs or the conditions under investigation. It is apparent then that MSCs are not 
tolerated in all cases highlighting the need for more study. An additional concern for 
stem cell therapies is the potential for the development of tumours as has been reported 
with embryonic stem cells(49). MSCs taken from adipose tissue and cultured in vitro 
have been reported to exhibit genetic stability for at least 12 passages with no evidence 
of tumourigenicity when given to immunodeficient mice intravenously (IV)(50, 51). This 
was corroborated by Bernardo et al demonstrating human bone marrow-derived MSCs 
cultured until passage 25 with no change in telomerase activity and subsequently 
telomere length(52). Conversely, another group reported malignant transformation after 
long term culture (up to 105 weeks) of human MSCs (hMSCs)(53). Moreover, MSCs 
were shown to promote metastasis of breast cancer cells(54). The tumorigenic potential 
of MSCs is another area of debate; again this will require more in depth investigation 
and highlights the necessity for long term studies of MSC administration in vivo as 
well as long-term follow up of patients that may receive MSC therapy. 
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MSCs have potent immunomodulatory potential; they may influence T lymphocytes, 
dendritic cells, natural killer (NK) cells and others conferring them with regulatory 
functions in both innate and adaptive immunity(55, 56). MSCs inhibit T cell proliferation 
and induce regulatory phenotypes in T cells through promotion of anti-inflammatory 
macrophages(57, 58). They dampen NK cell responses towards HLA class I-expressing 
cells and inhibit monocyte differentiation into dendritic cells(59, 60). Through these 
actions MSCs may prolong allogeneic graft survival given in different settings(61, 62). 
Cruz et al show that MSCs, monocytes and macrophages dampen 
hyperresponsiveness in Th2/Th17-mediated allergic airway inflammation modelling 
asthma(63). MSCs facilitated this effect through the induction of regulatory T cells and 
hindering Th17 function(64). MSCs have the inhernetn ability to home to sites of injury 
after systemic administration IV. Stromal cell-derived factor-1 (SDF-1) is released by 
injured cells(65, 66). SDF-1 is a ligand for the chemotactic receptor CXCR4 which is 
expressed on a small proportion of MSCs and mediates their homing to these sites(67). 
Furthermore,  SDF-1 binding enhances Akt kinase signalling thereby augmenting 
paracrine factor production highlighting the ability of MSCs to respond to signals in 
their environment(68). Extravasation of MSCs begins with adhesion and rolling along 
blood vessels and is mediated by vascular cell adhesion molecule-1 (VCAM-1) and P-
selectin found on endothelial cells. MSCs will form clusters with neutrophils and 
platelets which effectively slows MSCs down in the bloodstream to assist in adhesion 
and rolling(69, 70). MSCs appear to exit the vasculature by unconventional means. In a 
zebrafish model, Allen et al demonstrate the extravasation of MSCs by a process that 
they termed ‘angiopellosis’ characterised by single MSCs or clusters being enveloped 
by endothelial cell cytoplasmic projections and actively extruded into the peripheral 
tissues. Angiopellosis differs from conventional white blood cell diapedesis because 
the endothelial cells undertake the morphological changes required for the transition 
while the MSC remains relatively unchanged; this is a stark contrast to diapedesis 
where the white blood cell would contort itself allowing it to squeeze through the 
endothelial cell junctions(71). MSCs are relatively large cells and are known to become 
lodged in the pulmonary microvasculature. Gao et al reported MSC sequestration to 
the lungs after intravenous infusion with smaller amounts localising to the spleen and 
liver. Eventually MSCs were cleared from the lung and more were found preferentially 
in the liver(72).  
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1.2.2 MSCs in preclinical models of ARDS 
MSCs are being tested in a number of inflammatory conditions including myocardial 
infarction, acute renal failure and sepsis with evidence of therapeutic efficacy(73-75). 
This is also true of ARDS and lung injury where MSCs are also under thorough 
investigation. Intrapulmonary (IP) treatment of mice with endotoxin-induced lung 
injury using murine MSCs reduced alveolar epithelial barrier permeability and oedema 
improving survival(76). MSCs given intratracheally (IT) four hours after injury, were 
protective in an Escherichia coli (E. coli) pneumonia model of lung injury(77). 
Umbilical cord-derived MSCs given IV 24 hours after injury reduced inflammation 
and fibrosis in a bleomycin-induced lung injury model(78). Both human and rat MSCs 
improve repair of lung tissue after ventilator-induced lung injury(79, 80). In a sheep 
model of ARDS triggered by smoke inhalation and bacterial pneumonia human MSCs 
reduced pulmonary oedema and improved oxygenation(81). Lee et al demonstrate 
hMSCs ability to enhance alveolar fluid clearance in a human ex vivo lung perfusion 
model of endotoxin and bacteria-induced injury. (82, 83). MSCs show promise in sepsis 
models enhancing survival through promotion of bacterial clearance via augmented 
monocyte phagocytosis and induction of IL-10 production by macrophages(73, 84, 85). 
Such studies are of particular importance given that sepsis is a leading cause of ARDS 
with one of the highest mortality rates(86). 
 
1.2.3 MSC mechanisms in lung injury  
One of the biggest advantages of cellular therapies including MSCs is their ability to 
adapt and respond to cues in their environment. MSCs may exert a therapeutic effect 
targeting many elements of ARDS. MSCs are already known to act through numerous 
mechanisms. Because the alveolar epithelial barrier loses integrity during lung injury 
it was proposed that MSCs, having extensive differentiation potential could engraft 
into the alveolar epithelium. Such engraftment into the lung epithelium does occur, 
although it is an uncommon event with reports of less than 5% engraftment and so it 
is unlikely that this contributes significantly to their effects in these preclinical 
models(76, 87-91). Most evidence points towards the importance of paracrine factor 
secretion in exerting these effects (which forms the rationale for investigating 
paracrine mechanisms in this study). In a number of reports MSC secretion of 
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keratinocyte growth factor (KGF) mediated the restoration of alveolar fluid clearance 
through the rescue of epithelial sodium channel (ENaC) activity(82, 92, 93). 
Angiopoietin-1 (Ang-1), also produced by MSCs, is also known to play a role in 
reducing alveolar epithelial permeability(94). 
  
Researchers had concerns that the anti-inflammatory effects of MSCs could cause 
complications in treatment of ARDS patients by hindering the host’s ability to fight 
infection in sepsis or pneumonia-induced ARDS. Importantly, models of sepsis and 
bacterial pneumonia consistently report reduced inflammation and bacterial loads in 
MSC-treated animals. MSC immunomodulation also affords innate immune cells with 
improved antimicrobial capacity. Two different septic models show that MSCs 
increase the phagocytic capacity of blood monocytes and CD11b positive cells(73, 84). 
MSC enhancement of phagocytosis also extends to neutrophils; Hall et al report 
increased neutrophil activity in a cecal ligation and puncture model. In this study, 
depletion of neutrophils prevented MSC beneficial effects(95). In ex vivo-perfused 
human lungs injured with E. coli, KGF production by MSCs enhanced AM 
phagocytosis, reducing bacterial load which was associated with higher granulocyte-
macrophage colony stimulating factor (GM-CSF) levels in the BALF(83). MSCs 
produce antimicrobial proteins such as the human cathelicidin, LL-37 and lipocalin-2 
which blocks iron uptake by bacteria(77, 96). TNF stimulated gene protein-6 (TSG6) is 
contributes to immunomodulation by MSCs which is implicated in their therapeutic 
effects in myocardial infarction and wound healing(97, 98). In endotoxin-induced lung 
injury MSCs amplify TSG6 production which was necessary for their anti-
inflammatory effects(99). MSCs which are cultured on non-adherent surfaces form 
spheroid aggregates initiating caspase-dependent IL-1 signalling which augments their 
TSG6 production as well as other anti-inflammatory mediators(100). The formation of 
such clusters may explain the tendency for MSCs to become trapped in the pulmonary 
microvasculature. MSCs produce a number of anti-inflammatory cytokines; a subset 
of MSCs produce IL-1 receptor antagonist (IL-1ra) which blocked pro-inflammatory 
TNFα and IL-1α activity in bleomycin-induced lung injury(101). Prostaglandin E2 
(PGE2) is another mediator of MSC regulatory functions that encourages 
macrophages to produce anti-inflammatory IL-10 in sepsis modelled by cecal ligation 
and puncture(85).  Interestingly MSCs may also produce pro-inflammatory mediators 
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after certain environmental cues. MSCs can secrete both IL-6 and IL-8, which are 
associated with poor prognosis in ARDS(102, 103). IL-6 is a promiscuous cytokine with 
pro-inflammatory and anti-inflammatory functions(104-106). IL-6 contributes to the 
beneficial effects of MSCs in endotoxin-induced lung injury(107). The role of MSC-
derived IL-8 in lung injury is unknown, although IL-8 was shown to upregulate 
vascular endothelial growth factor (VEGF) production by MSCs proposing a potential 
pro-angiogenic element to the MSC effect(108). VEGF is well known for its pro-
survival effects on vascular endothelial cells(109, 110). Interestingly, TSG6 may bind IL-
8 preventing it’s activity(111). TSG6 may play a role in hindering neutrophil recruitment 
in this manner.  
 
MSCs also produce EVs, membrane-bound compartments which contain biologically 
active molecules(112, 113). These EVs are responsible for many of the modulatory effects 
of MSCs and will be discussed in detail in Section 1.5.3. A number of groups have 
reported mitochondrial transfer from MSCs to other cell types using tunnelling 
nanotubules (TNTs). One group was able to observe mitochondrial intercellular 
trafficking from MSCs to epithelial cells with the use of TNTs which was regulated 
by the Rho-GTPase Miro1. Importantly, the overexpression of Miro1 resulted in 
enhanced mitochondrial transfer and was associated with enhanced therapeutic effect 
of MSCs in allergen-induced asthma models(114).  Liu et al then demonstrated the 
formation of TNTs between MSCs and endothelial cells; the TNTs also facilitated 
mitochondrial transfer which enhanced survival of the endothelial cells in an 
ischaemia-reperfusion injury model in vitro(115). Our group has recently published a 
paper which demonstrated the ability of MSCs to transfer their mitochondria to human 
macrophages via these TNTs. We demonstrated that the transfer of mitochondria was 
responsible for their enhancement of phagocytosis and clearance of bacteria in human 
macrophages in vitro and reduced bacterial counts in the lung in an in vivo E. coli-
induced lung injury model(116). Studying the bioenergetics of human macrophages in 
MSC co-culture showed that MSCs were able to increase mitochondrial basal 
respiration and ATP turnover in these macrophages, which may offer an explanation 
for their increased phagocytic capacity. When TNT formation is prevented using 
cytochalasin B the improvement in bacterial clearance in vivo is lost, but interestingly 
CFU counts in lung homogenate are not only reversed but actually exceed the CFUs 
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of mice not receiving any MSCs. This suggests that MSCs without the ability to 
transfer mitochondria, and so not enhancing phagocytosis, actually worsen the host’s 
ability to combat infection. This is likely a result of blocking the antimicrobial 
functions of MSCs without affecting their immunoregulatory properties, resulting in 
a more hospitable environment for bacteria. The benefits of TNT formation extends 
beyond E. coli-induced pneumonia models of lung injury. MSCs were shown to 
generate TNTs allowing transfer of mitochondria to bronchial epithelial cells in 
cigarette smoke-induced lung injury, modelling chronic obstructive pulmonary 
disease (COPD)(117).  Interestingly, MSCs are not always the mitochondrial donors but 
may be the recipients; co-culture of MSCs with vascular smooth muscle cells resulted 
in enhanced proliferation of MSCs and was also facilitated by TNT-mediated 
mitochondrial transfer(118). Although the mechanisms of effect of MSCs in the context 
of lung injury continue to be defined, it is already apparent that their actions are 
multifaceted, impacting on the numerous components of the pathophysiology of 
ARDS.  
 
1.2.4 MSCs for the treatment of ARDS 
MSCs are being investigated in clinical trials for a number of conditions including 
ARDS(119-128). Simonson et al treated two patients with severe refractory ARDS with 
2x106 cells/kg of MSCs on a compassionate use basis. They performed a thorough 
analysis of the efficacy of these MSCs and performed in vitro functional assays to 
determine associations between their in vitro and in vivo performances. Both patients 
showed improvement measured by pulmonary and systemic inflammatory markers, 
epithelial apoptosis and pulmonary oedema. The same MSCs performed well in in 
vitro potency assays suppressing T cell activation and promoting regulatory T cells 
and monocytes(129). While these are the results from only two case studies, they do 
provide encouraging evidence of the potential efficacy of MSCs in severe ARDS and 
highlight the merit of potency assays in identifying optimal MSC preparations. A 
randomised, placebo controlled pilot study testing safety and feasibility of allogeneic 
adipose-derived MSCs (1x106 cells/kg of predicted body weight) in ARDS patients 
(PF (PaO2/FiO2) ratio < 200mmHg) reported that MSC treatment did not incite any 
adverse events(130). While this was a small cohort there were no apparent effects on 
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length of hospital stay or the number of ventilator or intensive care unit (ICU)-free 
days. Serum surfactant protein-D (marker for type II pneumocyte injury) levels 
trended downwards but conclusions in efficacy in this study tentative. A multicentre, 
open-label, dose-escalation study also tested safety and feasibility of allogeneic bone-
marrow derived MSCs in moderate-to-severe ARDS (PF ratio < 200mmHg, positive 
end-expiratory pressure (PEEP) > 8cm H2O). Three different doses of MSCs were 
investigated: low (1x106 cells/kg), intermediate (5x106 cells/kg) and high dose 
(10x106 cells/kg). Across all dosing regimens, no association with adverse events were 
reported(131). These studies were performed with very small patient numbers and short-
term follow-up but still support further investigation of MSCs as a treatment of ARDS 
in larger scale phase II trials (clinicaltrials.gov, NCT02097641). Long-term follow-up 
must be carried out to ascertain whether there are any delayed adverse events 
associated with MSC treatment. Naturally, these pilot studies used single dose 
regimens. Other clinical trials have investigated repeated dosing with MSCs 
(including a weekly dose for four weeks for treatment of Crohn’s disease(122) or two 
weekly doses for four weeks in graft versus host disease (GVHD)(127)) where they were 
well tolerated and resulted in improvement of clinical outcomes. Repeated MSC doses 
may be safe and potentially more effective than single doses but further study on safety 
is required before such studies can be approved.  
 
1.2.5 Optimisation of MSC therapeutic effects 
Preclinical research is essential in determining optimal culture conditions to maximise 
the therapeutic effects of MSCs. MSC function is affected by several parameters 
regarding their expansion and administration. The administration route may have 
significant impact on their effects in lung injury models; IP delivery was proven more 
effective than IN during lung injury in the neonate(88). IP injection of MSCs fared 
poorly relative to intratracheal (IT) or IV application in VILI(80). The optimal tissue 
source of MSCs is also under investigation. MSCs may be found in numerous sites 
throughout the body and have distinctive qualities associated with each(132-134) 
Comparison of human adipose, bone marrow and umbilical cord-derived MSCs 
demonstrated that umbilical cord MSCs have are more proliferative and senesce at a 
lower rate (as measured by p53 and p21 levels)(133). Umbilical cord-derived MSCs 
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may then be best suited for regenerative medicine applications. The conditions that 
MSCs encounter during ex vivo expansion and culture influence their function. 
Hypoxic pre-conditioning (mimicking a key element of ARDS), resulted in enhanced 
chemotaxis and viability of MSCs as well as increased production of paracrine 
factors(135). Hypoxia also resulted in better preservation of the stem/progenitor subset 
of MSCs which are believed to be the therapeutically active cells of this heterogeneous 
population(136). Interestingly, culturing MSCs in ARDS patient serum enhanced IL-1ra 
and IL-10 production in endotoxin-induced lung injury mice improving outcomes(137). 
Zheng et al implemented this pre-conditioning method of adipose tissue-derived 
MSCs in their phase I pilot study in ARDS patients(130). 
 
Artificial manipulation of MSC biology may hold the potential to enhance their 
therapeutic efficacy. MSC overexpression of soluble IL-1 receptor-like-1 (a decoy 
receptor for IL-33), enhanced their pro-reparative and anti-inflammatory effects in 
endotoxin-induced lung injury(138). IL-33 is constitutively expressed in endothelial and 
epithelial cells of the lung which is released after injury and triggers inflammation(139, 
140). Increasing Ang-1 production by MSCs using a vector amplifies their anti-
inflammatory functions and rescues alveolar barrier permeability to a larger degree in 
an LPS lung injury model(141). Even MSC lung engraftment may be augmented by 
inhibiting the Wnt/β-catenin signalling pathway(142). Treatment with TLR ligands can 
influence MSC phenotype. Waterman et al demonstrate that TLR3 ligation induces an 
immunosuppressive MSC phenotype whereas TLR4 ligation promotes pro-
inflammatory functions(143). TLR4 stimulation induced increased IL-6 and IL-8 
production and TLR3 ligation upregulated IL-4 and IL-1ra levels. Conversely, another 
report showed TLR3 stimulation inducing the highest extent of IL-6 and IL-8 
production(144). These contrasting studies tested the effects of TLR ligation on MSCs 
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1.2.6 MSC handling and quality control 
Progression of MSC to the clinic is slowed by incomplete understanding of MSC 
biology, poor characterisation of the MSC population and the inconsistency of their 
therapeutic actions. The European Medicines Agency and British Standards Institution 
both emphasise the requirement for improved characterisation of MSCs, better quality 
isolation and purification and more complete understanding of their mechanisms of 
effect. MSC sourcing and culture conditions heavily influence their 
immunomodulatory capacity; expanding MSCs in the presence of foetal calf serum 
(FCS) or platelet lysate modulates their ability to inhibit T-cell proliferation(145). Other 
factors including the MSC donor’s age and serum or glucose content in the culture 
medium will have profound effects(146-148). There is a significant effort to optimise 
MSC isolation and culture techniques(145, 149-152). Mimicking the extracellular matrix 
(ECM) of the bone marrow from which MSCs may be derived can promote stem cell 
functions and proliferation(153). Carrancio et al reported that supplementing culture 
medium with platelet lysate and exposure to hypoxia resulted increased MSC 
proliferation rates(154). Inconsistency in the efficacy of different MSC preparations has 
highlighted the need for potency assays to allow selection of the best cell product. 
TSG6 production was considered as a potential potency assay. TSG6 levels correlated 
positively with MSC anti-inflammatory effects in a model of chemically-induced 
corneal injury but it negatively correlated with osteogenic differentiation potential(155). 
A number of in vitro assays used in conjunction were predictive of MSC ability to 
enhance wound repair(156). These assays measured cell counts, bromodeoxyuridine 
incorporation and measurement of ATP levels to assess MSC growth and viability. 
MSCs scoring highly in these measurements were more effective in enhancing wound 
repair. Another important question which must be addressed is whether these MSCs 
may be stored for a period of time before administration or if they must be taken 
directly from continuous culture. Understandably, there is the concern that freezing 
and then thawing a preparation of MSCs may affect their efficacy. Indeed, there is 
some evidence that cryopreservation of MSCs impairs there immunosuppressive 
properties. Freshly thawed MSCs were shown in vitro to be less responsive to IFNγ, 
regarding upregulation of immunoregulatory indoleamine-2,3-dioxygenase, and less 
potent in their suppression of T cell proliferation(157). Conversely, Cruz et al showed 
in vivo that both thawed and unthawed MSCs were able to mitigate Aspergillus hyphal 
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extract-induced allergic airway inflammation to a similar degree(158). It is clear then 
that further investigation into the effect of cryopreservation on MSC function is 
required to determine whether or not it is a viable option for the treatment of different 
conditions. In summation it is critical that the protocols for selection, isolation, 
purification and expansion of MSCs be optimised for the condition under 
investigation. 
 
1.2.7 Future directions in MSC research  
As described above, there are a number of practical hurdles which must be overcome 
before MSCs may be effectively applied in a clinical setting. Apart from these issues, 
our understanding of MSC biology is still incomplete. A perspective article produced 
by Bianco et al addresses these ambiguities regarding the origin, identity and functions 
of MSCs(159). They argue that the widely used criteria to identify MSCs are too vague 
and do not necessarily imply stem cell functionality. The authors suggest that the 
criteria currently used to define MSCs are generally shared by most connective tissue 
cells and that the in vitro differentiation of MSCs under such artificial conditions does 
not demonstrate stem cell status, rather proper in vivo testing is required. Of course 
MSCs have proven successful in preclinical disease models and are being investigated 
widely in the clinic. A search on clinicaltrials.gov for ‘mesenchymal stromal cells’ 
returned 125 results of studies involving MSCs, many of which are actively recruiting 
(as of May 2016). While significant progress has been made, we do not yet fully 
understand the mechanisms of action of MSCs in preclinical models of disease 
including lung injury. It could be argued that MSCs have progressed too rapidly to 
clinical trials; there is always an additional risk associated with testing a new therapy 
in patients which hasn’t yet been fully characterised. Prockop et al remind us of the 
success of haematopoietic stem cell transplants (HSCT) and emphasise the arduous 
and prolonged scientific effort which was required to understand the concept and 
ultimately allow their effective application in the clinic(160). For example, one of the 
important developments in the history of HSCT research was the use of marrow-
ablated mouse models(161). Bone marrow depletion using radiotherapy allowed 
quantification of the contribution of different haematopoietic stem cell populations 
and their longevity in vivo using different marrow preparations as well as identification 
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of cell biomarkers(162). It is studies like these that are lacking in the MSC field; very 
little is known about the kinetics of MSCs in vivo which makes it substantially more 
difficult to establish an optimal delivery strategy. It is clear that there remains a 
significant amount of work that needs to be done to develop a complete understanding 
of MSC function in vivo. Whilst early stage clinical trials with MSCs have yielded 
some promising results in other conditions, there is still no evidence of efficacy of 
MSCs in patients of ARDS. This will become clearer with larger scale studies but it is 
likely that the current protocol for the isolation, culture and expansion, dosing and 
administration of MSCs is not optimal. Indeed, even after HSCT had become standard 
practice in medicine, its use was still subject to modification and improvement whether 
it was through superior tissue typing techniques or changes in preconditioning 
regimens before transplant(163, 164). Therefore if MSCs do have efficacy in treatment of 
ARDS, further preclinical research will still be essential for the optimisation of their 
application in the clinic. 
 
Mechanistic studies in lung injury will not only expand our knowledge of MSC 
biology but may also allow identification of potency assays or novel therapeutic 
targets. While there is generally consensus on the criteria for defining MSCs (although 
those criteria may be subject to change), effective biomarkers of potency are elusive. 
Osiris Therapeutics Incorporated developed Prochymal®, an industrial scale MSC-
like product for a clinical trial in acute GVHD. For selection of MSC batches in this 
trial they employed soluble TNF receptor-1 quantification and extent of inhibition of 
IL2Rα expression in T lymphocytes as potency readouts(165). In this study the therapy 
did show a high proportion of responders initially but this effect was transient in many 
patients, with recurring flares being reported. This study only included 32 patients, 
meaning that we cannot glean any information about the quality of these potency 
assays. We do however observe that effectiveness in in vitro assays is not necessarily 
predictive of their efficacy in vivo.  With regards to discovery of alternative therapeutic 
strategies, EVs represent a good example of how mechanistic studies can identify 
novel putative therapeutic agents. EVs (to be discussed in detail in Section 1.4) are 
membrane bound compartments produced by cells capable of transporting proteins, 
mRNAs, miRNAs and other soluble factors as well as organelles. Like most cells, 
MSCs produce EVs and they have been shown to recapitulate many of the beneficial 
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effects of the cells themselves(166-171). Researchers are now investigating the prospect 
of using MSC EVs in place of MSCs, with the rationale that this anuclear cell-derived 
product cannot itself form tumours. In addition, there is evidence to suggest that MSC 
EVs may even hinder tumour progression(166, 172, 173). While MSCs are not considered 
to be very immunogenic, EVs do not run as large a risk of eliciting an immune 
response in the host. Cells may also be augmented to alter the contents of their EVs 
which adds significant scope to prospect of their use in therapy(174). Although the 
number of studies are relatively few, a systematic review of the efficacy of MSC EVs 
in various disease models lends support to their investigation in patients. Progression 
towards this end will be accelerated with the contribution of further studies with proper 




The macrophage is a key component of innate immunity and is part of the first line of 
defence against invading microorganisms. Macrophages are tissue-resident cells 
derived from peripheral blood circulating monocytes which themselves originate in 
the bone marrow from myeloid progenitor cells(176). More recent evidence highlights 
the presence of embryonic macrophage precursors in many tissues which are capable 
of self-renewal in the resting state (177, 178). Macrophages are well known for their 
phagocytic functions and generation of pro-inflammatory cytokines which is crucial 
in clearance of pathogens. They also play roles in tissue homeostasis and remodelling, 
antigen presentation and in resolution of the inflammatory response(179-182). Whilst 
canonically associated with cells of the adaptive immune system, it seems that 
macrophages do possess an element of ‘memory’ although it may lack the specificity 
of lymphocyte responses. Lipopolysaccharide (LPS) was shown to phosphorylate the 
stress-response transcription factor ATF7, releasing it from the chromatin thereby 
creating a more accessible chromatin structure. LPS-treated cells exhibited increased 
expression of pro-inflammatory genes and these effects were maintained for three 
weeks. The ‘memory’ induced by the priming of macrophages with LPS three weeks 
earlier was associated with improved resistance to bacterial infection(183). 
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The macrophage population of the lung is comprised primarily of AMs and interstitial 
macrophages (IMs) which reside in the connective tissues encompassing the airways. 
AMs represent approximately 63% of the total pulmonary macrophage population and 
IMs make up the remainder(184). Morphological studies show that the AM is larger 
with a higher nuclear to cytoplasmic ratio compared to IMs which more closely 
resemble blood monocytes, suggesting that the IM represents an intermediate stage for 
the differentiation of monocytes into mature AMs(185, 186). Functionally however, AMs 
had higher phagocytic capacity than IMs and IMs had more pronounced expression of 
MHC class Ia and CD54 both of which are integral to antigen presentation(185). 
Moreover AMs exhibit a more activated phenotype, with increased production of 
TNFα and nitric oxide, increased tumoricidal activity and can more efficiently 
phagocytose opsonised erythrocytes. IMs are more adept in mediating specific 
immune responses, evidenced by higher expression of MHC class II and production 
of IL-1 and IL-6(187, 188). The distinctive functional disparities between the two cell 
types would argue that they are in fact unique and that IMs are not simply 
intermediaries between monocytes and AMs. Further complexity is added by the 
presence of subpopulations of both AMs and IMs. Researchers utilising density 
centrifugation are able to separate AMs into subgroups, and this is also true of IMs. 
These subgroups also display functional differences including chemotactic sensitivity, 
production of PGE2 and phagocytic tendencies(189-191).  
 
AMs exhibit an exceptionally long life-span compared to other types of macrophage. 
In the resting state, it was found that they may last over 8 months with minimal 
replacement by the periphery(192). However, there is accumulating evidence that AM 
progenitor cells inhabit the lung during early development which are derived from 
foetal monocytes, These then differentiate and persist throughout adulthood and 
gradually replenish the AM population(177, 193). During Streptococcus pneumoniae (S. 
pneumoniae) infection, cell death is accelerated dramatically, with 60% of AMs being 
replaced in just 24 hours(194). While some of these AMs are replaced by infiltrating 
monocytes, the AM-progenitor pool contributes substantially to this repopulation. 
This would suggest that peripheral monocyte replenishment of macrophages is more 
of a transient phenomenon during inflammation. AMs are the immune sentinels of the 
distal lung and reside in the airspaces where they perform crucial functions in 
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homeostasis and defence. GM-CSF mediates AM differentiation and promotes 
adhesion, phagocytosis and surfactant catabolism by these cells(195). The AM is 
presented with a difficult task; it must be able to mount immune responses to infectious 
agents whilst minimising collateral damage to the delicate alveolar compartment. At 
the same time it should avoid overt reactions to harmless particulate matter or antigens 
which they are exposed to continuously. By nature, the AM is inhibitory and this 
suppressive state is mediated by epithelial cell expression of αvβ6 integrin allowing 
activation of latent transforming growth factor beta (TGFβ) which may then promote 
quiescent AMs(196). Indeed, AMs are known to commonly reside at the alveolar septal 
junctions in close proximity to interstitial dendritic cells so that they may inhibit their 
maturation and antigen presentation capacity(197). The depletion of AMs by 
clodronate-containing liposomes resulted in an enhanced response to antigen delivered 
intratracheally(198).  
 
When a genuine need arises AMs will respond by initiating the inflammatory cascade. 
Inhaled microbes will bind TLRs on the AM cell surface resulting in their 
activation(199). They will subsequently produce inflammatory cytokines and mediate 
resistance to viral and bacterial infection. This includes production of TNFα, IL-8, IL-
6 and IL-1α, which orchestrates the recruitment of neutrophils and monocytes to assist 
in clearance of pulmonary pathogens such as Pneumocystis carinii (P. carinii) and 
Pseudomonas aeruginosa (P. aeruginosa) (200-204). The AM chemokine profile is also 
comprised of monocyte chemoattractant protein-1 (MCP-1), macrophage 
inflammatory protein-1α (MIP-1α) and MIP-1β. Their release was shown to be elicited 
by the interaction of the hyaluronic acid (HA) receptor CD44 on AMs with low 
molecular weight fragments of HA, which are produced at sites of inflammation(205). 
The AM itself also encounters chemotactic signals in the form of regulated on 
activation, normal T cell expressed and secreted (RANTES) and GM-CSF from 
alveolar epithelial cells, the strength of which is amplified when the epithelial cells are 
exposed to IL-1α(206). It is well established that there is extensive communication 
between these two cell types in an inflammatory setting. AM derived-TNFα was able 
to augment the production of pro-inflammatory mediators by epithelial cells including 
MCP-1 and IL-6(207, 208). Some of these cell interactions are contact dependent. A 
seminal article in the field was produced by Westphalen et al (Nature Medicine, 2013) 
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where they demonstrate that many AMs are in fact immobile and remain affixed to the 
alveolar epithelium. This subset of cells form connexin-43-dependent gap junctions 
with epithelial cells allowing calcium flow between cells. This interplay and calcium 
signalling activated the Akt pathway and had an immunosuppressive effect evidenced 
by the enhanced neutrophil recruitment with an AM-specific connexin-43 
knockout(209). It is clear that cellular communication and co-ordination of responses in 
the lung are imperative for the effective clearance of pathogens and maintenance of 
homeostasis for respiratory function. 
 
1.3.2 Macrophage polarisation 
Environmental cues and diversity 
The many functions of macrophages are facilitated by the existence of a plethora of 
different phenotypes. The induction of a given macrophage phenotype is referred to 
as polarisation. Put simply, macrophages may be driven towards an M1 pro-
inflammatory phenotype or an M2 anti-inflammatory phenotype. The M1 class is 
induced by TLR ligands such as LPS or Th1 cell-derived IFNγ and is chiefly 
associated with propagation of inflammation and the killing of pathogens. One type of 
M2 class can be triggered by Th2 cell-derived IL-4 and 13 and is involved in resolution 
of inflammation(210, 211).  In reality, M1 and M2 macrophages represent the extremes 
in a broad spectrum of phenotypes, highlighted in Figure 1.3.2. These phenotypes are 
defined by the expression of surface markers, cytokine and chemokine profiles, their 
phagocytic capacity as well as other functions. The pro-inflammatory M1 macrophage 
produces cytokines and chemokines including TNFα, IL-12, IL-23, CCL3 and CCL4 
and express markers like inducible nitric oxide synthase (iNOS) and CD40(212, 213). 
Their pro-inflammatory properties enable them to inhibit tumour cell growth and 
promote anti-tumour Th1 lymphocyte responses(214). The M1 macrophage is adept at 
killing pathogens due to the production of anti-microbial factors and a highly 
phagocytic phenotype. These macrophages produce reactive nitrogen intermediates 
and reactive oxygen species through iNOS and nicotinamide adenine dinucleotide 
phosphate (NADPH) phagocyte oxidase respectively which are crucial to the killing 
of bacteria and limiting their replication(215-218).  
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Fig 1.3.2: The complexity of macrophage polarisation 
Rőszer, T., 2015(219) 
 
Many more subtypes of the alternatively activated M2 macrophage phenotype have 
been described, each induced by different ligands and demonstrating a unique set of 
functions. Some of the earlier described M2 macrophage subsets were labelled M2a, 
induced by IL-4 and IL-13, M2b, triggered by co-stimulation with TLR ligands and 
immune complexes and M2c, generated by IL-10 and glucocorticoids(220). M2 
macrophages are associated with wound healing, tissue remodelling and resolution of 
inflammation(221-224). The possible overlap of M1 and M2 macrophage properties is 
evidenced in the ‘regulatory’ M2b phenotype of macrophage that is induced by 
ligation of Fcγ after initial LPS stimulation, which produces less pro-inflammatory IL-
12, more anti-inflammatory IL-10 and yet maintains TNFα secretion(225, 226).  
 
 




The cell signalling pathways and transcriptional regulation involved in regulating 
macrophage polarisation is complex. Interferon regulatory factor 5 (IRF5) is induced 
in macrophages by LPS stimulation, and particularly so in those differentiated using 
GM-CSF. IRF5 induced expression of IL-12p40 and suppressed IL-10, and these M1 
macrophages were capable of potentiating Th1 and Th17 responses(227). Specific 
depletion of suppressor of cytokine signalling 3 (SOCS3) in the myeloid lineage of 
mice to induce a strong M1 macrophage bias was associated with an enhanced 
phagocytic capacity(228). Notch receptor signalling through recombination signal 
binding protein for immunoglobulin kappa J region (RBPJ) modulates production of 
IRF8 which then elicits expression of M1 macrophage genes including IL-12 and 
NOS2 (inducible nitric oxide synthase)(229). Peroxisome proliferator-activated 
receptor-γ (PPARγ) is a nuclear receptor commonly known for its expression in 
adipose tissue and its roles in the regulation of adipocyte differentiation and glucose 
homeostasis(230, 231). PPARγ is also upregulated in activated macrophages where it 
inhibits the signalling of the transcription factors activator protein (AP-1), signal 
transducer and activator of transcription 1 (STAT1) and NF-κB(232). It is through such 
functions that PPARγ is able to regulate inflammatory responses. This transcription 
factor was shown to induce M2 differentiation in primary human monocytes which 
was associated with enhanced anti-inflammatory activity(233). NF-κB is of course 
involved in M1 polarisation, but p50, a subunit of the NF-κB complex, is inhibitory to 
NF-κB function and is thereby involved in M2-type responses(234). Krüppel-like factor 
4 (KLF4) is strongly expressed in M2 macrophages and interacts with STAT6 to 
initiate a M2 genetic program. Accordingly, KLF-4 deficient macrophages showed 
enhanced M1 function through amplified pro-inflammatory and anti-bacterial 
activity(235). Many other factors have been associated with M2 polarisation including 
cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), 
Jumonji domain containing-3 (Jmjd3) and cMyc(236-238). The abundance of factors 
regulating macrophage polarisation is unsurprising given the vast number of inciting 
stimuli that can influence macrophage phenotype and function and consequently the 
multitude of activation states that macrophages can occupy. 
 




Another element which differs between macrophage phenotypes is their metabolic 
tendencies. One such differentiation can be observed in the glucose metabolism of 
these subsets. Macrophages polarised to IFNγ or TLR ligands advocate anaerobic 
respiration through the glycolytic pathway with the aim of facilitating bactericidal 
activity in hypoxic environments whereas alternatively activated macrophages showed 
no substantial shift in glycolytic processing(239). Rather the M2 macrophage employs 
the use of fatty acid oxidation and oxidative glucose metabolism which is sustained 
for longer time periods and this is essential for their functions in tissue remodelling 
and repair which are lengthy and highly energy-dependent processes(240). Lipid 
metabolism is another distinguishing factor in macrophage polarisation, unsurprising 
considering the prominent role of PPARγ in both regulating macrophage phenotype 
and in lipid metabolism(241). Martinez et al performed transcriptome analysis of human 
MDMs (hMDMs) and highlighted the increased expression of cyclooxygenase-2 
(COX-2) along with downregulation of COX-1 and arachidonate 5-lipoxygenase in 
M1 macrophages. M2 cells had increased expression of COX-1 and the M2 marker 
15-lipoxygenase(242). The COX enzymes are responsible for production of 
prostaglandin synthesis, an important anti-inflammatory mediator(243). This study also 
showed the differential regulation of sphingolipid mediators including sphingosine 1-
phosphate and ceramide 1-phosphate. There is evidence suggesting an anti-
inflammatory role for sphingosine 1-phosphate in murine macrophages where the lipid 
mediator was able to reduce TNFα production and increase arginase-1 activity(244). 
Ceramide 1-phosphate has been shown to promote survival and the proliferation of 
macrophages(245, 246). As mentioned earlier M2 macrophages utilise fatty acid 
oxidation for respiration and the energy produced is important for their function. It has 
also been observed that saturated and unsaturated fatty acids will differentially affect 
macrophage phagocytosis, with polyunsaturated fatty acid supplemented 
macrophages capable of more phagocytosis(247). The amino acid L-arginine is handled 
by iNOS in M1 macrophages to produce nitric oxide, which is an important 
antimicrobial effector(248, 249). Nitric oxide also has a broad impact on immune 
responses of other cells, targeting T cells and NK cells for example(250, 251). Moreover, 
mice deficient in iNOS presented aberrant immune responses characterised by an 
amplified Th1 response, susceptibility to parasitic infection and resistance to LPS-
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induced mortality(252). M2 mouse macrophages however utilise arginase-1, which is 
regulated by STAT6, to convert L-arginine to L-ornithine(253). L-ornithine represents 
a precursor for L-proline which modulates collagen production, an important element 
of tissue remodelling(254). One of the homeostatic functions of macrophages involves 
modulating the availability of iron. Human macrophages stimulated with LPS and 
IFNγ suppression in ferroportin (an iron exporter) expression and amplified H ferritin 
(an iron storage protein) expression leading to iron sequestration. Conversely, 
differentiation in M2-promoting IL-4 resulted in the opposite effect and increased 
extracellular iron levels(255). The aim in M1 macrophage iron retention is to deplete 
the environment of this micronutrient which is essential for bacterial growth. The M2 
macrophages efflux of iron can result in enhanced cell proliferation and collagen 
synthesis thereby facilitating tissue remodelling(256, 257). 
 
Murine vs. human macrophages 
A majority of work in the field of macrophage polarisation was produced by 
investigating murine macrophages. It is increasingly apparent however that there are 
significant differences in human and murine macrophages with regards to 
characterisation of the various phenotypes. For example, mouse M1 macrophages are 
known to express NOS, however this is not true of human M1 macrophages(258). 
Mouse M2 macrophages are often identified using Arginase-1 and Ym1 markers, 
however these are not expressed on human alternatively activated macrophages(259). 
One of the few markers which are consistent between the two species is 
transglutaminase-2, expressed by both human and mouse M2 macrophages(260). A 
number of groups have focused their attentions on characterising human macrophages 
under the influence of different polarising stimuli. Tarique et al found that hMDMs 
exposed to M1 stimuli LPS and IFNγ consistently expressed CD64 and CD80, 
whereas IL-4/IL-13 treated M2 MDMs were identified by CD11b and CD209(261). The 
markers CD163 and CD206 are considered robust markers for the identification of 
human M2 macrophages and have been used in a number of studies(233, 262-265). With 
the ever expanding diversity of macrophage populations, there is a growing need to 
create a standardised nomenclature and definition process. Secondly, the methods 
employed by different groups in the culture methods for macrophages can have 
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profound effects on macrophage phenotype and function making comparisons 
difficult. A collaborative work in 2014 addressed this issue and proposed a set of 
guidelines for the field encouraging transparent and detailed publication of culture 
techniques and the labelling of macrophage phenotypes with the inciting stimuli e.g. 
M(IL-10)(266). This will hopefully facilitate consensus in an area of macrophage 
biology which is currently lacking in it.  
 
1.3.3 The alveolar macrophage (AM) in lung injury 
The importance of macrophage polarisation and function in disease is becoming 
increasingly apparent. Whilst macrophages are essential for many normal 
physiological functions and homeostasis, in aberrant conditions they contribute to 
disease pathophysiology (Fig 1.3.3). The classically activated macrophage is essential 
for the clearance of pathogens but there is often extensive collateral damage to the 
surrounding tissue as a result of reactive oxygen and nitrogen species production(267, 
268). If the pro-inflammatory state of these macrophages is not tightly regulated this 
can lead to a number of chronic inflammatory disorders such as atherosclerosis, 
multiple sclerosis and chronic venous leg ulcers(269-271). Conversely, a type of 
alternatively activated macrophage described as tumour associated macrophages have 
been shown to enhance tumour growth and metastasis, through mechanisms such as 
angiogenesis(272).  
 
Macrophage polarisation also plays a role in lung injury. Compared with other groups, 
AMs from patients of ARDS have been shown to have increased expression of 27E10, 
a marker associated with acute phase monocytes and macrophages, along with 
decreased RM3/1 which is linked to dampening inflammation. This suggests a skew 
towards a more pro-inflammatory M1 phenotype(273). In the same study by Rosseau et 
al., it was observed that continued expression of M1 markers as well as increased 
levels of MCP-1, a key pro-inflammatory cytokine produced by these macrophages, 
was linked to a poorer prognosis. Furthermore, production of M1 cytokines IL-1, IL-
1β and IL-8 by AMs of patients of ARDS was higher than that of healthy controls and 
the higher IL-8 levels were linked to increased mortality of these patients(274, 275). In 
humans, study of the potential role of AMs in the resolution phase of ARDS is limited. 
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It has been observed that in septic patients of ARDS a continuing increase in 
neutrophil numbers accompanied by a decrease in AMs in the BALF of these patients 
at days 7 and 14 portended a poorer outcome(276). It could be speculated that AMs 
enhance resolution through mechanisms such as efferocytosis of apoptotic neutrophils 
leading to the production of anti-inflammatory TGFβ and lipoxins(277-279).  
Fig 1.3.3: Macrophages in development, homeostasis and disease. 
Wynn T. et al, 2013(280)  
While human data are limited, there is an abundance of evidence defining the AM as 
a key player in the pathophysiology of ARDS from injury to resolution. In an 
ischaemia-reperfusion model of lung injury, depletion of AMs using clodronate-
containing liposomes resulted in decreased pulmonary vascular leakage, TNFα, MCP-
1 and MIP-2(281). Depletion of AMs in a model of ventilator-induced lung injury 
reduced development of pulmonary oedema(282). These studies outline the heavy 
involvement of AMs in the initiation of lung injury. Another study demonstrates 
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however that the removal of AMs triggers an over three-fold increase in neutrophilia 
after endotoxin-induced lung injury. This suppressive effect on recruitment appeared 
to result from AM inhibition of alveolar epithelial cell monocyte chemoattractant 
protein-1 production(283). A similar study shows that without AMs, mice succumb to 
Klebsiella pneumoniae (K. pneumoniae) infection with no survival after 3 days. 
Intriguingly, this was associated with much greater neutrophil influx and levels of 
TNFα and macrophage inflammatory protein-2(284). While all of these studies confirm 
that AMs are important in lung injury pathology, the effects of their absence seem to 
vary and suggest both promotion of inflammation but also its regulation. The 
discrepancies here are possibly due to the differences in the models being investigated; 
in non-infectious models, depletion of AMs mitigates injury whereas they are required 
to stifle excessive neutrophil recruitment and promote effective bacterial clearance in 
infectious models of lung injury. As for resolution, a study assessing pulmonary 
macrophage populations in Pseudomonas aeruginosa (P. aeruginosa)-induced lung 
injury demonstrates an association between M1 macrophages in the initial stages of 
injury but increased prevalence of M2 macrophages during the resolution phase(285). 
This would suggest that the M2 macrophage plays a role in the resolution of injury 
and that promotion of an M2 AM profile therapeutically may reduce injury and 
improve outcomes. 
 
1.3.4 Interactions of MSCs with macrophages 
As described earlier, MSCs possess extensive immunomodulatory capacity and 
influence many kinds of immune cell. MSCs and macrophages interact very closely 
and through these interactions MSCs have a strong influence on the inflammatory 
balance in these tissues. Their ability to induce T regulatory cells was shown to be 
partly mediated by the promotion of monocyte derived-M2 type macrophages 
characterised by CD206 and CD163 expression(58). MSCs have been shown to 
modulate macrophages in a cecal ligation and puncture of model of sepsis to increase 
their IL-10 production through PGE2 production. Moreover, the depletion of 
macrophages in this model diminished the beneficial effects of MSCs, suggesting that 
macrophages are cellular mediators of the MSC effect in vivo(85). Maggini et al 
described the ability of murine MSCs to inhibit TNFα and IL-6 while increasing IL-
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10 production by LPS treated peritoneal macrophages(286). Corroborating these 
findings with human cells, Kim and Hematti describe “MSC-educated macrophages” 
which exhibit increased CD206 expression, high IL-10 and IL-6 but low IL-12 and 
TNFα production(287).  
 
Concentrated culture medium from bone marrow MSCs was able to increase 
recruitment of macrophages to wounds in mice and was associated with accelerated 
wound healing(288); wound repair is a function associated with alternatively activated 
macrophages. These findings are further supported with a myocardial infarction model 
where human MSCs were able to reduce total monocyte/macrophage counts whilst 
increasing the proportion of M2 macrophages present. MSC treatment resulted in 
enhanced fractional shortening 2 weeks after myocardial infarction(289). hMSCs which 
had formed spheroid aggregates produced higher levels of PGE2 which resulted in 
more potent induction of an M2-macrophage phenotype defined by increased IL-10 
and IL-1ra secretion and expression of the M2 marker CD206 (mannose receptor)(290). 
The MSC regulatory effect on macrophages is also mediated by microvesicles 
containing miRNAs which are known to suppress TLR signalling and macrophage 
activation. This was necessary for the acceptance of mitochondria from the MSCs and 
subsequent enhancement in bioenergetics of the macrophage(291). MSCs have also 
been shown to modulate AMs; MSCs or their culture medium were able to increase 
arginase activity (M2) and decreased iNOS expression (M1) in AMs of LPS-injured 
mice. MSCs in this model reduced lung injury which was partly mediated by insulin-
like growth factor-1(292). Use of adipose, umbilical cord or bone marrow-derived 
MSCs resulted in increased alveolar macrophage numbers in a mouse model of 
allergic asthma and diminished key features of asthma including hyperresponsiveness 
and eosinophilic infiltration. Artificial removal of the macrophage compartment using 
clodronate-containing lysosomes reversed the beneficial effect of MSCs(293). It is clear 
that MSCs communicate with many cells in their environment, not least the 
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1.4 Extracellular vesicles (EVs) 
1.4.1 Introduction 
Initially cell-cell contact and the release of soluble mediators were thought to be the 
sole means of cellular communication. More recently an additional mode of 
communication has been identified, the transfer of extracellular vesicles. EVs were 
first described by Trams et al in 1981(294). These membrane-bound compartments may 
carry a plethora of different cargos from proteins to different species of RNA(295). 
Secretion of EVs is known to regulate many important biological functions including 
sperm motility, antigen presentation and promoting tumour progression(295-297). EVs 
may be subdivided into two groups based on their size; EVs ranging from 
approximately 40-100nm in diameter are termed exosomes and larger EVs of up to 
1000nm are often called microvesicles (MVs)(298). However the distinction between 
these two classes is often difficult given that size, morphology and protein 
composition often fail to separate them(299).  
 
EV secretion has been reported in virtually all cell types including adipocytes, 
endothelial progenitor cells, macrophages and microglia and is also present in bodily 
fluids such as blood, saliva and cerebrospinal fluid(300-306). EVs are secreted by two 
key pathways (Fig 1.4.1); fusion of multivesicular endosomes with the plasma 
membrane and direct budding from the plasma membrane(307, 308). EVs will target 
neighbouring cells and are received either through fusion of the EV membrane with 
the cell membrane of the target cell or through endocytosis(309, 310). It is apparent that 
transfer of EVs between cells has an element of specificity, for example B lymphocyte 
exosomes solely bind dendritic cells of the lymphoid follicles and EVs from intestinal 
epithelial cells interact more efficiently with dendritic cells than with lymphocytes(311, 
312). Whilst the mechanisms regulating EV-cell interactions are not fully understood, 
a number of conditional and cell-specific elements are emerging. Such evidence is 
provided by the observation that T cells selectively bind MHC class II-containing 
exosomes from dendritic cells produced after interactions between these two cell 
types(313). This recruitment was dependent on induction of an altered state of leukocyte 
function-associated antigen-1 (LFA-1) brought about by T cell activation(314). 
Unsurprisingly, it seems that the EV membrane protein profile modulates cell 
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targeting. Tetraspanins are a family of small transmembrane proteins which form 
intricate and complex interactions with a broad range of integral proteins and the 
expression of certain tetraspanins on the EV surface influences their targeting(315). For 
example, tetraspanin-8-expressing exosomes preferentially bind endothelial and 
pancreatic cells(316).  
Figure 1.4.1: Transfer of EVs 
Raposo G. and Stoorvogel W., 2013(298) 
 
1.4.2 MSC-derived EVs 
As mentioned earlier, MSCs also produce EVs. The role of MSC-derived EVs in their 
therapeutic effects is a relatively recent addition to their paracrine repertoire. Indeed, 
the potential therapeutic effect of MSC-EVs is being investigated in a range of 
preclinical disease models. The systematic review referenced earlier by Akyurekli et 
al focuses on a range of these studies in the context of acute kidney injury, liver injury 
and myocardial infarction amongst others(175). In glycerol-induced acute kidney injury, 
MSC-EVs were found to be therapeutic to a similar extent as the cells themselves with 
reduction in tubular necrosis, lesion size and blood urea nitrogen levels(167). MSC-EVs 
have been shown to inhibit tumour progression in vivo and induce cell death in a 
number of tumour cell lines in vitro(166). MSC-derived exosomes were also capable of 
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reducing infarct size following myocardial ischaemia/reperfusion injury in mice(169). 
Moreover, Cruz et al were able to demonstrate that MSC-EVs mirror the beneficial 
effects of MSCs in their Aspergillus hyphal extract-induced airway inflammation 
model(168). In the context of lung disease, MSC exosomes were found to reduce 
pulmonary hypertension through the suppression of hypoxia-induced STAT3 
expression(170). MSC-derived EVs alone were capable of attenuating E. coli-induced 
lung injury in mice and recapitulating many of the therapeutic effects of the cells 
themselves, including decreases in pulmonary oedema and inflammation. mRNA 
coding KGF contained within these vesicles was partially responsible for this 
phenomenon(317). Recently, Monsel and colleagues demonstrated that MSC-EVs were 
taken up by human alveolar epithelial cells and monocytes, which was dependent on 
the CD44 receptor. Monocytes which had received EVs demonstrated enhanced 
phagocytosis(171). Interestingly, in vivo imaging depicts the formation of connexin-43 
based gap junctions between MSCs and alveolar epithelial cells allowing the transport 
of mitochondria to the epithelia via EVs. The resultant increase in adenosine 
triphosphate (ATP) levels concomitantly resulted in restoration of surfactant secretion 
by type II pneumocytes, reduced alveolar permeability and mortality in a 
lipopolysaccharide (LPS) injury model(318).  
 
Whilst it is well established that many of the benefits of MSC paracrine factors are 
due to EVs, work is ongoing in discerning the exact contents of MSC-EVs and the 
functional aspects of these contents. EVs contain a range of different proteins but there 
has been a particular interest in the extensive microRNA content of MSC-EVs. 
miRNA screening of bone marrow MSC-EVs highlighted a multitude of miRNAs 
which are associated with vital cell processes such as cell survival and differentiation, 
organ development and in immune regulation(319). MSC-derived exosomes were 
capable of transferring miR-133b to neurones and astrocytes and promoting neurite 
outgrowth(320). A recent paper attributes pro-angiogenic properties to adipose-derived 
stem cells; it was observed that treatment of these stem cells with medium used to 
promote endothelial differentiation enhanced their angiogenic effects towards venous 
endothelial cells in vitro and murine aortic rings ex vivo(321). EV-derived miR-31 which 
targets the anti-angiogenic protein, factor-inhibiting hypoxia-inducible factor-1 (HIF-
1), was responsible for these effects. An elegant study by Phinney et al highlights 
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MSC export of depolarised mitochondria via EVs to human macrophages which 
enhances their bioenergetics whilst alleviating oxidative stress from the MSCs. The 
exosome fraction containing miRNAs resulted in the suppression of toll-like receptor 
(TLR) signalling by macrophages which facilitates the uptake of the foreign 
mitochondria(291). In the same study, this group also observed differential miRNA 
profiles in the MSC exosomes and their cells of origin. For example, miR-451a and 
miR-1202 were present at 316 and 45-fold higher levels respectively in exosomes 
compared to MSCs. Conversely, miR-125b levels were 148-fold higher in the cells 
compared to exosomes. This suggests that there are mechanisms in play which actively 
recruit specific miRNAs to exosomes for their export. Accumulating evidence on the 
benefits of MSC-EVs in preclinical models not only sheds light on mechanisms of 
MSC effect but also raises the possibility of the use of isolated EVs in place of the cell 
therapy. This has the potential advantage of reducing the risk of erroneous 
differentiation of engrafted cells or the development of MSC-derived tumours. 
Although this is not to say that EVs have no oncogenic tendencies, and this should 
also be investigated.  A phase I clinical trial in stage III/IV melanoma patients using 
exosomes isolated from dendritic cell cultures showcased the feasibility of large-scale 
production of clinical grade exosomes for administration to patients(322). There are 
currently a number of trials registered investigating the effects of EVs in patients, 
including the role of MSC-EVs in type I diabetes mellitus (registered on 
clinicaltrials.gov, identifier: NCT02138331). 
 
1.5 MicroRNA (miRNA) 
1.5.1 Introduction 
miRNA are a species of RNA which are single-stranded and little over 20 nucleotides 
in length and are essentially regulators of gene expression at the post-transcriptional 
stage(323). The miRNA biogenesis process is outlined in Figure 1.5.1. miRNAs are 
transcribed by RNA polymerase II and III to form the primary miRNA (pri-miRNA) 
transcript, which consists of a hairpin stem attached to two single strands and a 
terminal loop(324). This transcript is processed by the Drosha-DiGeorge critical region 
8 (DGCR8) complex within the nucleus resulting in cleavage of the hairpin stem, 
removing sections of both the 3’ and 5’ strands and producing precursor miRNA (pre-
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miRNA)(325). Pre-miRNA is then transported to the cytoplasm by the Exportin-5/Ran-
GTP complex where the RNase III enzyme Dicer cleaves the terminal loop from the 
pre-miRNA leaving a double-stranded miRNA structure or duplex(326, 327). This duplex 
consists of a guide strand and a passenger strand which are separated by the activity 
of helicases including p68 and RNA helicase A(328, 329). The passenger strand is subject 
to degradation while the functional guide strand may then be incorporated into the 
RNA-induced silencing complex (RISC) which is facilitated by Argonaute2(330). When 
bound to a guide strand, the RISC complex will bind to specific mRNA targets of the 
miRNA based on complementary base pairing. The RISC complex may then inhibit 
translation by degrading the mRNA or preventing translational initiation or 
elongation(331, 332).  
Figure 1.5.1: The miRNA biosynthesis pathway 
Winter J. et al, 2009(324) 
 
Unlike small interfering RNA (siRNA), miRNA does not require absolute 
complementary base pairing with its target mRNA and this helps explain the capacity 
of one miRNA to bind multiple mRNA targets(333). With the diversity of miRNAs and 
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the promiscuity of their function, it is no surprise that they have been implicated in 
cellular processes including differentiation, proliferation and metabolism(334, 335). Then 
of course miRNAs also play roles in disease such as cancer and multiple sclerosis(336, 
337). 
 
1.5.2 miRNAs and macrophages 
Macrophage function and phenotype are heavily influenced by miRNAs. Firstly, the 
maturation of monocytes to macrophages is regulated partially by miR-155, miR-222, 
miR-424 and miR-503. miR-155 promotes cessation of the cell cycle by hindering 
progression of the G2 phase of the cell cycle and miR-222 promotes apoptosis. miR-
424 and miR-503 repress cell cycle regulators Cyclin D1 and Cyclin E1 thereby 
inhibiting the G1 phase. Furthermore, miR-424 and miR-503 both target the transcript 
sequence of miR-9-3 which itself has anti-differentiation properties(338). A plethora of 
miRNAs have emerged which modulate macrophage activation in inflammatory 
responses and other functions. miR-155 is upregulated robustly in macrophages in 
response to IFN-β and the TLR3 ligand polyriboinosinic:polyribocytidylic acid 
(poly(I:C))(339). miR-155 is also induced by LPS and enhances TNFα production while 
miR-125b is concomitantly suppressed. miR-125b binds the 3’ untranslated region of 
TNFα mRNA preventing its translation and so its suppression is an important 
requirement for proper TNFα production in these inflammatory responses(340). A 
homologue of miR-125b, miR-125a-5p, decreases macrophage production of other 
inflammatory cytokines in response to oxidised low density lipoprotein including IL-
6, TNFα and TGFβ(341). The treatment of human mononuclear cells from peripheral 
blood with LPS induces expression of miR-21 through MyD88 and NF-κB. miR-21 is 
a negative regulator of TLR4 signalling and acts through targeting the tumour 
suppressor and pro-inflammatory protein programmed cell death 4 (PDCD4). This 
results in increased IL-10 secretion and lesser activation of NF-κB(342). Inflammatory 
responses from innate immune cells must be tightly regulated to prevent excessive 
collateral tissue damage; whilst some miRNAs are involved in promoting the 
inflammatory responses, others may provide a negative feedback effect. One such 
miRNA is miR-146a, induced by S.pneumoniae in macrophages, which acts to 
suppress interleukin-1 receptor-associated kinase 1 (IRAK1) and TRAF6 of the TLR2 
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pathway and also COX2 and IL-1β, two key inflammatory mediators(343). Phagocytic 
capacity of macrophages may also be affected by miRNAs, as described by Jiang et 
al(344). miR-615-3p in splenic macrophages targets ligand-dependent nuclear receptor 
corepressor (LCoR) and its downregulation allows unmitigated PPARγ expression to 
occur. PPARγ is then responsible for enhancing phagocytic activity. A recent study 
emphasises the importance of miRNA in regulating macrophage autophagy but also 
the ability of pathogens to exploit miRNA function for their own benefit. 
Mycobacterium tuberculosis (M. tuberculosis) is able to survive when internalised by 
macrophages and achieves this through promoting miR-33 expression. This miRNA 
blocks autophagy by targeting mediators like autophagy-related gene 5 (ATG5) and 
lysosome-associated membrane protein (LAMP1) but also inhibiting forkhead box O3 
(FOXO3) and transcription factor EB (TFEB) allows lipid accumulation providing 
nourishment and fuelling M. tuberculosis replication(345). Macrophage polarisation 
results from a substantial shift in the gene expression profile, as does any change in 
cell phenotype.  
 
Macrophage phenotype may also be augmented at the post-transcriptional level by 
miRNAs. Consistent with the enhanced TNFα production with miR-155, this miRNA 
has also been demonstrated to promote polarisation of M2 tumour-associated 
macrophages towards the pro-inflammatory M1 phenotype. Macrophages driven 
towards the M1 phenotype by overexpressing miR-155 exhibited anti-tumour 
properties(346). Conversely, miR-223 is a regulator which induces an alternatively 
activated macrophage phenotype, evidenced by increased expression in IL-1β, IL-6 
and TNFα but reduced PPARγ and Arginase 1 in bone marrow-derived macrophages 
deficient in miR-223(347). LPS stimulation of murine macrophages reduces miR34a 
levels, another negative regulator of TLR signalling which binds Notch1(348). 
Interestingly, while the TNFα suppression function of miR-125b would imply anti-
inflammatory activity, this miRNA has also been shown to amplify and extend NF-κB 
signalling and so promoting pro-inflammatory functions. This is achieved through the 
inhibition of a negative regulator of NF-κB, tumour necrosis factor alpha-induced 
protein 3 (TNFAIP3), and reducing IRF4 expression(349, 350). Macrophages with high 
levels of miR-125b are attributed with exaggerated antigen presentation capacity and 
so more efficiently stimulate T cells. 
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1.5.3 miRNAs and MSCs 
MSC express a multitude of miRNAs and a number of studies have screened MSCs 
and their MVs for their miRNA profiles(291, 319, 351). miRNAs responsible for MV-
mediated MSC beneficial effects in preclinical models were discussed in Section 1.4.2 
and will not be repeated. miRNAs, like in the macrophage, influence MSC function 
and phenotype and also facilitate stem cell activities. miR-145 provides an inhibitory 
signal on chondrogenic differentiation of MSCs by targeting SRY-related high 
mobility group-Box gene 9 (Sox9). Downregulation of miR-145 is necessary for 
efficient differentiation into chondrocytes and this can be accomplished with TGFβ3 
stimulation(352). During osteogenic differentiation of MSCs, miR-20a is increased and 
using mimic miR-20a promoted their differentiation by induction of BMP/Runx2 
signalling(353). This miRNA targets PPARγ, an inhibitor of BMP/Runx2 signalling. 
Proliferation and immunoregulatory capacity of MSCs may be partly diminished by 
increased miR-181a levels, which occurs in severe preeclampsia. miR-181a 
transfected MSCs exhibited increased IL-6 expression with more pronounced 
activation of the p38 and JNK pathways(354). miR-27b targets SDF-1 and inhibits its 
production by mouse MSCs and this was associated with attenuated migration of 
MSCs to burn wounds of the epidermis in mice and subsequently abrogated wound 
repair(355). MSCs have been reported to promote cancer cell invasion and metastasis(54, 
356). The miRNA let-7 is downregulated in MSCs associated with prostate cancer 
which alleviates inhibition of IL-6 expression by these cells. IL-6 production was 
responsible for the pro-tumour effects of these MSCs(357).  
 
1.6 Mitochondria 
Mitochondria are a membranous organelle found ubiquitously in eukaryotic cells and 
are best known for their role in oxidative respiration and as the ‘powerhouse’ of the 
cell(358). In the presence of oxygen, the electron transport chain, situated in the inner 
membrane of mitochondria, facilitates the active pumping of protons into the 
intermembrane space. The resultant proton gradient is utilised by ATP synthase to 
phosphorylate adenosine diphosphate (ADP) to ATP. Apart from respiration, 
mitochondria perform other essential cellular functions. Mitochondria can mediate 
apoptosis via the intrinsic pathway through the release of cytochrome c(359). 
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Cytochrome c contributes to the formation of the apoptosome which activates caspase 
9 and this is turn initiates the death machinery. Mitochondria are an important source 
of reactive oxygen species including superoxide and nitric oxide(360). Reactive oxygen 
species (ROS), produced during respiratory burst in macrophages and neutrophils, are 
known to facilitate bacterial killing(361). Moreover, ROS have been shown to promote 
production of pro-inflammatory cytokines in response to LPS(362). Mitochondrial ROS 
production in macrophages is enhanced when the cells receive signals through TLR1, 
2 and 4. This TLR signalling gathers mitochondria towards phagosomes where the 
TLR signalling molecule TNF receptor-associated factor 6 (TRAF6) interacts with 
evolutionarily conserved signalling intermediate in Toll pathways (ECSIT) and 
augments ROS production(363). Interestingly though, the inhibition of mitochondrial 
function through the use of carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
(FCCP) (uncouples oxidative phosphorylation) or oligomycin (a F0 ATPase inhibitor) 
had no effect on phagocytic capacity in human neutrophils(364). However FCCP was 
able to inhibit chemotaxis and prolonged oligomycin treatment hindered the initiation 
of respiratory burst.  
 
The role of mitochondria in innate immune functions goes beyond ROS generation. 
Mitochondria are integral to TLR-independent responses to viral infection. Viral RNA 
is sensed by cytosolic helicases known as retinoic acid-inducible gene-1 (RIG-1) and 
melanoma differentiation-associated gene 5 (MDA-5)(365, 366). These then activate 
mitochondrial antiviral-signalling protein (MAVS) found on the outer membrane of 
mitochondria which recruits TRAF-3 and TRAF-6 ultimately leading to IRF-3 and 
IRF-7 activation for transcription of type I IFN genes as well as NF-κB for expression 
of yet more pro-inflammatory mediators(367-370). Mitochondrial ROS does not only 
contribute to phagocytic respiratory burst and killing of intracellular microbes but has 
been linked with activation of the NLRP3 inflammasome(371). Given mitochondrial 
remnants from necrotic cells, macrophages would respond with caspase-1 and IL-1β 
production, two key functions of the NLRP3 inflammasome(372). Moreover, when 
autophagy, the process responsible for normal organelle turnover, is inhibited, 
dysfunctional mitochondria will accumulate and produce ROS in abundance. This is 
accompanied with amplified IL-1β and IL-18 responses after LPS and ATP-induced 
inflammasome activation(373). There is a long-standing theory that mitochondrial 
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function is a major contributor to the natural aging process(374). They are major 
producers of free radicals which are believed to inflict oxidative damage to cells 
throughout our lifetime(375, 376). This damage includes DNA strand breakage, the cross-
linking of DNA to protein, as well as protein to protein, and lipid oxidation. 
Mitochondria themselves will become altered with age both morphologically and 
functionally. It has been observed that in aging rat neurones their mitochondria 
develop abnormal filamentous bodies and glycogen deposits altering their inner 
matix(377). Similarly, in aged human skeletal muscle, there are reports of enlarged 
mitochondria which have disorganised and discontinuous cristae(378). The 
mitochondria of aged cells have been shown to exhibit decreased activity in complexes 
I and IV of the electron transport chain whereas complexes II and III are more or less 
consistent with that of younger mitochondria. This is interesting given that 
mitochondrial DNA encodes complexes I and IV and complexes II and III are derived 
from nuclear DNA(379).  
 
Further support is afforded to mitochondrial implication in the aging theory with the 
observation that patients of human immunodeficiency virus (HIV) treated with anti-
retroviral drugs age more prematurely. Payne et al show that patients who had received 
this treatment had increased prevalence of defective cytochrome c oxidase-succinate 
dehydrogenase in skeletal muscle compared to healthy controls or even HIV patients 
not receiving this treatment. They then went on to demonstrate that cells with these 
defects had increased total mitochondrial DNA content compared to normal cells of 
the same tissue sample. This would suggest that this phenomenon is a result of 
increased mitochondrial DNA propagation rather than increased occurrence of 
mutagenesis(380). The premature aging offers an explanation for the high prevalence of 
cardiovascular and neurological complications reported in these patients, unsurprising 
since cardiomyocytes and neurones are examples of post-mitotic cells and so are more 
susceptible to functional decline(381, 382). As mentioned earlier, MSCs are capable of 
mitochondrial transfer through the use of TNTs or microvesicles(116, 117, 291, 318). This 
mitochondrial donation can have profound effects on the recipient cells including the 
enhancement of bioenergetics and phagocytic capacity(116, 291, 318). The enhancement 
in phagocytosis by human macrophages demonstrated by our group through TNT-
mediated mitochondrial transfer could be explained simply by the improved 
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bioenergetic profile. It is feasible that a larger supply of ATP could be utilised by these 
macrophages for phagocytosis which requires extensive cytoskeletal rearrangement 
and is a highly energy-dependent process(383, 384). It is already understood that 
mitochondrial propagation and function are dependent on nuclear gene expression(385). 
In fact, many of the proteins required for the oxidative phosphorylation process are 
encoded in the nuclear DNA. Nuclear respiratory factors (NRF), NRF1 and NRF2 are 
important activators of mitochondrial transcription factor A, a key promotor of 
mitochondrial gene expression, for example(386). But it appears that this interplay is 
bidirectional and that mitochondria may also influence the function and phenotype of 
the cell that it resides in. Indeed, mitochondrial transfer appears to have influence 
beyond metabolic dynamics as evidenced by Acquistapace et al who demonstrated 
that mitochondrial transfer from adipose tissue MSCs to mature cardiomyocytes 
resulted in their dedifferentiation towards a progenitor-like phenotype(387). This effect 
was associated with “partial” fusion of MSCs with the cardiomyocytes and the transfer 
of MSC mitochondria to these myocytes. Another study highlights the importance of 
proper mitochondrial function in the ability of embryonic stem cells (ESCs) to 
differentiate. This was shown when the uncoupling of oxidative phosphorylation in 
mitochondria resulted in diminished differentiation capacity which was associated 
with aberrant Hox gene expression in ESCs(388). Mitochondrial DNA mutations are 
also strongly associated with cancer progression, including prostate cancer. Mutations 
in the cytochrome oxidase subunit 1 gene were found to be prevalent in patients of 
prostate cancer. Moreover, the artificial introduction of this mutant gene into a prostate 
cancer cell line resulted in 7-fold accelerated tumour growth when introduced into 
mice compared to the untreated cancer cells(389). 
 
1.7 Aims of the study 
ARDS is a devastating clinical disorder in ICUs worldwide which currently has no 
effective therapy available. ARDS arises from a multitude of aetiologies and has a 
complex pathophysiology which may explain the difficulty experienced thus far in 
developing an effective intervention. AMs are central to the orchestration of 
inflammatory responses in the lung including that of patients of ARDS(275, 281-283, 285, 
390). A therapy capable of modulating alveolar macrophage function could therefore 
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help to dampen inflammatory responses thereby reducing the extent of lung injury and 
perhaps improving outcomes. MSCs represent a promising candidate cellular therapy 
for patients of ARDS. Supported by an abundance of literature reporting their 
beneficial effects in preclinical models of lung injury, MSCs have progressed to 
clinical trials in these patients. Several of their mechanisms of effect, which appear to 
be paracrine in origin, have been elucidated but their modes of action have not been 
fully investigated yet. It is imperative that any given therapy is thoroughly understood 
for their safe, appropriate and effective application in the clinic. The study of MSCs 
in the context of lung injury to date has heavily favoured the use of mouse models and 
whilst this is crucial for the determination of an effect in vivo, its relevance to human 
patients is limited. Research of hMSCs in physiologically relevant models, using 
human cells and samples of ARDS patients will provide invaluable insight into how 
these cells may behave as a cellular therapy. Moreover, mechanistic studies of these 
interactions may facilitate more effective therapeutic application through the 
development of potency assays and may even identify further therapeutic targets. 
Potency assays are of particular importance in cellular therapy given the heterogeneity 
that exists between donor cells. Reliable readouts which enable selection and then 
propagation of a quality, clinical grade, off-the-shelf cell therapy is a necessity. 
 
Given that MSCs are renowned for their immunomodulatory tendencies, it was 
hypothesised that: 
Human MSCs will promote an anti-inflammatory M2-like phenotype in human MDMs 
through paracrine mechanisms. 
The aims of this project are therefore to: 
 Determine the effect of hMSCs on hMDM function and phenotype 
 Elucidate the mechanisms of these effects. 

















Materials and methods 
 




2.1 Human MSC culture 
2.1.1 Culture of human bone marrow-derived MSCs 
Bone marrow-derived hMSCs were provided by the Texas A&M Health Science 
Center College of Medicine Institute for Regenerative Medicine at Scott & White 
through a grant from NCRR of the National Institute of Health (NIH), Grant # 
P40RR017447. These hMSCs were extensively characterised by the supplier testing 
for plastic adherence, expression of key mesenchymal markers and absence of 
haematopoietic markers, as well as differentiation capacity for a number of 
mesenchymal lineages. These assessments fulfil the criteria put forward by the 
International Society for Cellular Therapy for characterisation and identification of 
MSCs. MSCs were cultured under standard tissue culture conditions; 37ºC, 5% CO2 
and 21% O2. hMSCs were grown in T175 culture flasks using α-Minimal Essential 
Medium (α-MEM) supplemented with 16.5% heat-inactivated foetal bovine serum 
(FBS), 1% L-glutamine and 50μg/mL penicillin-streptomycin (PS) (all from Gibco, 
Thermofisher) and fed every three days. 20mL of media was used to ensure complete 
coverage of the T175 flask. hMSCs were grown to 70% confluence before being 
passaged. hMSCs were lifted from culture by first aspirating the media, washing once 
with deionised PBS (DPBS) and adding trypsin-EDTA (both from Gibco, 
Thermofisher) diluted in DPBS to a concentration of 0.05% for 3-4 minutes at 37ºC 
and 5% CO2. The flasks were then tapped forcefully to encourage detachment. Once 
detached, an equal volume of α-MEM16.5%FBS+PS was added to neutralise the trypsin. 
The cell solution was then centrifuged at 1200rpm for 5 mins and the supernatant 
aspirated. The pellet was resuspended in a volume of media equating to 1mL of α-
MEM16.5%FBS+PS per T175 flask of cells before performing a cell count. 
 
2.1.2 Cell counting  
With the cell solution ready, a cell count was performed using a Neubauer 
haemocytometer. 20μL of cell solution was mixed with 20μL of trypan blue and 20μL 
of this mixture was added to the haemocytometer to determine cell number and 
viability. Excluding trypan blue stained dead cells, cells were counted on the four 
corner grids and an average was taken. Only live cells were taken into account in the 




seeding for experiments. Once counted, MSCs were then sub-cultured for expansion 
across more T175 flasks or prepared at a suitable concentration for experiments 
described later.  
 
2.1.3 Resuscitation, expansion and freezing of hMSCs 
Cryovials containing 1 million MSCs were taken from liquid nitrogen storage and 
quickly thawed at 37ºC in a water bath for 2 minutes. The 1mL cell suspension was 
then added to 10mL of pre-warmed α-MEM16.5%FBS+PS. The cells were centrifuged at 
1200rpm for 5 mins and the supernatant was decanted off, removing the 
dimethylsulfoxide (DMSO) (Sigma Aldrich). The pellet was resuspended in 1mL of 
media before being added to a pre-warmed T175 flask and returned to the incubator. 
If the hMSCs were for expansion, before 24 hours the hMSCs were lifted using trypsin 
as described earlier, counted and seeded across T175 flasks at a cell density of 60 
cells/cm2. Low density seeding helps to maintain the stem/progenitor cell populations 
of the hMSCs, whereas excessive and prolonged confluency will trigger 
differentiation of the hMSCs(391-393). When the cells reached 70% confluence they 
were detached, pooled, counted and diluted in media to a concentration of 2 million 
cells/mL. The cell solution was then diluted 1:1 using freezing medium consisting of 
α-MEM50%FBS+PS and DMSO at a ratio of 9:1, bringing the cell concentration to 1 
million cells/mL. 1mL of the cell solution/freezing solution mixture was then added 
to each cryovial, placed in a freezing container filled with isopropanol and stored 
overnight at -80ºC. The next morning the cryovials are transferred to liquid nitrogen 
for long term storage. 
 
2.2 Human monocyte-derived macrophage culture 
2.2.1 Isolation of human monocytes from buffy coats 
Buffy coats from single donors were obtained from the Northern Ireland Blood 
Transfusion Service (NIBTS); these buffy coats are what remains after blood 
donations are processed to extract the majority of the red cell fraction. Ethical approval 
for the use of these buffy coats was acquired through the Queen’s University Belfast 
Research Ethics Committee (Ref: 14/35 Title: Investigating regulation of 




inflammation and repair in the Acute Respiratory Distress Syndrome using blood cells 
extracted from buffy coat). This leaves a white cell enriched sample, which is depleted 
of platelets and a large proportion of red cells. Took blood from buffy coat 
(approximately 40-65mL) and diluted in HBSS minus Ca2+ and Mg2+ (Gibco, 
Thermofisher) up to a volume of 140mL. Added 15mL of Ficoll Paque Premium (GE 
Healthcare) to a 50mL falcon tube and then slowly layered the blood mixture on top 
at a 45ᵒ angle, being careful not to mix the two layers, to produce four 50mL falcons. 
Centrifuged at 480g for 20 minutes at 20ºC with the brakes off. This separates the 
blood components by density centrifugation and produces a white layer containing 
lymphocytes and monocytes. Used a Pasteur pipette to extract the white cell layer from 
the tubes taking care not to remove red cells. Pooled the cells from each tube into one 
falcon before adding HBSS up to 50mL. Centrifuged at 1200rpm for 5 minutes at 4ᵒC. 
Aspirated the supernatant, taking care not to lose the cell pellet. This is done to remove 
any residual Ficoll that would have been extracted along with the cells. Repeated the 
wash step with HBSS two more times. Resuspended the cell pellet in 20mL of Roswell 
Park Memorial Institute (RPMI) (Gibco, Thermofisher) media supplemented with 1% 
heat-inactivated FBS and 50μg/mL penicillin-streptomycin and prepared an aliquot 
with a 10x dilution of cells in media. Added 20uL of this to a haemocytometer and 
place in the incubator for 5 minutes to allow monocytes to adhere. Performed a cell 
count using a light microscope and haemocytometer, adherent monocytes will appear 
cloudy/translucent. Seeded the monocytes at the desired density in RPMI1%FBS+PS for 
at least 2 hours to allow adherence of the monocytes. All other contaminating cells, 
e.g. erythrocytes and lymphocytes, will not adhere. Monocytes were seeded at 300,000 
per well in 24-well plates and 1,000,000 per well in 6-well plates.  
 
2.2.2 Generation of hMDMs from monocytes 
Aspirated the RPMI1%FBS+PS from the adherent monocytes and washed twice with 
HBSS to remove contaminating cells. Added RPMI10%FBS+PS further supplemented 
with 10ng/mL of GM-CSF (R&D Systems, Biotechne). GM-CSF will differentiate the 
monocytes into macrophages over the 6 to 7-day incubation.  
 
 




2.3 Co-culture experiments 
2.3.1 Non-contact co-culture of human MSCs and human MDMs 
After 6-7 days of differentiation hMDM co-culture with hMSCs could begin. Before 
beginning the experiment, hMDMs were serum starved in unsupplemented RPMI for 
2 hours. MSCs used in experiments were passage 3-5. hMSCs would be suspended in 
culture above the hMDMs using 0.4μm porous hanging cell culture transwell inserts 
(Merck Millipore). These required pre-soaking in media for at least 20 mins prior to 
adding the cells to facilitate cell adherence and to allow co-culture without contact. 
For all co-culture experiments, hMSCs were prepared at a 5:1 ratio of hMDMs to 
hMSCs. In some experiments, normal human lung fibroblasts were used as a cell 
control for the MSCs, to determine whether the effects observed were specific to 
hMSCs. Conditions were prepared in RPMI1%FBS+PS with any additional stimuli at a 
volume of 500μL for 24-well plates and 2mL for 6-well plates.  
 
2.3.2 In vitro stimulation experiments 
To generate an inflammatory environment, E. coli LPS O111:B4 (List Biological 
Laboratories) was added to the hMDMs and hMSCs at a working concentration of 
10ng/mL in RPMI1%FBS+PS. In later experiments, to mimic the microenvironment of 
the alveolar compartment of patients with ARDS, BALF from ARDS patients was 
used for stimulation in place of LPS. These BALF samples were of those taken from 
the HARP study performed by Craig et al and published in 2011, where they 
investigated the use of simvastatin as a treatment for ARDS(394). BALF samples used 
for these stimulation experiments were baseline samples taken prior to any 
intervention. BALF from nine of these patients were pooled to generate a stock and 
the pooled sample was then diluted to 30% in RPMI1%FBS+PS before stimulation. When 
possible healthy volunteer BALF was included to demonstrate whether it is ARDS 
patient BALF or BALF in general that is responsible for the observed effects. Healthy 
volunteer samples were taken from the study published by Shyamsundar et al in 2014 
investigating the effects of KGF in mild, LPS-induced lung injury(395). The healthy 
volunteer BALF samples used for these stimulations were from individuals who had 
received neither LPS nor KGF. In some experiments, as a positive control for M2 




macrophage activation, recombinant human IL-4 and IL-13 (R&D Systems, 
Biotechne) were added to hMDMs at a concentration of 10ng/mL. 
 
2.3.3 Lactate dehydrogenase (LDH) assay  
For pilot ARDS patient BALF stimulation experiments, cytotoxicity assays were 
performed on the hMDMs using the Cytotoxicity Detection Kit (LDH) (Life Sciences, 
Roche). hMDMs were cultured in BALF at concentrations of 100%, 50% and 30% for 
24 hours. After the 24 hours, the supernatants were lifted and cell debris was removed 
by centrifugation at 10,000rpm. 50μL of each sample was added in duplicate to wells 
of a Maxisorp 96-well ELISA plate (Nunc). Assay mixture was prepared by mixing 
250μL of the diaphorase/NAD+ catalyst with 11.25mL of the iodotetrazolium 
chloride/sodium lactate dye solution. 50μL of the assay mixture was added to each 
well on top of the samples and mixed on a shaker for 1 minute. The assay mixture is 
pink and will turn red as the assay develops. The 96-well plate is then incubated at 
room temperature for 30 mins before being read by a spectrophotometer at 490nm. A 
number of controls are included for this assay; a background control is 100μL of the 
assay mixture and is used as a blank which is subtracted from all other values. There 
is an untreated control of hMDMs cultured in RPMI1%FBS+PS alone to determine basal 
LDH release. Then there is the cell death control which consisted of RPMI1%FBS+PS 
with 2% Triton-X detergent (Sigma Aldrich) to induce total cell death. Cell death was 
calculated as a percentage relative to the cell death control.  Absorbance readings of 
the background control were subtracted from all other readings. Then the following 
calculation was used for the test conditions: 
Cytotoxicity (%) = (experimental value/cell death control value) x 100 
 
2.4 Cytokine analysis 
2.4.1 Enzyme-linked Immunosorbent Assay (ELISA)  
Human TNFα, IL-8, KGF, adiponectin, Ang-1, lipocalin-2 and TIMP3 levels in cell 
supernatants were quantified using ELISA duoset kits (R&D Systems, Biotechne). 
Exact working concentrations of the kits constituents may be found in the 




manufacturer’s instructions. Capture antibody for the cytokine of interest was 
prepared in 1xPBS (Gibco, Thermofisher) to the desired concentration and 100μL of 
this solution was added to each well of a Maxisorp 96-well ELISA plate (Nunc). The 
plate was then sealed and incubated overnight at room temperature. The capture 
antibody was aspirated and the wells washed using wash buffer (1xPBS with 0.05% 
Tween-20 (Sigma Aldrich)) three times, blotting against clean paper towels after each 
wash. Care was taken to remove as much liquid as possible after the final wash when 
blotting. Non-specific binding was prevented by blocking the plates with 300μL of 
reagent diluent per well (1xPBS with 1% bovine serum albumin (BSA) (Sigma 
Aldrich)) for at least 1 hour. Again, the plates were washed three times with wash 
buffer and blotted before addition of the cytokine standards and supernatant samples. 
A two-fold dilution series was used to prepare a range of standard concentrations and 
then 100μL of these and the samples were added to each well for a 2 hour incubation. 
The wells were washed three times and 100μL of detection antibody prepared in 
reagent diluent was added for another 2 hour incubation. After another three washes, 
100μL of streptavidin-horse radish peroxidase diluted 1:40 in reagent diluent was 
added to each well, and incubated for 20 mins protected from light. A final three 
washes was performed and 100μL of 3,3’,5,5’-tetramethylbenzidine (TMB) substrate 
solution (Life technologies) was added and incubated for 20 mins, or until the 
standards had suitably developed, protected from light. 50μL of 2M sulphuric acid 
stop solution was added to each well and the plate gently tapped to ensure mixing. The 
ELISA was then immediately analysed using the Versamax spectrophotometer set to 
read at 450nm and 540nm wavelength. A subtraction of the wavelength absorbance 
readings at 540nm was taken from the readings at 450nm for correction. 4-parameter 
standard curves were produced using Softmax Pro v2.6 and concentrations of samples 
were extrapolated. TSG6 ELISA was purchased from Cusabio and was performed 
according to manufacturer’s instructions; this assay followed a very similar protocol. 
 
2.4.2 Bioplex 
The measurement of multiple other cytokines and chemokines was performed using a 
custom Luminex Performance Assay Multiplex kit (R&D Systems, Biotechne). The 
analytes for this assay were the cytokines IL-1β, IL-1ra, IL-10, IL-12, IL-23 and IFNγ 




and the chemokines CCL5, CCL17, CCL18 and CCL22. The assay was performed 
according to manufacturer’s instructions. The kit was used along with a Luminex 
analyser that uses a dual laser flow-based sorting and detection platform. Each 
analyte’s antibody is provided already coated onto coloured microparticles. Standards 
are provided for the analytes and a 3-fold dilution series is used to generate a range. 
50μL of either the standard/microparticle or sample/microparticle mixtures were 
added to the plate provided. The plate was then incubated at room temperature for 3 
hours with gentle agitation on a shaker before washing with 100μL of the wash buffer 
provided with the kit. Wash buffer was then removed with a vacuum manifold 
dispenser which siphons the liquid through filters on the base of the plate. This wash 
step was repeated two more times. 50μL of streptavidin-phycoerythrin was added to 
each well and incubated for 30 mins protected from light on a shaker. Three more 
washes were performed and a fourth wash was allowed to sit for two minutes before 
aspiration. There are lasers present in the apparatus which are specific to each of the 
colour-coded microparticles which should be conjugated to the antibody-analyte 
complexes. Another laser will excite any of the streptavidin-phycoerythrin 
fluorophore which has now bound and is present in levels proportional to the amount 
of analyte in the samples. The plate is then analysed and sample analyte concentrations 
were deduced by plotting the standard concentrations against the median fluorescence 
intensity (MFI) using a five parameter logistic fit. 
 
2.5 Flow cytometry 
2.5.1 Preparation for flow cytometry 
Flow cytometry was used to assess the purity of hMDMs after isolation and 
differentiation, analysis of macrophage surface markers, phagocytosis assays and EV 
characterisation. After the experimental timepoint was reached inserts and 
supernatants were removed from the hMDMs and the cells were washed with PBS. 
1mL of flow buffer (PBS 5%FBS) was added to the cells and they were gently scraped 
from the well plates using a cell scraper. The cell solution was then added to 5mL 
polystyrene flow tubes (Sarstedt, Fisher Scientific) and centrifuged at 350g for 5 mins 
at 4ᵒC to pellet the cells. The tubes were then decanted to remove the flow buffer, 
leaving 200μL in the tube. The cells were resuspended in 0.5mL of flow buffer and 




20μL of human FcR binding inhibitor (eBioscience) was added. The cells were 
incubated on ice for 20 mins to block nonspecific binding. Following this the 
antibodies (see Table 2.5.1.1 and Table 2.5.1.2) would be added at the necessary 
dilution and incubated for 30 mins on ice, protected from light. For each experiment a 
number of controls were included, an unstained control, isotypes for each fluorophore 
in use and single stain controls for each fluorophore. For experimental groups, all 
antibodies of interest were added to each tube. After the antibody incubation, 3mL of 
flow buffer was added to each tube and the cells were centrifuged at the same settings 
as earlier. The supernatant was aspirated and the wash step repeated. After the second 
wash, 200μL was left in each flow tube and the samples were run. Samples were 
processed using the FACSCantoII flow cytometer and FACSDiva software (BD 
Biosciences). Where necessary, compensation between fluorophores was performed 
on the FACSDiva software by using single stain controls. Data was then analysed 
using FlowJo v7 software (Treestar). Assessment of purity of hMDMs demonstrated 
that >95% of cells expressed myeloid specific CD14 and the remaining cells were 
CD3 positive lymphocytes. 
Table 2.5.1.1: Antibodies used for assessing purity of hMDMs 
Cell surface marker Fluorochrome conjugate Manufacturer 
Anti-human CD14 PE-Cyanine7 eBioscience 
Anti-human CD3 FITC eBioscience 
 
Table 2.5.1.1: Antibodies used for macrophage markers 
Cell surface marker Fluorochrome conjugate Manufacturer 
Anti-human CD40 FITC eBioscience 
Anti-human CD54 PE eBioscience 
Anti-human CD163 APC eBioscience 
Anti-human CD206 PE-Cyanine7 eBioscience 
 
2.5.2 Flow cytometric phagocytosis assay 
To determine the phagocytic capacity of hMDMs with or without co-culture of 
hMSCs, fluorescently labelled pHrodo® green E. coli BioParticles® (Thermofisher) 




were used. Briefly, after 24 hours of co-culture, the supernatant is removed and the 
hMDMs are washed twice with PBS. E. coli particles were then suspended in 
RPMI1%FBS+PS with 10μL of stock per 1mL of media (provides particles at a 20:1 ratio 
particles to hMDMs). E. coli bioparticles were then added to hMDMs in a total volume 
of 2mL for 6-well plates. The plates were then centrifuged at 350g for 5 mins at 4ºC 
to ensure contact between the hMDMs and the particles. hMDMs were incubated at 
37ºC and 5%CO2 for 90 minutes, protected from light, to allow phagocytosis to occur. 
A number of wells are not treated with particles and serve as an unstained control. As 
recommended by the manufacturer, a number of wells were treated with the particles 
but incubated on ice as a control. These cells should not be capable of phagocytosis 
and any signals detected in these wells should be subtracted as background. After the 
incubation, the supernatant was aspirated, and the cells were washed twice in PBS. A 
final 1mL of PBS was added to each well and the hMDMs are gently scraped. The cell 
solution was centrifuged at 350g 4ºC for 5 mins and the supernatant aspirated before 
adding 200μL of PBS to the tube for resuspension. The samples were then analysed 
by flow cytometry. 
 
2.6 Paracrine factor studies 
2.6.1 Blockage experiments 
In order to test the importance of lipocalin-2 (LCN2), IL-6, PGE2, lipoxin A4 and 
TGFβ in the hMSC effects, their functions were inhibited within hMSC-CM and added 
to hMDM with LPS. LCN2, IL-6 and TGFβ were neutralised using antibodies 
obtained from R&D systems at the doses recommended by the manufacturer. hMSCs 
were first seeded into 24 well plates at 60,000 cells per well (coinciding with the 
number of cells used in the 1:5 non-contact co-culture experiments with hMDMs) in 
fully supplemented α-MEM. The following day when the hMSCs had adhered, they 
were washed with PBS and the media was replaced with RPMI1%FBS1+1%PS to generate 
culture medium (CM). 24 hours later the CM was taken into eppendorfs and 
centrifuged at 10,000g to remove detached cells and cell debris. The supernatant was 
lifted and then treated with the antibodies which were incubated for 30-60 mins before 
addition to the hMDMs along with LPS.  




PGE2 production was inhibited using ibuprofen (Abcam) which was added to hMDMs 
with LPS with or without hMSC-CM at a concentration of 100μM (recommended by 
manufacturer). Ibuprofen acts to prevent PGE2 production through the inhibition of 
COX2 and COX1 enzymes(396). Lipoxin A4 function was blocked using the selective 
FPRL1 antagonist WRW4 at 10μM (recommended by manufacturer). This was also 
added to hMDMs along with LPS with or without hMSC-CM. Lipoxin A4 has 
previously been attributed to the protective effects of hMSCs in endotoxin-induced 
lung injury(397). Blockage of the lipoxin A4 receptor using WRW4 substantially 
mitigated the protective effects of hMSCs in that model. Ibuprofen and WRW4 
inhibitors were added to the hMDMs without pre-incubation. For all of these blockage 
experiments, the hMDMs were cultured with these conditions for 24 hours before 
lifting the supernatants for cytokine measurement by ELISA. 
 
2.6.2 Lipocalin-2 (LCN2) stimulation of hMDMs 
To further assess the function of LCN2, 500ng/mL of recombinant human LCN2 
(R&D systems) was added to hMDMs along with LPS to assess their inflammatory 
response. This dose of recombinant LCN2 was previously described in a study on 
LCN2 function(398).  
 
2.7 Extracellular vesicle studies 
2.7.1 CD44 blockage experiments 
As previously demonstrated by Monsel et al, CD44 expression on hMSC-EVs was 
important for the uptake of EVs by recipient cells, namely human monocytes and 
alveolar type II epithelial cells(171). To determine if hMSC-EVs were responsible for 
hMSC effects on hMDMs, blockage studies were performed. hMSC-CM was 
generated as described in Section 2.6.1. The CM was treated with an antibody for 
human CD44 (mouse anti-human CD44, BD Biosciences) or isotype control (mouse 
IgG2B, R&D Systems, Biotechne) to a final concentration of 3μg/mL or given no 
antibody. They were incubated for 30mins at 37ᵒC with gentle mixing to allow the 
antibody to bind any EVs present in the CM and then added on to serum starved 
hMDMs with 10ng/mL of LPS as described earlier. Importantly CD44 is also 




expressed on macrophages(205), so in order to control for any effects of this antibody 
on hMDMs directly, additional groups were included where hMDMs were treated with 
the antibodies without hMSC-CM. After 24 hours of stimulation, supernatants were 
extracted for cytokine analysis. 
 
2.7.2 Generation of EV-free FBS 
For EV work, media was prepared with heat-inactivated FBS which was free of all 
contaminating EVs. FBS was taken in 40mL centrifuge tubes (Hitachi) and 
ultracentrifuged at 100,000g using the Himac CP100WX ultracentrifuge (Hitachi) for 
3 hours at 4ᵒC with a P28S rotor (Hitachi). The supernatant was then taken and used 
to supplement either αMEM or RPMI for treating the MSCs. 
 
2.7.3 Isolation of hMSC-EVs 
hMSCs were grown to around 60-70% confluence under standard conditions before 
having their media replaced with 15mL of EV-depleted αMEM16.5%FBS+PS (for 
microvesicle characterisation experiments) or RPMI1%FBS+PS (for addition to MDMs 
after preparation). The hMSCs were incubated for 48 hours at 37ᵒC and 5%CO2 and 
the culture medium was collected. Firstly, the medium was centrifuged at 10,000g at 
4ᵒC for 20 mins to remove cells and cell debris. The supernatant was then 
ultracentrifuged at 100,000g for 2 hours at 4ᵒC and the supernatant was aspirated. The 
pellet of EVs was resuspended in PBS to fill the 40mL tubes before centrifuging again 
at the same settings. This acts as a wash to minimise contamination with protein 
aggregates. The PBS supernatant is then discarded and the EV pellet is finally 
resuspended for downstream processing. 
 
2.7.4 Quantification of hMSC-EVs  
In a pilot experiment, hMSC-EVs were isolated as described above and the 
concentration of RNA and protein was assessed using the Nanodrop 2000 
(ThermoFisher). Briefly, hMSC-EVs were washed and resuspended in 100μL of PBS. 
1μL of this resuspension was added to the Nanodrop 2000. The RNA concentration 




was found to be 0.47ng/μL corresponding to 47ng of RNA from the isolation. The EV 
isolation had a protein concentration of 1470μg/mL corresponding to 147μg of protein 
in the isolation. These values are similar to those reported by Monsel et al when 
assessing RNA and protein content of their hMSC-EV isolations(171). 
 
2.7.5 Characterisation of hMSC-EVs by flow cytometry 
To provide an indication of the size of hMSC-EVs, hMSC-CM was processed by flow 
cytometry with the addition of aldehyde/sulphate latex beads (ThermoFisher) which 
have a diameter of 4μm. The latex beads provide a reference point to compare with 
the EVs in FSC vs SSC plots. hMSCs were grown to confluence and stained with a 
number of different reagents. Stains used for the characterisation of EVs are listed in 
Table 2.6.5.1. hMSCs were treated with human FcR binding inhibitor for 20 minutes 
at 4ºC to prevent non-specific binding. They were stained with CellMask™ Orange 
(cell membrane), propidium iodide (necrosis), Annexin V (apoptosis), anti-human 
CD44 (or isotype control) and MitoTracker® Deep Red FM for 45 minutes at 4 ºC in 
the dark. 
Table 2.7.5.1: Stains used for the characterisation of hMSC-EVs 
Stain Fluorochrome conjugate Manufacturer 
CellMask™ Orange PE ThermoFisher 
Propidium iodide PerCP-Cy5.5 Sigma Aldrich 
Annexin V Pacific Blue Biolegend 
Anti-human CD44 PE-Cy7 eBioscience 
MitoTracker® Deep Red FM APC ThermoFisher 
 
After the incubation, hMSCs were washed three times in PBS and EV-free 
αMEM16.5%FBS+PS was used to prepare CM. After 24 hours, CM was lifted and 
processed immediately by flow cytometry (FACSCantoII flow cytometer and 
FACSDiva software). Unstained hMSC-CM was processed first in order to determine 
the necessary FSC and SSC voltage settings required to detect the EVs. Single stain 
controls were then tested, as well as the isotype for anti-CD44, to set gates for these 
stains and to perform the necessary compensation. The gating strategy was as follows: 




EVs were gated for by FSC vs SSC; cell membrane positive events were selected using 
CellMask™; events which were negative for propidium iodide (necrosis) staining 
were then gated for; Annexin V staining (apoptosis) was excluded. This final gate was 
then used to determine the extent of CD44 expression by EVs and the proportion of 
these EVs which contained mitochondria. To provide some information on the size of 
these EVs, latex beads with a diameter of 4μm were processed by flow cytometry first 
separately and then in combination with hMSC-CM. FSC vs SSC plots of the latex 
beads provided a reference point to compare with the size of the EVs. 
 
2.8 Animal studies 
C57BL/6 male mice (8 to 10 weeks old; Harland Institute, UK) were used. Animals 
were maintained in the Biological Services Unit (BSU) at Queen’s University Belfast. 
Experiments were sanctioned and approved by the UK Home Office and Queen’s 
University Belfast Ethical Review Committee. 
 
2.8.1 Bronchoalveolar lavage (BAL) 
Mice were culled with intraperitoneal (IP) injection of 300μL of xylazine/ketamine 
mixture. The skin of the upper body and neck was cut open and the trachea was 
exposed. The connective tissue surrounding it was cut away and a length of string was 
placed in behind the trachea. A small hole was cut in the anterior wall of the trachea 
and a severed 21 gauge needle was introduced through the opening. The string was 
then tied around the trachea anchoring the needle in place and 1mL of PBS was 
instilled into the lungs. The PBS was flushed in and lifted out 7-10 times to ensure 
thorough sampling of the bronchoalveolar compartment and to isolate as much AMs 
as possible. 
 
2.8.2 Ex vivo culture of mouse AMs 
A 20μL aliquot of the BALF samples were mixed with 20μL of trypan blue and a cell 
count was performed (see Section 2.1.2). Murine AMs were seeded into 6 well plates 
at 3 million per well in the PBS they were extracted in but then spiked with FBS to 




generate PBS1%FBS. The AMs were given 4 hours to adhere before they were gently 
washed with PBS and then treated with hMSC-EVs suspended in RPMI1%FBS or media 
alone. For EV-treated AMs, each well was treated with the EVs generated from 10 
million hMSCs over 48 hours (approximately ?) (for EV isolation, see Section 2.6.3). 
AMs were cultured ex vivo for 48 hours before they were detached using 1mL of 
Accutase® cell detachment reagent (Innovative Cell Technologies) incubated for 5 
mins at 37ºC. Any cells remaining attached were gently dislodged with a cell scraper. 
The cell viability was determined using trypan blue staining and another cell count 
was performed. The cells were then centrifuged at 5000g for 5 mins, the supernatant 
aspirated and the AMs resuspended in PBS such that 35μL of solution contained 
2.5x105 AMs.   
 
2.8.3 LPS model of lung injury 
Mice were first anaesthetised by isoflurane inhalation for 1-2 minutes individually. 
Mice were given 0.8μg of LPS per gram of body weight. LPS was administered 
intranasally (IN) diluted in PBS at a volume of 35μL. Control mice were given PBS 
alone. Mice were observed until they recovered from the isoflurane. 4 hours after the 
LPS instillation, mice were anaesthetised once again using 100μL of 
xylazine/ketamine injected using a 25 gauge needle IP. Mice were then treated with 
either vehicle control (PBS), ex vivo-cultured hMSC-EV-treated AMs or untreated 
AMs (2.5x105 AMs per mouse) IN in a volume of 35μL. Mice were observed until 
recovery and returned to holding. 24 hours after LPS instillation, mice were culled and 
subjected to BAL (Section 2.9.2) to be used for cell counts, protein quantification and 
cytokine analysis. 
 
2.8.4 Total cell counts  
BALF samples were first diluted 2-fold in PBS into fresh eppendorfs, 20μL of this 
was mixed with 20μL of trypan blue and then 10μL of this mixture was added to each 
side of a Countess® cell counting chamber slide (Invitrogen, Thermofisher). Total cell 
counts were carried out using the EVE™ automated cell counter (NanoEnTek, VWR). 




Two counts were taken for each BALF sample and dilutions were accounted for in the 
final cell counts expressed as cells/mL. 
 
2.8.5 Cytospin preparation, imaging and neutrophil counts 
After taking the aliquot for total cell counts, BALF samples were centrifuged at 5000g 
for 5 mins to remove the cells from suspension. Supernatants were lifted and placed 
in a fresh eppendorf then stored at -20ᵒC for future processing. The cell pellet was 
resuspended in 300μL of PBS and centrifuged at 10,000rpm for 5 mins using the 
StatSpin Cytofuge®2 (Beckman Coulter, VWR) onto microscope slides. Slides were 
given 2 hours to dry and then stained using the Speedy Diff kit (Clin-tech). Slides were 
given another hour to dry before imaging using the Leica Epifluorescence DM5500 
microscope at 20x magnification. Enough images were taken of each slide in order to 
count a total of 400 cells. Cells were counted using ImageJ software and the percentage 
of neutrophils was determined. Using this percentage, total neutrophil counts were 
calculated from the total cell counts taken earlier. 
 
2.9 Transfection with anti-miRNA inhibitors 
hMSCs were seeded in 12 well plates at 100,000 cells per well and allowed to adhere 
for 24 hours. The cells were washed with OptiMEM reduced serum media (Invitrogen, 
Thermofisher) and then another 400μL of OptiMEM was added to the cells before 
returning them to the incubator. Prepared a tube containing 89μL of OptiMEM and 
1μL of anti-miR125b inhibitor or negative control inhibitor per well (yielding a 10nM 
solution when given to the cells) (Ambion, Thermofisher), mixed and incubated at 
room temperature for 5 mins. Next prepared a tube with 7μL of OptiMEM and 3μL of 
oligofectamine transfection reagent (Invitrogen, Thermofisher) per reaction, mixed 
and added 10μL of this per reaction to the tubes containing the inhibitors. This final 
mixture was incubated for a further ten minutes before adding 100μL to each well, in 
a drop-wise fashion, to the hMSCs, totalling 500μL per well. The cells were returned 
once again to the incubator for 6 hours, at which point an additional 500μL of 
OptiMEM, this time supplemented with 20% FBS was added to the cells giving a 10% 




FBS solution. The cells were kept in culture for 72 hours to allow efficient 
transfection. 
 
2.10 RNA processing and real-time polymerase chain reaction (RT-
PCR) 
2.10.1 RNA isolation 
hMSCs were seeded at 100,000 cells per well in 12 well plates and processed for 
transfection as described in Section 2.7.1. To show the efficiency of the transfection, 
total RNA was isolated, miRNA was reverse transcribed to cDNA and RT-PCR was 
performed. RNA isolation was carried out using the RNeasy mini kit (Qiagen) as per 
manufacturer’s instructions. After the transfection, hMSCs were washed in PBS and 
then 350μL of RLT lysis buffer supplemented with β-mercaptoethanol (inhibits the 
action of RNase enzymes, 10μL per 1mL of lysis buffer) was added to each well. To 
ensure complete lysis of cells, scraped the base of each well using a fresh cell scraper 
and then collected the lysates in a sterile eppendorf. Samples were homogenised by 
passing the solutions through a 25 gauge microneedle 10 times. Further processing of 
RNA was maintained at 4ᵒC throughout. An equal volume of 70% ethanol was added 
to the lysates and the solutions were mixed before placing in the spin columns and 
centrifuging at full speed for 30 seconds. The flow through was discarded and 700μL 
of RW1 buffer was added. Columns were centrifuged again and the flow through was 
aspirated. Next 500μL of RPE buffer, supplemented with ethanol, was added and again 
centrifuged. This RPE buffer wash was repeated one more time and then the collection 
tube holding the spin column replaced with a fresh one before centrifuging once again. 
This step is used to ensure that all ethanol has been removed from the columns, as 
ethanol interferes with the final RNA elution step. The spin columns are then placed 
in a final collection eppendorf and 30μL of RNase free water is placed in the column. 








2.10.2 Quantification of RNA   
Total RNA purity and concentration was determined using the Nanodrop 2000. The 
software was first initialised and then a baseline blank was established by placing 1μL 
of RNase free water on the platform of the device. After setting a blank, 1μL of the 
RNA samples were then added and analysed. Between sample additions, the platform 
was cleaned using a paper towel soaked with 70% ethanol to prevent any sample 
mixing. Two readings were taken for each sample and an average was calculated. A 
260/280 purity ratio of 1.8 or higher was considered pure enough for downstream 
processing. Before proceeding to reverse transcription, the concentrations of all 
samples were first normalised to the lowest sample concentration of that batch using 
RNase free water. 
 
2.10.3 Reverse transcription of miRNA  
Reverse transcription was carried out using the TaqMan advanced miRNA cDNA 
synthesis kit (Thermofisher) following the manufacturer’s instructions. The first step 
is polyadenylation; 2μL of the RNA sample was mixed with 3μL of a cocktail 
consisting of buffer, ATP and the polyadenylation enzyme. The samples were then 
heated to 37ᵒC for 45 mins and 65ᵒC for 10 mins for the reaction. Next is ligation, 
where a mixture of buffer, ligation adaptor, RNA ligase and polyethylene glycol was 
added to the sample. This reaction was performed at 16ᵒC for 1 hour. Reverse 
transcription was achieved by adding buffer, a mixture of deoxynucleotides, universal 
RT primer and RT enzymes to the samples and heating to 42ᵒC for 15 mins followed 
by 5 mins at 85ᵒC. The last step for this kit was amplification of the newly synthesised 
miRNA cDNA. This step is important for detection of lowly expressed target miRNAs 
by RT-PCR and importantly this step does not discriminate between different miRNAs 
and so amplifies all of them equally preserving their relative expression in the samples. 
A cDNA master mix and primer mix was added to the cDNA and heated to 95ᵒC for 
5 mins to activate the polymerase enzyme. cDNA was denatured at 95ᵒC for 3 seconds 
then annealed and extended at 60ᵒC for 30 seconds (repeated for 14 cycles). 
Amplification was stopped by heating to 99ᵒC for 10 minutes. cDNA was then used 
immediately for RT-PCR or kept for long term storage at -80ᵒC.   
 





RT-PCR was carried out using TaqMan universal PCR master mix (mRNA) or 
universal PCR master mix, no AMPErase UNG (miRNA) along with TaqMan primer 
assay (mRNA) or TaqMan advanced miRNA assay primers (Thermofisher). PCR 
reactions were prepared in a 96 well plate with a total volume of 20μL per reaction: 
Reagent Volume (per reaction) 
Master mix (2X) 10μL 
Primer assay (20X) 1μL 
cDNA diluted in ddH2O 9μL 
 
For every PCR plate prepared, a no template control and a no reverse transcription 
control was included. The no template control contained master mix, the primers of 
interest and only ddH2O. The no reverse transcription control contained master mix, 
primers and an equal amount of RNA which had not been converted to cDNA. Each 
sample was added in duplicate for each assay being run. Once the plate had been 
loaded, the wells were sealed with strip caps, the plate was mixed on a shaker for 30 
seconds and then centrifuged at 1500rpm for 2 mins to collect the solutions to the base 
of each well. The plate was loaded into a Stratagene Mx3005P PCR device (Agilent 
Technologies) and the RT-PCR reaction was setup like so: 
Step number Condition settings Number of cycles 
1 50ᵒC for 2 mins 1 
2 95ᵒC for 10 mins 1 
3 95ᵒC for 15 secs 
60ᵒC for 1 min 
50 
 
2.11 Mitochondrial studies 
2.11.1 Studying mitochondrial transfer 
hMSCs were grown to confluence and pre-stained with MitoTracker® Red for 45 mins 
at 37ºC before being washed three times with PBS. hMDMs were treated with hMSC-
CM (prepared for 24 hours after staining) or cultured with hMSCs on Transwell inserts 




for 24 hours. hMDMs were washed with PBS before being taken up from culture and 
prepared for flow cytometry. hMDMs were assessed for positivity of MitoTracker® 
Red staining, indicative of uptake of hMSC mitochondria. To provide further evidence 
of mitochondrial transfer, fluorescence microscopy was used. hMSCs were once again 
pre-stained with MitoTracker® Red and washed with PBS. CM was prepared from 
pre-stained hMSCs for 24 hours. hMDMs had their nuclei pre-stained with Hoechst 
33342 (Sigma Aldrich) and their mitochondria pre-stained with MitoTracker® Green 
(Thermofisher) for 45 mins at 37ºC. hMDMs were also washed with PBS before 
treating with hMSC-CM and incubating the hMDMs for 24 hours to allow EV uptake. 
hMDMs were washed once more with PBS and treated with fully supplemented 
RPMI. Fluorescence imaging of live hMDMs was performed using the EVOS® FL 
Auto Imaging System (Life technologies) at 20x magnification. 
 
2.11.2 Generating dysfunctional mitochondria 
Loss-of-function experiments were performed to assess the importance of 
mitochondrial transfer from hMSCs in their effects on hMDMs. In order to produce 
dysfunctional mitochondria, hMSCs were treated with rhodamine 6G (Sigma Aldrich) 
at a concentration of 1μg/mL for 48 hours at 37ºC as previously described(399). Because 
mitochondrial respiration would be blocked by this treatment, hMSCs had their media 
supplemented to support glycolysis. Standard α-MEM16.5%FBS+PS was supplemented 
further with uridine to produce a concentration of 50μg/mL and sodium pyruvate to a 
concentration of 2.5mM. After 48 hours, hMSCs were washed three times with PBS 
before generating CM for experiment. To further study the importance of 
mitochondrial respiration in hMDM function, hMDMs were treated with 3μg/mL of 
oligomycin which was prepared in DMSO and added to RPMI1%FBS+PS. DMSO alone 
was used as a vehicle control.  
 
2.11.3 Assessing mitochondrial respiration 
To determine the efficiency of rhodamine 6G as a mitochondrial inhibitor and to assess 
the effect of hMSC-CM on hMDM mitochondrial activity, the Seahorse XF Cell Mito 
Stress Test Kit (Agilent Technologies) was used. hMSCs or hMDMs were seeded into 




XF 96-well tissue culture plates at densities of 10,000 and 30,000 cells per well 
respectively and allowed to adhere overnight. The cells were then treated with the 
various conditions for 24-48 hours depending on the experiment. During this 
incubation a cartridge plate provided with the kit, which contained the probes for 
measuring oxygen consumption, was soaked in XF calibrant solution and left to 
incubate at 37ºC and 0% CO2. Cells were washed twice with XF basal medium which 
had been supplemented with 10mM glucose, 1mM pyruvate and 2mM glutamine. 
180μL of XF basal medium was added to each well and the cells were placed in the 
incubator at 37ºC and 0% CO2 for 1 hour. Meanwhile the oligomycin, carbonyl 
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) and rotenone/antimycin-A 
inhibitors were prepared as per the manufacturer’s instructions. The probe cartridge 
was collected from the incubator and the inhibitors were added to specific ports of 
these cartridges. 20μL of oligomycin was added to port A, 22μL of FCCP was added 
to port B and 25μL of rotenone/antimycin-A was added to port C for each well. These 
inhibitors would be sequentially injected into the cell solution during the Mito Stress 
Test. The loaded cartridge plate was then placed in the XFe96 Extracellular Flux 
Analyser (Agilent Technologies) for calibration. After calibration, the XF 96-well 
tissue culture plate containing the cells was added to the machine and the Mito Stress 
Test was performed. Oxygen consumption rate (OCR) readouts produced by the assay 
were analysed using the Wave software (Version 2.2) (Agilent Technologies). 
 
2.12 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5 software. Experiments for 
each hMDM donor were performed in triplicate; the average of these three technical 
replicates was taken as a single donor replicate. These average values were taken as a 
single data point for each donor and pooled together for statistical analysis. Pooled 
data was presented as the mean with standard deviation. Normality was determined 
using histograms of frequency distribution. For parametric data, Student’s t-test (two 
groups) or one way ANOVA (three or more groups) with post-hoc analysis using 
Bonferroni’s selected comparisons was performed. For non-parametric data, Kruskal-
Wallis with post-hoc analysis using Dunn’s selected comparisons was used. Statistical 
significance was regarded as p<0.05.    
















hMSCs promote an unconventional 
M2-like phenotype in hMDMs in in 

















hMSCs represent a promising candidate as a cell-based therapy for ARDS. Their 
mechanisms of effect in the context of lung injury have been a topic of great interest 
in the past decade. Previously, MSCs have been shown to act through the production 
of numerous paracrine factors including soluble mediators, microvesicles and contact-
dependent mechanisms(94, 101, 116, 137, 171, 317, 318, 397, 400). Whilst the effectors produced 
by MSCs have been well studied, their cellular targets and the precise influence it has 
on them has not been so thoroughly investigated. The AM is the key immune cell of 
the lung and their polarisation has been shown to play an important role in the 
pathophysiology of lung injury with a predominance of the pro-inflammatory M1 
macrophage during the acute or injurious phase and an increased proportion of the M2 
macrophage during resolution(273-275, 285). This would suggest that the AM represents a 
good therapeutic target given that promotion of the M2 anti-inflammatory macrophage 
phenotype may reduce the extent of inflammation and injury in ARDS. When 
characterising macrophage phenotypes, one important element to consider is their 
secretory profile. M1 macrophages will produce pro-inflammatory cytokines and 
chemokines including TNFα, IL-12, CCL5 and CXCL10 whereas M2 macrophages 
will secrete anti-inflammatory factors such as IL-10, CCL17 and CCL22 in order to 
facilitate their divergent functions(212, 213, 220, 266). Variations in cell surface marker 
expression also provide information regarding macrophage phenotype. Examples 
include CD163, which is found in some M2 macrophage phenotypes or CD40 in M1 
macrophages(213, 401).  
 
It is important to appreciate the complexity of macrophage polarisation; macrophages 
are often described as inhabiting a M1 or M2 phenotype but these are extremes and 
represent collective groups containing many unique subtypes of macrophage. It is 
therefore unsurprising that certain macrophage phenotypes may exhibit elements of 
both M1 and M2 classes such as the tumour associated macrophage described by Tsai 
et al in a mouse cancer model. This macrophage had high levels of iNOS and 
Arginase-1 expression, markers typical of M1 and M2 macrophages respectively(402). 
MSCs ability to influence immune cells including macrophages is well established. 
MSCs have been shown to promote a more regulatory M2-like macrophage phenotype 




in models such as asthma and sepsis(287, 403, 404). The effect of MSCs on AMs in the 
context of ARDS has not been so well studied. Another important functional feature 
of macrophages is their phagocytic capacity; macrophage polarisation can 
significantly influence phagocytosis. Macrophage phagocytosis represents an 
important functional aspect of their phenotype and has significant implications in 
ARDS of infectious aetiology. These include sepsis and pneumonia-induced ARDS 
which are the most common and devastating cases(86, 405). The ability of macrophages 
to phagocytose apoptotic neutrophils is diminished by LPS stimulation and this was 
dependent on the resulting TNFα production by the macrophage(406). However LPS-
treated peritoneal macrophages are more efficient in clearance of opsonised 
erythrocytes, suggesting that M1 macrophages excel at the phagocytosis of red blood 
cells(407).  Human MDMs were shown to bind and phagocytose virulent 
Mycobacterium tuberculosis (M.tuberculosis) strains through the use of complement 
receptors and the mannose receptor (CD206)(408). Conversely, a predominant M2 
macrophage phenotype present in chronic rhinosinusitis with nasal polyps was 
associated with poorer clearance of Staphylococcus aureus (S.aureus)(409). It is clear 
then that phagocytosis is influenced by macrophage activation state. Many of the 
earliest studies investigating macrophage polarisation were performed in mice. While 
informative, the relevance to human macrophage biology is limited; certainly both 
innate and adaptive immunity of mice and man differ to some degree(410). There is an 
increasing effort to switch to primary human macrophage studies in vitro(213, 411); even 
in vivo mouse models are being ‘humanised’ in a bid to increase the relevance of our 
research by introducing human cells into mice(412, 413). This is essential in drawing 












3.2 Aims   
The main objective for this chapter was to study the effect of hMSC non-contact co-
culture on hMDM phenotype in in vitro models of ARDS. The inflammatory stimuli 
chosen to simulate those present in ARDS were E. coli LPS and the BALF from 
patients of ARDS. The main objective of this chapter can be divided into three specific 
aims: 
 To investigate the effect of hMSCs on the hMDM cytokine and chemokine 
profile 
 To investigate how hMSCs modulate expression of surface markers associated 
with M1 and M2 macrophage phenotypes 
 To determine the effect of hMSCs on hMDM phagocytosis 
 
3.3 hMSCs reduce TNFα and IL-8 secretion by hMDMs stimulated with LPS 
without cell contact 
hMDMs were stimulated with LPS for 24 hours with or without the co-culture of 
hMSCs or fibroblasts. Fibroblasts were included as a cell control to determine whether 
MSC effects are cell specific. Fibroblasts were chosen as they are also of mesenchymal 
lineage but lack the stem/progenitor population found in MSCs responsible for their 
multipotency. IL-4/13 were included as a positive control for M2 macrophage 
activation. The supernatants were extracted and the levels of TNFα and IL-8 were 
analysed by ELISA. TNFα and IL-8 are key pro-inflammatory cytokines associated 
with ARDS pathophysiology and severity(20, 27, 414). The LPS produced a robust 
response from the hMDMs and both cytokines were secreted. Results show that the 
levels of TNFα are reduced by MSCs (2465.1±1102.6 vs 1038.1±206.7 pg/mL) 
(p<0.05) and fibroblasts (2465.1±1102 vs 1157.5±236.8 pg/mL) (p<0.05) in non-
contact co-culture suggesting an anti-inflammatory effect on the hMDMs by both cell 
types (Fig 3.1 A). IL-8 levels were decreased by hMSCs (11180.7±2957.7 vs 
8107.2±2355.3 pg/mL) and fibroblasts (11180.7±2957.7 vs 9670.7±3984.2 pg/mL) 
but this did not reach statistical significance (Fig 3.1 B). Importantly, when the same 
number of hMSCs used in co-culture are cultured alone and stimulated with LPS they 
also produce IL-8 (6172±86.9 pg/mL, n=2, data not shown). 






















Fig 3.1 hMSCs reduce TNFα secretion by hMDMs stimulated with LPS without 
cell contact 
Supernatants from LPS-treatd hMDMs were extracted and the levels of TNFα and IL-
8 were determined by ELISA. Error bars show standard deviation (SD). (A- n=3-5 per 






































3.4 hMSCs suppress both M1 and M2-associated cytokine/chemokine secretion 
by hMDMs in the presence of LPS 
To further characterise the MSC-induced macrophage phenotype, supernatants 
produced from the LPS non-contact co-culture experiments described in Section 3.3 
were also analysed by bioplex array. This array included the M1 macrophage-
associated cytokines and chemokines IL-1β, IL-12, IL-23, IFNγ and CCL5 as well as 
the M2 macrophage-associated cytokines and chemokines IL-1ra, IL-10, IL-17, 
CCL17, CCL18 and CCL22(211, 266). hMSC co-culture resulted in reduced levels of 
CCL18 (904.3±604.3 vs 292.2±190.3 pg/mL) (p<0.05) and CCL22 
(106210.6±67672.8 vs 22486.0±13266.5 pg/mL) (p<0.05) (Fig 3.2 E and F), had no 
effect on the amount of IL-1ra, IL-23, CCL5 and CCL17 produced (Fig 3.2 A-D) and 
IL-1β, IL-10, IL-17 and IFNγ were below detection limits (data not shown). This data 
demonstrates that hMSCs also induce a downregulation of both M1 and M2 
macrophage-associated chemokines produced by hMDMs in the presence of LPS. The 
positive control for M2 activation IL-4/IL-13 strongly upregulated CCL17 and CCL18 
production in LPS-treated hMDMs (Fig 3.2 D and E). No statistical analysis could be 



























Fig 3.2 hMSCs suppress both M1 and M2-associated cytokine/chemokine 
secretion by hMDMs in the presence of LPS 
Supernatants from LPS-treated hMDMs were extracted and tested by bioplex for 
levels of IL-1ra, CCL17, CCL18, CCL22, (M2) IL-23 and CCL5 (M1). Error bars 
represent SD (n=6 for LPS and LPS MSC groups, n=2 for LPS IL-4/13 group) (One 
way ANOVA with Bonferroni’s post hoc test, except CCL17 which was analysed by 
Kruskal-Wallis with Dunn’s post hoc test, *p<0.05). 
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3.5 hMSCs induce expression of the M2 macrophage marker CD206 in hMDMs 
in the presence of LPS 
Next cell surface marker expression profile of hMDMs in co-culture with hMSCs was 
investigated. Initially, hMDMs were assessed for their expression of well recognised 
M2 macrophage polarisation markers CD200R1, MHC class II and transglutaminase 
2(260, 415, 416) as well as M1 markers CD64 and CD80(417, 418) by RT-PCR. Preliminary 
data from these experiments showed that hMSCs had no effect on the expression of 
any of these markers by hMDMs (data not shown). hMDMs were then stained for 
established M1 markers CD40 and CD54 as well as the M2 markers CD163 and 
CD206(213, 401, 419, 420) and analysed by flow cytometry. The total percentage of cells 
positive for each of these markers was quantified and the MFI was determined. The 
expression of the M1 markers CD40 and CD54 was not affected by the presence of 
MSCs in co-culture by either percentage of cells positive for expression or MFI (Fig 
3.3 A and B). The M2 marker CD163 expression levels were very low in LPS treated 
hMDMs and this was not altered by the presence of hMSCs (Fig 3.3 C). However, 
CD206 marker expression was upregulated by hMSCs. hMSCs increased the 
proportion of hMDMs expressing CD206 by an average of 7-fold (23.3±9.5 vs 
63.5±16.3 %) (p<0.05) and whilst the MFI of its expression was increased by 10-fold 
(361.5±97.8 vs 1672.3±1119.6), this did not reach statistical significance (Fig 3.3 D). 
Notably, CD206 was the only marker in this panel that was influenced by IL-4/IL-13 
treatment, the positive control for M2 macrophage activation, suggesting that it may 
be the only reliable indicator of M2-like macrophage polarisation in this in vitro 
system. Of course IL-4/IL-13 are associated with M2a-type polarisation 


























Fig 3.3 hMSCs induce expression of the M2 macrophage marker CD206 in 
hMDMs the presence of LPS (continued overleaf) 
After stimulation with LPS for 72 hours hMDMs were stained for M1 markers CD40 
(A) and CD54 (B) and M2 markers CD163 (C) and CD206 (D, overleaf) and analysed 
by flow cytometry. Data is presented as both percentage positive cells and the MFI for 
each marker. Error bars represent SD (n=4 for all groups, except for LPS and IL-4/13 




























































































































Fig 3.3 (continued) hMSCs induce expression of the M2 macrophage marker 
CD206 in hMDMs the presence of LPS 
Data is presented as both percentage positive cells and the MFI for each marker. Error 
bars represent SD (n=4 for all groups, except for LPS and IL-4/13 group which is n=3) 




















































3.6 hMSCs increase the proportion of phagocytic hMDMs stimulated with LPS 
hMDM function with LPS stimulation was further studied using a flow cytometric E. 
coli bioparticle phagocytosis assay. The total percentage of hMDMs which ingested 
E. coli bioparticles and the extent of this phagocytosis was determined by flow 
cytometry. LPS induced a non-significant decrease in the percentage of phagocytic 
hMDMs (12.3±5.0 vs 7.2±3.4 %). hMSCs were then able to increase the proportion of 
phagocytic hMDMs in the presence of LPS (7.2±3.4 vs 21.2±4.9 %) (p<0.01) (Fig 3.4 
A). Phagocytic MFI, determined by FITC fluorescence, was unaffected by LPS and 










Fig 3.4 hMSCs increase the proportion of phagocytic hMDMs stimulated with 
LPS 
hMDM phagocytic activity was assessed using E. coli bioparticles and flow 
cytometry. Data is presented as percentage of macrophages which have phagocytosed 
bioparticles (A) and MFI (B) as a measure of the extent of phagocytosis. Error bars 
represent SD (n=5 for all groups except IL-4/13, which is n=4) (One way ANOVA 
with Bonferroni’s post hoc test, **p<0.01). 
 
 












































3.7 hMSCs reduce TNFα production by hMDMs stimulated with BALF from 
patients with ARDS 
Before beginning cytokine analysis, I first performed a dose response using the pooled 
BALF samples. hMDMs were treated with 100%, 50% and 30% BALF for 24 hours 
and cytotoxicity was determined by LDH assay. A large degree of cell death occurred 
in the 100% and 50% concentrations but 30% BALF did not induce cell death of the 
hMDMs (data not shown). hMDMs were treated with pooled BALF from patients with 
ARDS diluted to 30% volume in RPMI1%FBS+PS. They were stimulated for 24 hours in 
the presence or absence of hMSCs in co-culture at a 1:5 ratio of hMSC to hMDM. 
Once again, hMSCs were placed on porous transwell inserts hanging above the 
hMDMs. After 24 hours the supernatants were taken and TNFα levels were quantified 
by ELISA as before. The pooled BALF itself was also assayed to determine the levels 
of TNFα that could be attributed to the samples and therefore was not produced by the 
hMDMs in culture. There was no detectable TNFα present in both the healthy 
volunteer BALF and the ARDS BALF (data not shown). In some pilot experiments 
healthy volunteer BALF was included as a control to show that the stimulation is 
specific to ARDS patient samples. Healthy volunteer BALF elicited a small TNFα 
response from the hMDMs (97.3±3.9 pg/mL). Pooled BALF from patients with ARDS 
elicited a more pronounced but still very mild TNFα response (230.2±30.3 pg/mL). 
The presence of hMSCs in non-contact co-culture reduced hMDM TNF-α production 
to levels comparable with the healthy volunteer BALF-treated group (109.1±37.4 





























Figure 3.5 hMSCs reduce TNFα production by hMDMs stimulated with BALF 
from patients with ARDS 
Supernatants were collected and the levels of TNFα were quantified by ELISA. HV- 
healthy volunteer. Error bars represent SD (healthy volunteer BALF n=3, ARDS 

























3.8 hMSCs increase expression of the M2 marker CD206 by hMDMs in the 
presence of ARDS patient BALF  
hMDMs were treated with pooled BALF for 72 hours. After stimulation the 
supernatants were aspirated and the cells washed before preparing them for flow 
cytometric analysis of CD206 expression. hMDMs cultured in RPMI1%FBS+PS alone 
exhibited similar CD206 expression as those treated with ARDS BALF. hMSC co-
culture resulted in an increase in the percentage of hMDMs expressing CD206 with 
ARDS BALF stimulation (24.6±3.3 vs 56.0±8.1 %) (p<0.01) (Fig 3.6 A). The MFI of 
CD206 expression was also increased by hMSCs (254.4±62.1 vs 629.8±129.3) 








Fig 3.6 hMSCs increase expression of the M2 marker CD206 by hMDMs in the 
presence of ARDS patient BALF 
hMDMs were analysed by flow cytometry for the expression of the CD206 surface 
marker. Expression is presented as the percentage of hMDMs which are positive for 
CD206 (A) and the MFI of CD206 expression (B). Error bars represent SD (n=3 all 












































3.9 hMSCs enhance the phagocytic capacity of hMDMs stimulated with ARDS 
patient BALF  
hMDMs were treated with ARDS BALF for 24 hours with or without hMSC in co-
culture. After 24 hours the supernatant was aspirated, the cells were washed and 
treated with E. coli bioparticles for the analysis of phagocytic capacity by flow 
cytometry. ARDS BALF had no effect on the percentage of phagocytic hMDMs. 
hMSCs were able to increase this percentage (14.4±2.1 vs 27.0±3.7 %) (p<0.01) (Fig 








Fig 3.7 hMSCs enhance the phagocytic capacity of hMDMs stimulated with 
ARDS patient BALF 
hMDMs were treated with ARDS BALF for 24 hours with or without hMSCs. 
hMDMs were treated with E. coli bioparticles and phagocytosis was quantified by 
flow cytometry. Phagocytic capacity is expressed as the percentage of hMDMs which 
had phagocytosed bioparticles (A) and the MFI representing the phagocytic index (B). 
Error bars represent SD (n=4 all groups) (One way ANOVA with Bonferroni’s post 















































3.8 Discussion  
MSC regulation of macrophage phenotype and function has been studied previously; 
the general consensus is that they promote a regulatory phenotype with increased 
phagocytic capacity; my results are mostly consistent with these reports(286, 287). This 
data demonstrates that hMSCs are capable of influencing hMDM phenotype in the 
presence of the inflammatory stimulus LPS. Firstly, hMSCs exhibited the ability to 
downregulate a number of cytokines and chemokines produced by hMDMs. These 
results demonstrate a substantial decrease in the amount of TNFα produced by 
hMDMs when hMSCs are in co-culture without contact. Total IL-8 levels were also 
decreased by hMSCs albeit not significantly, however it is important to remember that 
the hMSCs themselves produced IL-8 and so it is still possible that they were 
effectively reducing IL-8 production by the hMDMs. This data taken alone would 
suggest an anti-inflammatory effect of the hMSCs on the hMDMs. TNFα and IL-8 are 
two key pro-inflammatory cytokines associated with ARDS pathophysiology(414, 421, 
422). It is possible then that reducing levels of such cytokines may reduce the extent of 
inflammation and injury in these patients leading to improved outcomes. Of course 
this is an in vitro model with only hMSCs and hMDMs present; in vivo there are also 
lung parenchymal cells and microvascular cells to consider. Pulmonary microvascular 
endothelial cells isolated from patients of ARDS are known to produce higher levels 
of IL-8 than those of control individuals(423). Furthermore, AM-derived TNFα induces 
secretion of many pro-inflammatory mediators from alveolar type II pneumocytes 
including MCP-1, IL-6 and keratinocyte chemoattractant (KC), the murine equivalent 
of IL-8(424). These cells all contribute to the inflammatory milieu in the alveolar 
compartment and the effects of MSCs on inflammatory functions of these cells are 
also of importance. A number of studies have been published demonstrating the ability 
of MSCs to reduce levels of pro-inflammatory cytokines in preclinical models of 
sepsis and lung injury(73, 76, 141). However, these preclinical studies do not identify the 
cells being influenced by MSCs in order to reduce cytokine levels. The findings in this 
chapter corroborate the findings observed by Kim and Hematti in hMDMs where MSC 
co-culture was found to reduce intracellular TNFα levels(287). Notably, the normal 
human lung fibroblasts were also able to reduce TNFα production by hMDMs. It is 
perhaps not surprising that the fibroblasts were capable of exerting a similar anti-
inflammatory effect, as fibroblast immunomodulation has been reported in the past. 




Fibroblasts, when stimulated with T lymphocyte-derived IFNγ, produce indoleamine 
2,3-dioxygenase (IDO) and actively suppress T cell proliferation(425). This suggests 
that immunomodulation may be a trait common to cells of mesenchymal lineage but 
these are in vitro based studies and so we cannot assume that fibroblasts would be 
efficacious in vivo. Indeed, while MSC therapeutic effects in preclinical models in vivo 
or ex vivo are widely reported, fibroblasts given alongside them have not been able to 
create the same effects(76, 82).  
 
The bioplex data shows a largely unchanged secretory profile with downregulation of 
two M2-associated chemokines, CCL18 and CCL22. While the secretion of IL-23, 
CCL5 and CCL17 were also decreased, this was not statistically significant. IFNγ, IL-
1β, IL-10, IL-12 and IL-17 levels were below the limits of detection of the assay for 
hMDMs in all conditions. Whilst not all cytokines and chemokines investigated in this 
chapter have been implicated in ARDS pathophysiology, they have all been associated 
with macrophage polarisation towards either the M1 or M2 macrophage phenotypes. 
CCL18, also known as dendritic cell-specific CC chemokine and alternative 
macrophage activation-associated CC chemokine 1, is a chemoattractant for naïve T 
cells and B cells(426, 427). CCL22, or macrophage-derived chemokine, is able to recruit 
regulatory T cells, NK cells, monocytes and dendritic cells(428, 429). CCL18 and CCL22 
have not been implicated in ARDS but they do appear to play a role in pulmonary 
fibrosis. CCL18 is produced by AMs in patients of idiopathic pulmonary fibrosis (IPF) 
which acts to accelerate collagen synthesis by human lung fibroblasts and CCL22 is 
another prevalent chemokine in patients of IPF which is associated with poorer 
outcomes(430, 431). Given that fibrosis is an element of late stage ARDS that hinders the 
proper regenerative process of the alveolus, it could be speculated that decreased levels 
of CCL18 and CCL22 may benefit patients of ARDS.  
 
My hypothesis was that hMSCs would induce an M2-like human macrophage 
phenotype. While pro-inflammatory cytokine production was decreased, there was no 
upregulation of any M2-associated anti-inflammatory cytokines or chemokines. On 
that basis it seems unjustified to refer to this macrophage phenotype as anti-
inflammatory if there is no evidence that the macrophages themselves can exert anti-




inflammatory effects. Rather it seems that the hMSCs have promoted a suppressed 
macrophage phenotype with a dampened secretory profile reducing the pro-
inflammatory capacity of the macrophages. To the best of my knowledge, there has 
been no macrophage phenotype previously described which shares all of these traits 
but some comparisons can be made to other studies. A tolerant M2-like macrophage 
phenotype can be promoted by repeated exposure to TLR ligands such as LPS, defined 
by a lack of TNFα response to subsequent treatments and no IL-10 response either(432). 
The comparison could also be made between the MSC-induced phenotype shown here 
and that of unchallenged macrophages. It was unexpected that the levels of IFNγ, IL-
1β, IL-10, IL-12 and IL-17 would be so low given the body of literature reporting 
production of these cytokines by macrophages(433-436). However the lack of such 
responses in these hMDMs could perhaps be explained by the stimulus used. This was 
an in vitro model of sterile inflammation with only E. coli LPS present. This TLR4 
ligand alone may not be sufficient to induce all of these M1 macrophage-associated 
cytokines. For example, there is evidence that human monocytes may produce IL-1β 
with TLR4 stimulation alone however macrophages require a concomitant ATP 
stimulation for proper inflammasome activation and processing of pro-IL-1β(434). IFNγ 
and IL-12 are primarily associated with intracellular infections by pathogens including 
Mycobacterium tuberculosis and more potent IL-12 induction occurs after priming 
with IFNγ(433, 437). IL-10 production is also very low in these cultures which may be a 
reflection of the monocyte differentiation protocol used here (culture in GM-CSF for 
6 to 7 days). Minimal IL-10 production by human macrophages has been reported in 
GM-CSF-differentiated, LPS-stimulated cells whereas levels are higher in M-CSF 
cultured MDMs with the same LPS treatment(438).  
 
Next the effect that hMSCs have on hMDM surface marker expression in the presence 
of LPS was investigated. No effect was observed on the expression of established M2 
markers MHC class II, CD200R1 and transglutaminase 2(260, 415, 416) or M1 markers 
CD64 and CD80 by hMSCs determined by RT-PCR. The marker panel was extended 
to investigate M1 markers CD40 and CD54 as well as M2 markers CD163 and CD206 
by flow cytometry to further characterise the hMSC-induced hMDM phenotype. 
hMSCs were able to increase expression of the M2 marker CD206 but had no effect 




on CD163 expression or either of the M1 markers CD40 and CD54. The absence of 
modulation of many macrophage markers by the various conditions in this study may 
highlight the lack of robust, validated markers for the characterisation of human 
macrophage phenotype. The hMSC-induced increase in expression of CD206 has 
previously been attributed to IL-6 production by the MSCs in systemic lupus 
erythematosus (SLE)(439). CD40 ligand expressed on activated T cells binds with 
CD40 on macrophages to elicit IL-12 secretion, another M1 macrophage function(440). 
Based on these functions, CD40 has been used as a marker of M1 human macrophages 
in a number of studies(213, 411). CD54, or intercellular adhesion molecule (ICAM-1), 
belongs to the immunoglobulin supergene family and mediates cell adhesion to other 
cells as well as matrix components. CD54 contributes to leukocyte extravasation 
through interactions with its ligand LFA-1 and serves as a co-stimulatory molecule in 
the activation of Th1 cells(419, 441, 442). ICAM-1 is constitutively expressed but its 
expression level is increased by pro-inflammatory cytokines including TNFα, IL-1β 
and IFN-γ owing to NF-κB transcriptional regulation(443-445).  
 
As mentioned earlier, CD163 is a haemoglobin/haptoglobin scavenger receptor 
capable of eliciting an IL-10 response by monocytes and has been established as a 
marker of alternatively activated human macrophages(265, 411, 446). The mannose 
receptor, CD206, is amongst the most commonly used M2 macrophage markers(411, 
418). Ambarus et al demonstrated that CD163 is selectively upregulated in human 
macrophages using IL-10 as the polarising stimuli and that IL-4 potently induces 
CD206 expression(418). In this study, MSCs increased expression of CD206 but not 
CD163 in human MDMs and consistent with Ambarus’ findings using IL-4, my 
positive control of IL-4 and IL-13 together also induced CD206 expression but not 
CD163. Notably, IL-10 was not detected by bioplex in co-culture experiments which 
is consistent with the low CD163 expression. Very few of the MDMs in my 
experiments expressed CD163 regardless of the condition which may be a result of 
the GM-CSF based differentiation protocol used, which has been reported before(447). 
In the same report, van der Does et al describe reduced CD163 expression in M-CSF 
differentiated macrophages in response to LL-37, an anti-microbial peptide produced 
by MSCs(96). It is perhaps unsurprising then that CD163 expression was low in these 
MDMs and that MSCs did not act to enhance its expression. Jaguin and colleagues 




conducted a thorough study characterising human macrophage polarisation using a 
variety of different stimuli(448). Their results show that CD206 expression did not 
distinguish between M1 and M2 macrophages polarised using IFN-γ/LPS and IL-4 
respectively. The present study does not show a significant increase in CD206 
expression by MFI either, although this may have been achieved with data from more 
donors. The disparity in these results could be explained by the culture methods for 
isolated monocytes; Jaguin et al had used M-CSF as opposed to GM-CSF. This could 
have resulted in the difference in the percentage of CD206 expressing macrophages at 
baseline. Jaguin et al reported 63.5% of unstimulated macrophages expressing CD206 
whereas an average of less than 20% was observed in this study. The M1 markers 
CD40 and CD54 were expressed on virtually all MDMs that were stimulated with LPS 
and to a higher degree than unstimulated cells. Neither MSCs nor IL-4 and IL-13 had 
any effect on this expression either by percentage or MFI. It is known however that 
macrophages may exhibit both M1 and M2 macrophage properties. For example, 
adipose tissue macrophages of mice given a high fat diet adopt an M1/M2 phenotype 
characterised by enhanced IL-12p40 and IL-1β production yet diminished iNOS and 
CD86 expression (M1), along with increased Arg-1 and IL-1ra levels (M2)(449). 
Importantly, CD206 was the only marker analysed which was influenced by either 
hMSCs or the IL-4/IL-13 positive control suggesting that this may be the only reliable 
marker for alternative macrophage activation in this in vitro system. Inclusion of 
additional M2-inducers including IL-10 or glucocorticoids may have influenced these 
markers. Also of note, while fibroblasts matched the TNFα suppressing capacity of 
hMSCs, they were not able to upregulate CD206 expression by hMDMs suggesting 
that hMSC and fibroblasts do not exert identical effects on macrophage phenotype. 
 
Next the effect that hMSCs had on hMDM phagocytosis was investigated through the 
use of E. coli bioparticles. LPS treatment resulted in a slight but non-significant 
decrease in the proportion of phagocytic MDMs whereas hMSCs were able to increase 
this. It is difficult to compare these results to the literature given the diversity in the 
macrophage source, culture methods, stimulation and the phagocytic target that are 
published. These results complement the work of Michlewska et al showing that LPS 
and subsequent TNFα production inhibit macrophage phagocytosis although this was 
of apoptotic neutrophils and not E. coli(406). LPS was shown to increase clearance of 




opsonised red blood cells by peritoneal macrophages(407). It is generally accepted that 
M1 pro-inflammatory macrophages are more adept in their antimicrobial functions 
compared to M2 macrophages. But this is not to suggest that M2-like macrophages 
are inefficient in phagocytosis or bereft of antimicrobial function in general. Smythies 
et al describe human intestinal macrophages exhibiting “inflammatory anergy” 
evidenced by their lack of IL-1, IL-6, IL-10, TGFβ and TNFα production, yet they 
showed substantial phagocytosis and killing of Salmonella typhimurium (S. 
typhimurium) and E. coli(450). hMSCs have been repeatedly shown to enhance bacterial 
clearance in a number of preclinical disease models of sepsis and lung injury(77, 83, 84, 
451). These effects could be partially attributed to production of antimicrobial factors 
including LL-37 and lipocalin-2 but the ability of MSCs to enhance the phagocytosis 
of blood monocytes and alveolar macrophages is also vital(77, 83, 84, 96).  
 
The LPS experiments suggest that hMSCs are able to promote an M2-like hMDM 
phenotype with enhanced phagocytic activity. LPS is a pathogen-associated molecular 
pattern (PAMP) that likely contributes to inflammation in patients with ARDS 
triggered by the likes of E. coli and P. aeruginosa, previously reported to account for 
14% and 17% of bacterial infections respectively(452). Of course LPS alone does not 
replicate live bacterial infection. Furthermore, AMs in vivo would also be exposed to 
cytokines and other such factors produced by alveolar epithelial cells and invading 
neutrophils which would accumulate in the alveoli. In order to more closely mimic the 
complex microenvironment that exists in the alveolar space in ARDS, hMDMs were 
treated with ARDS patient BALF. BALF from these patients has been shown to 
contain factors including TNFα, IL-8, matrix metalloproteinase (MMP)-2, MMP-9 
and elastase(414, 453, 454), providing a more representative stimulus to the hMDMs. 
Chastre et al reported that BALF from ARDS patients with ventilator-associated 
pneumonia can also test positive for cultures of S. aureus and P. aeruginosa(455). It is 
important to remember though that due to the nature of the BAL procedure, the BALF 
will present these various factors to the hMDMs at a lower concentration. This is not 
the first study to use human samples for in vitro experiments. In 1969, Robinson et al 
collected urine samples from 50 individuals, either healthy or with various types of 
leukemia, to test their effects on the growth of bone marrow colonies(456). Human 
saliva was used in in vitro wound closure assays to determine the factors responsible 




for the accelerated wound closure observed in the oral cavity compared to the skin(457). 
Human BALF samples have also been used experimentally. To study the effects of 
antenatal steroids and chorioamnionitis on alveolar epithelial wound repair in the 
context of preterm infants, BALF was used in an in vitro scratch assay(458). Another 
group pooled the BALF taken from five patients with cystic fibrosis and used it to 
stimulate peripheral blood neutrophils to elucidate the effects on TLR2, 4 and 5 
expression(459). The ARDS BALF samples used in the present study were taken from 
the HARP study published by Craig et al and the healthy volunteer BALF samples 
were taken from the simvastatin study carried out by Shyamsundar et al(394, 395). These 
samples are described in Section 2.3.2 of the Materials and Methods. 
 
hMDMs stimulated with ARDS BALF produced modest levels of TNFα. The extent 
of this TNFα response was substantially lower than that of LPS-treated hMDMs. 
Notably, the concentration of LPS used (10ng/mL) was very high and so a pronounced 
inflammatory response would be expected. In the case of the ARDS BALF, the low 
TNFα production could be explained by the dilute nature of these samples. In the 
HARP study from which these BALF samples were taken, the BAL was performed 
by instilling three separate 50mL aliquots of saline into a portion of the right middle 
lobe(394). 150mL is a large volume and this dilution could explain the mild 
inflammatory response seen in this experiment. Furthermore, the BALF was diluted 
in media to 30% by volume to prevent cytotoxicity. There are a number of potential 
factors contained in the ARDS patient BALF samples which could have been 
responsible for activating the hMDMs. This could have been anything from 
inflammatory cytokines to bacterial products. TNFα was not deteactable in the BALF 
samples alone. This is incongruous with Suter et al’s finding showing that during 
severe ARDS, patients could present with levels of TNFα averaging approximately 
10ng/mL. In the same study they observed vast quantities of soluble TNF receptors I 
and II (sTNFR) in patient BALF(414). Furthermore, mild ARDS severity averaged 
376pg/mL of TNFα in the BALF. Park et al found that TNFα was only detectable in 
the BALF of 28.6% of patients with established ARDS at day 1, a value which 
decreased with time(460). The use of 30% BALF, the course of freeze/thaw cycles that 
the samples have undergone over time and the possibility of sequestration of TNFα by 
its endogenous decoy receptors, sTNFRI and II, may explain the apparent absence of 




this cytokine in the BALF. The absence of TNFα however does not necessarily suggest 
that there were no pro- or even anti-inflammatory cytokines present that may have 
influenced the hMDM response. For example the endogenous IL-1β antagonist, IL-
1ra, is abundant in ARDS patient BALF(454). IL-10 is also detectable in ARDS BALF 
and lower levels of these anti-inflammatory mediators was associated with increased 
mortality(461).  
 
In healthy volunteer BALF-treated hMDMs there was also TNFα produced 
(97.3pg/mL). BALF, regardless of the source, will likely have some form of innocuous 
material present. The AM is inherently tolerant to these substances and have a 
relatively high threshold for activation, an advantageous quality which prevents 
excessive and unnecessary inflammation in the airways. This threshold is maintained 
by the endogenous levels of TGFβ produced in response to their interactions with 
alveolar epithelial cells(196). These hMDMs in vitro would not encounter this inhibitory 
TGFβ signal which could have resulted in the small TNFα response seen here. 
Importantly, the presence of hMSCs in co-culture resulted in the reduction of TNFα 
production by hMDMs treated with ARDS BALF. This mirrors the findings of the 
LPS experiments and suggests that hMSCs are able to reduce pro-inflammatory 
cytokine secretion by human macrophages when exposed to the inflammatory milieu 
of the distal lung in ARDS. Flow cytometry revealed that hMSCs were able to increase 
CD206 expression in hMDMs stimulated with ARDS BALF based on both total 
percentage positivity and the extent of expression (MFI). When we compare the effects 
of LPS and BALF on hMDM CD206 expression as well as the effects of hMSCs in 
both cases, the two results are quite comparable. Neither LPS nor ARDS BALF had 
any effect on CD206 expression compared to untreated control hMDMs. Additionally, 
hMSCs increased the percentage of CD206 positive hMDMs from approximately 20% 
to 60% in each case. The only considerable difference between the LPS and BALF 
experiments is the change in MFI of CD206 expression with hMSC co-culture. hMSCs 
increased CD206 MFI non-significantly in LPS but significantly in BALF due to the 
extent of donor variation. However the average CD206 MFI in LPS-treated hMDMs 
was much higher than BALF-treated hMDMs. This is likely a result of the variation 
in stimuli. One explanation could be proposed from the apparent difference in the 
potency of each stimulus. ARDS BALF induced a much smaller TNFα response than 




LPS, and it may be that the hMSCs modulatory functions were not activated to the 
same degree in BALF as they were in LPS. MSCs are known to be very responsive to 
signals from their environment. For example, MSCs that are primed with sphingosine-
1-phosphate have increased efficacy compared to non-primed MSCs in an animal 
model of pulmonary artery hypertension(462). A study by Herold et al demonstrated a 
progressive increase in the proportion of CD206-expressing M2 macrophages with 
time in pneumonia-associated ARDS patients(463). This complements an animal study 
describing the dynamics of macrophage populations in the lung during lung injury, 
depicting an increased prevalence of M2 macrophages during the later resolution 
stage(285). The BALF samples used in the current study were taken immediately after 
recruitment (within 48 hours of diagnosis) which would be during the acute or 
injurious phase where M1 macrophages predominate(273). These results suggest that 
hMSCs promote an M2-like phenotype in hMDMs which were exposed to the pro-
inflammatory stimuli within ARDS BALF. Shifting AMs towards the M2 phenotype 
at an earlier stage may reduce the severity of lung injury and improve outcomes in 
ARDS. 
 
Lastly, hMSCs were able to increase the proportion of phagocytic hMDMs in the 
presence of ARDS BALF. As was observed with LPS, the BALF alone resulted in a 
trend towards downregulation of phagocytic activity, which was reversed and then 
enhanced by hMSCs. It has previously been shown that clearance of pulmonary P. 
aeruginosa in septic mice is greatly hindered compared to non-septic mice. AMs 
isolated from septic mice were less able to ingest and kill P. aeruginosa ex vivo and 
this phenomenon was partly due to elevated IL-10 in the lungs of these mice(464). As 
mentioned earlier, ARDS patient BALF may contain IL-10 which could explain the 
trend towards decreased phagocytosis seen in these experiments. The hMSCs ability 
to enhance hMDM phagocytosis supports similar findings studying phagocytosis by 
human monocytes in vitro and human AMs ex vivo(83, 171). It is promising that hMSCs 
are able to enhance hMDM phagocytosis in the presence of ARDS BALF. This may 
be of great importance in sepsis and pneumonia-induced ARDS. There are limitations 
to the experiments described in this chapter. E. coli LPS is a potent inflammatory 
stimulus but LPS alone does not replicate the complexity of the alveolar inflammatory 
milieu in ARDS. The use of ARDS BALF much more closely resembles a clinically 




relevant inflammatory stimulus for these hMDMs. However for the present study 30% 
BALF was used instead of 100%; a dilution of an already dilute sampling of the 
bronchoalveolar compartment of the patient. The clinical relevance of this in vitro 
treatment is limited by this fact although it is still considerably more relevant than 
other in vitro approaches to model ARDS. The strength of these BALF studies is that 
they incorporate a plethora of soluble mediators that occur in vivo. On that note, given 
the complexity of these patient samples, it cannot be deduced what specific elements 
are actively stimulating the hMDMs and hMSCs; this makes it difficult to perform 
mechanistic studies with the aim of identifying hMSC-derived factors responsible for 
the shift in macrophage phenotype. For that reason, as well as the scarce and valuable 
nature of these BALF samples, subsequent experiments will return to the use of LPS 
as an inflammatory stimulus to elucidate the MSC mechanism(s). 
 
3.9 Summary and conclusions 
The conclusions from this chapter are: 
 hMSCs suppress pro-inflammatory cytokine secretion and M2-associated 
chemokine secretion in the presence of LPS 
 hMSCs increase the expression of the M2 macrophage surface marker CD206 
with LPS 
 hMSCs enhance the proportion of phagocytic hMDMs with LPS treatment 
 hMSCs can modulate TNFα secretion, increase CD206 expression and 
enhance the phagocytosis of hMDMs in the presence of ARDS patient BALF 
 
Taken together, these results suggest that hMSCs are capable of promoting an 
unconventional M2-like macrophage phenotype in hMDMs in in vitro models of 
ARDS. This hMSC-induced M2-like macrophage phenotype is characterised by a 
dampened secretory profile, upregulated CD206 expression and enhanced phagocytic 
capacity. Promotion of this phenotype in AMs could represent one mechanism by 
which hMSCs exert their beneficial effects in lung injury, mediating increased 
bacterial clearance and reduced inflammation. 
 













Investigating the mechanism(s) by 
which hMSCs modulate hMDM 





















The previous chapter characterised the macrophage phenotype that is induced by 
hMSCs without contact in the presence of E. coli LPS and BALF from patients with 
ARDS. The next aim of this project was to elucidate the mechanism(s) by which they 
exert these effects. Due to the diverse functions of hMSCs including differentiation, 
regeneration and immunoregulation(56, 465, 466), there is great interest in their potential 
therapeutic applications. Certainly, they have been tested in a number of clinical trials 
ranging from acute GVHD to Crohn’s disease to ARDS(122, 123, 131). In order to facilitate 
such a broad range of therapeutic effects in several unique inflammatory and 
degenerative diseases, the modes of action for MSCs must be complex and 
multifactorial. Another important element of MSC biology is their responsiveness to 
environmental stimuli, allowing them to tailor their responses to a particular setting. 
The list of immunomodulatory factors produced by MSCs is extensive. In response to 
IFNγ, MSCs produce IDO which will inhibit T-cell proliferation(57). Galectin-1 also 
contributes to the suppression in T-cell responses and reduced TNFα, IFNγ  and IL-2 
production by peripheral blood mononuclear cells(467). PGE2 was found to mediate the 
switch towards an anti-inflammatory, IL-10-producing macrophage phenotype in 
sepsis(85). MSCs also communicate with peritoneal macrophages through TSG6, 
which binds to their CD44 receptor, diminishing TLR-2-dependent NF-κB 
activation(468). As expected, MSCs can exert more pronounced effects when in contact, 
evidenced by more potent T-cell inhibition; this could be a result of contact-
mechanisms in addition to soluble mediators(469). Contact may also facilitate the 
transfer of mitochondria from MSCs to neighbouring cells enhancing their 
bioenergetics(116, 117, 318).  
 
MSC engraftment rates are very low in models of lung injury(91, 470) and this suggests 
that paracrine factor secretion is the primary mode of action for MSCs in vivo. For that 
reason, this project is focusing on the non-contact-dependent modulation of hMDM 
phenotype by hMSCs. Determining which factors are responsible for the effects seen 
on hMDMs is difficult because MSCs produce such a large variety of soluble 
mediators. A number of potential candidates were tested before determining that 
mitochondria-containing EVs were facilitating many of these effects (Chapter 5). The 




current chapter describes the negative results that were obtained when testing several 
candidates. The factors initially considered were IL-6, TGFβ, IL-10, PGE2, lipoxin 
A4, adiponectin, Ang-1, lipocalin-2 (LCN2), TIMP3 and TSG6. IL-6 has previously 
been shown to play a role in MSC beneficial effects in lung injury and is capable of 
exerting anti-inflammatory functions(105, 107). MSCs also produce TGFβ(471), a cytokine 
capable of decreasing macrophage nitric oxide and TNFα production(472). While IL-10 
is known to be a potent inducer of M2 macrophages(473) and mediates MSC 
immunomodulatory effects(474), IL-10 was not detectable by bioplex in Chapter 3 and 
was not investigated further. Nemeth et al’s seminal paper in the field demonstrates 
that MSC-derived PGE2 induces anti-inflammatory IL-10 producing macrophages in 
an animal model of sepsis(85). Lipoxin A4 production by MSCs was found to help 
facilitate MSC protective effects in endotoxin-induced lung injury(397). Lipoxin A4 is 
capable of inhibiting NF-κB to reduce TNFα expression by macrophages(475). 
Adiponectin and lipocalin-2 are often referred to as adipokines; they are produced by 
MSCs and have both been shown to modulate macrophage function(77, 476). 
Adiponectin is known to induce a more M2-like macrophage profile defined by 
increased CD206 and IL-10 expression along with decreased TNFα production and 
attenuated ROS production(477). A previous study by our group highlights the critical 
importance of LCN2 secretion by murine MSCs in facilitating their anti-microbial 
effects in E. coli-induced pneumonia in vivo(84). LCN2 also promotes an M2-like 
profile through activation of PPARγ and is capable of mitigating LPS-induced pro-
inflammatory cytokine secretion(398). Ang-1 is best known for its roles in the 
maintenance of blood vessel homeostasis through reducing permeability and 
providing survival signals(478, 479). Its capacity for promoting barrier integrity also 
extends to the alveolar epithelium; MSCs overexpressing Ang-1 are more effective in 
preventing permeability and protein leakage into the BALF than unmodified MSCs in 
LPS-induced lung injury(141). Interestingly, Ang-1 appears to have anti-inflammatory 
functions; it has been shown to block NF-κB activation in LPS-treated macrophages 
by signalling through the Tie2 receptor and can block IL-8 production by endothelial 
cells(480, 481). TIMP3 deletion was shown to promote TNFα production by increasing 
the activity of TNFα-converting enzyme(482). TIMP3 is also produced by MSCs and 
represented another potential candidate for the suppression of TNFα by MSCs(483). 
TSG6 has previously been accredited with a number of MSC anti-inflammatory 
functions including decreased NF-κB activation in macrophages(97, 468). In vivo, TSG6 




exerts its anti-inflammatory activity by forming complexes with inter-alpha-inhibitor, 
a regulator of plasmin which propagates inflammation partly through inducing M1 
polarisation in monocytes(484, 485). TSG6 knockdown in hMSCs prevented their anti-
inflammatory effects almost entirely in LPS-induced lung injury(99). With such a 
diverse secretome, consisting of cytokines, chemokines, adipokines, anti-microbial 
peptides and EVs, deciphering the mechanisms of MSC effect is a challenging task. 
 
4.2 Aims 
The second aim of this project was to determine the mechanism of the hMSC effect 
on hMDMs. A literature search identified a number of potential candidate factors 
produced by MSCs which are known to modulate macrophage function. Candidates 
were chosen which showed evidence of producing an M2-like macrophage phenotype 
with reduced pro-inflammatory cytokine secretion, resembling the phenotype that was 


















4.3 IL-6 and TGFβ 
hMDMs were treated with LPS for 24 hours with non-contact co-culture of hMSCs. 
Anti-IL-6 or anti-TGFβ antibody were added to co-culture wells to determine the 
effect of IL-6 and TGFβ on LPS-induced TNFα production by hMDMs. LPS triggered 
a TNFα response in hMDMs which was reduced by hMSCs in non-contact co-culture 
(1093.8 vs 823.9 pg/mL). Anti-IL-6 antibody had no effect on the suppression of 
TNFα production by hMSCs (823.9 vs 849.3 pg/mL) and neither did anti-TGFβ 
antibody (823.9 vs 835.6 pg/mL) (Fig 4.1). This result suggested that neither IL-6 nor 











Figure 4.1 IL-6 and TGFβ 
Supernatants were taken from LPS-stimulated hMDMs after co-culture with hMSCs 
in the presence or absence of anti-IL-6 or anti-TGFβ neutralising antibodies and TNFα 























4.4 PGE2 and lipoxin A4 
The potential role of PGE2 and lipoxin A4 in the hMSC effects on hMDM 
inflammatory responses were assessed using specific inhibitors. hMDMs were treated 
with LPS along with ibuprofen to inhibit PGE2 synthesis or WRW4 to compete for 
the lipoxin A4 receptor on hMDMs. These inhibitors were also added to hMDMs 
which were in non-contact co-culture with hMSCs. Ibuprofen had no effect on TNFα 
production by LPS-treated hMDMs alone (8520.8 vs 8362.1 pg/mL). WRW4 exerted 
an anti-inflammatory effect on hMDMs given LPS but without hMSC co-culture 
(8520.8 vs 6188.9 pg/mL). hMSCs reduced TNFα production (8520.8 vs 3259.3 
pg/mL) which was unaffected by the addition of ibuprofen (3259.3 vs 3725.8 pg/mL) 
or WRW4 (3259.3 vs 2988.2 pg/mL) (Fig 4.2). This result suggests that PGE2 and 










Fig 4.2 PGE2 and lipoxin A4 
Supernatants were extracted after 24 hours of hMDM stimulation with LPS, with 
hMSC co-culture and the addition of PGE2 and lipoxin A4 inhibitors. TNFα levels 

























4.5 Lipocalin-2 and adiponectin  
LCN2 and adiponectin production by hMSCs and hMDMs were first quantified. 
hMDMs and hMSCs were cultured for 24 hours separately and in co-culture with or 
without LPS stimulation. Supernatants were collected and tested by ELISA for 
lipocalin-2 and adiponectin. hMDMs produced LCN2 and the extent of secretion was 
unaffected by LPS treatment (366.7±130.3 vs 345.3±165.2 pg/mL). Surprisingly, 
hMSCs produced LCN2 at levels barely detectable by the ELISA and this was 
unchanged with LPS stimulation (15.2±13.0 vs 20.2±15.1 pg/mL). Cells in co-culture 
with LPS displayed a trend towards a more than additive increase in LCN2 production 
(513.3±72.7 pg/mL) (Fig 4.3 A). Adiponectin was undetectable by either hMDMs or 
hMSCs in any condition (data not shown). Given that there was some evidence of 
increased lipocalin-2 production in co-culture LCN2 function was investigated further. 
Antibody for LCN2 or isotype was added alongside hMSC-CM to determine whether 
it would reverse TNFα suppression. hMSC-CM with isotype antibody non-
significantly reduced TNFα production (998.0±991.8 vs 282.1±288.2 pg/mL) and this 
was not prevented with the blockage of LCN2 (282.1±288.2 vs 391.2±401.9 pg/mL) 
(Fig 4.3 B) suggesting that LCN2 is not involved in the hMSC effect. The rejection of 
this hypothesis was further supported by the observation that hMDMs treated with 
recombinant human LCN2 produced more IL-8 in response to LPS (17641.1 vs 






























Fig 4.3 Lipocalin-2  
LCN2 levels were measured in the supernatants of hMSCs and hMDMs with or 
without LPS (A) (n=2 all groups). LCN2 was neutralised by antibody in hMSC-
hMDM co-culture with LPS and TNFα was quantified (B) (n=2 all groups). The effect 
of recombinant human LCN2 on hMDM IL-8 secretion after LPS treatment was tested 
(C) (n=1). Error bars represent SD.  























































Ang-1 production was determined by ELISA in hMDM and hMSC supernatants with 
or without LPS. hMDMs produced modest levels of Ang-1 which were not affected 
by LPS (271.5±28.2 vs 251.0±21.1 pg/mL). hMSCs produced more Ang-1 than 
hMDMs, but again, LPS did not influence its production (591.3±140.0 vs 548.8±63.7 
pg/mL). Surprisingly, hMDM-hMSC co-culture resulted in total Ang-1 levels 
comparable to hMDMs cultured alone (251.0±21.1 vs 291.4±35.0 pg/mL) (Fig 4.4). 
This is less than additive and even seems to suggest that hMSC secretion of Ang-1 is 














Fig 4.4 Angiopoietin-1 
hMDMs and hMSCs were cultured for 24 hours with or without LPS stimulation either 
individually or in non-contact co-culture. Ang-1 secretion was measured in the 

































hMDM and hMSC TIMP3 production was assessed after 24 hours with or without 
LPS. hMDMs produced very little TIMP3 in the presence and absence of LPS 
(64.8±8.5 vs 61.9±10.2 pg/mL). hMSCs produced more TIMP3 than the hMDMs and 
this appeared to be more pronounced after LPS treatment (96.7±8.3 vs 134.1±9.0 
pg/mL). Much like Ang-1, TIMP3 production in the co-culture was less than additive 
and levels mirrored those produced by hMDMs alone (50.2±8.9 pg/mL) (Fig 4.5). 













Fig 4.5 TIMP3  
hMDMs and hMSCs were cultured for 24 hours in the presence or absence of LPS. 



























hMDMs and hMSCs were then tested for their TSG6 production. A specialised ELISA 
kit for TSG6 developed by Cusabio was used. hMSCs did not produce any detectable 
TSG6 either with or without LPS. hMDMs produced massive levels of TSG6 both 
with LPS and without at concentrations exceeding the top standard of the ELISA at 
10ng/mL. This is in spite of diluting these samples by a factor of 30, suggesting that 
hMDMs were producing TSG6 at concentrations beyond 300ng/mL (data not shown). 
While accurate quantities cannot be given from these results, the abundance of TSG6 
production by hMDMs alone would suggest that hMSCs were not acting through 
additional TSG6 production. The rationale here was that the factors responsible for 
the hMSC effect should be produced solely by the hMSCs or at least to a larger degree 
by the hMSCs. 
 
4.9 Discussion 
In this chapter a number of soluble mediators which may potentially mediate the 
effects of hMSCs on hMDMs were considered. IL-6 and TGFβ inhibition had no effect 
on hMSC suppression of hMDM TNFα production. This was unexpected given reports 
of the anti-inflammatory capacity of IL-6 and its importance in mediating MSC 
protective effects in endotoxin-induced lung injury. In this study IL-6-deficient MSCs 
reduced TNFα expression in injured lungs to a lesser degree(107). TGFβ also has the 
capacity to decrease macrophage TNFα expression(472). However the current study is 
investigating TNFα production at the protein level as opposed to TNFα mRNA, in 
addition to the fact that these are human macrophages while these groups were 
investigating mouse cells. Similarly, neither PGE2 nor lipoxin A4 appear to play a role 
in the hMSC effect. These factors have both been implicated in exerting anti-
inflammatory effects on macrophages. Kure et al show reduced TNFα production after 
lipoxin A4 treatment however this study used a mouse macrophage cell line 
(RAW264.7 cells)(475). Nemeth et al show increased IL-10 production by macrophages 
in mice which had received MSCs in a murine sepsis model; this was also associated 
with decreased TNFα in the serum(85). The difference in results in the present study 
are likely a reflection of the vastly different models used; mouse sepsis in vivo is not 
comparable to LPS treatment of hMDMs in vitro. The results in this chapter suggest 




that hMSCs produce LCN2, Ang-1 and TIMP3 in keeping with the literature(77, 141, 483, 
486). However neither adiponectin nor TSG6 were measurable in these supernatants, 
even though these are also reportedly produced by MSCs(99, 468, 476, 487). It was 
surprising that hMSCs stimulated with LPS would not produce TSG6. TNFα is of 
course an inducer of TSG6 and whilst this would not be present in the hMSC alone 
culture, LPS is another inducer of TSG6 as demonstrated in fibroblasts(488). Because 
these samples were all above the highest standard in the TSG6 ELISA, it could not be 
determined whether there was an increase in TSG6 levels with hMSCs in co-culture. 
It would be plausible in that condition given that they would have been exposed to 
TNFα. It is likely however that the increase would have been negligible given Lee et 
al’s reports of approximately 2.5ng/mL of TSG6 being produced by MSCs with TNFα 
stimulation, a very small fraction of the >300ng/mL produced by the hMDMs 
observed here(97). For that reason, the hypothesis that TSG6 was responsible for the 
immunomodulatory effects of hMSCs on these hMDMs was rejected. This finding 
undermines the potential application of quantifying TSG6 production as a potency 
assay to assess MSC immunomodulatory capacity(155, 489). Adiponectin was not 
detectable in either hMSC or hMDM cultures. Abraham et al demonstrated increased 
adiponectin levels in the serum of mice that received bone marrow transplant 
suggesting that MSCs are contributing to this increase(476). These were murine MSCs 
in vivo which is not easily comparable to the current study. Winter et al show 
adiponectin gene expression in bone marrow-derived MSCs by RT-PCR rather than 
protein quantification(487). Another study suggests that adiponectin production by 
MSCs only ensues after driving adipogenic differentiation rather than non-committed 
MSCs(490). Both Ang-1 and TIMP3 were produced by hMSCs and hMDMs. In single 
cell cultures hMSCs produced higher levels of these factors than hMDMs. 
Interestingly, co-culture showed a less than additive quantity of both Ang-1 and 
TIMP3. It is possible that the paracrine communication between the two cell types 
resulted in downregulation of expression by either cell type or even both. 
 
LCN2 levels were quite low in hMSC culture whereas hMDMs produced LCN2 to a 
higher degree. Gupta et al were able to demonstrate LCN2 production in MSCs after 
LPS stimulation but this was in murine cells. They observed increased LCN2 levels in 
the BALF of mice treated with MSC during E. coli-induced pneumonia(77). 




Importantly, the increase in LCN2 levels within the BALF was substantially higher 
than the amount being produced by the MSCs alone; this would suggest that the 
increased LCN2 is resulting from MSC-induced LCN2 production by other cells. This 
is in keeping with the results from the current study where co-culture of hMSCs and 
hMDMs results in increased LCN2 production. It may be that the hMSCs have 
increased hMDM LCN2 secretion. In this case LCN2 would not be the hMSC-derived 
factor mediating their effect on hMDMs, rather it would be released by hMDMs in 
response to that factor. Induction of LCN2 production by hMDMs may simply 
represent the acquisition of heightened antimicrobial capacity due to hMSCs or it may 
also serve to further promote induction of the hMSC-induced M2-like macrophage 
phenotype in an autocrine manner. The role of LCN2 in LPS-induced hMDM TNFα 
production was studied. Blockage of LCN2 by antibody neutralisation did not abrogate 
hMSCs ability to suppress TNFα production and recombinant LCN2 even augmented 
the IL-8 response with LPS stimulation. Zhang et al demonstrated that 500ng/mL of 
recombinant LCN2 reduced macrophage TNFα production(398). This is a much higher 
level than those observed in my in vitro cultures which may not be sufficient to 
mitigate the hMDM inflammatory response. 
 
4.10 Summary and conclusions 
Based on the results in this chapter, a number of soluble mediators suggested by the 
literature were disregarded as potential candidates responsible for the hMSC effect. 
So far, the mechanisms of hMSC effect on hMDM phenotype and function in this 
model remain unknown. Results from this chapter suggest that: 
 IL-6, TGFβ, PGE2 and lipoxin A4 do not facilitate the anti-inflammatory 
effects of hMSCs on hMDMs 
 Adiponectin is not produced by hMSCs with or without LPS stimulation 
 Lipocalin-2 is produced to a larger degree by hMDMs but plays no role in their 
modulation by hMSCs 
 Ang-1 and TIMP3 are produced by hMSCs and hMDMs but seem to be 
downregulated in co-culture suggesting that they do not play a role 
 TSG6 is produced by hMDMs but not substantially by hMSCs













Investigation of mechanisms of 
macrophage modulation mediated by 
hMSC-EVs 
 




Having tested a range of different paracrine factors which were shown to play no role 
in the hMSC effects observed on hMDMs, the next candidate to investigate was 
hMSC-derived EVs. Described in detail in Chapter 1, EVs are small membrane-
bound compartments produced by cells which may contain a plethora of soluble 
factors including proteins, miRNA and even organelles(291, 295). These vesicles provide 
another means of cellular communication and have key roles in cellular processes 
including coagulation, angiogenesis and metastasis(301, 491, 492). MSCs are known to 
have a high capacity for EV secretion(493) and these have been shown to be responsible 
for a number of their beneficial effects in preclinical models investigating tumour 
growth, airway inflammation and pulmonary hypertension amongst others(166, 168, 170). 
This is also the case in lung injury models; a number of studies have provided evidence 
that MSC-EVs are able to improve survival, reduce lung injury, measured by the extent 
of protein-rich pulmonary oedema, reduce inflammation based on neutrophil influx 
and cytokine levels and improve bacterial clearance though the augmentation of 
monocyte phagocytosis(171, 317). Importantly Monsel et al highlight the importance of 
CD44 expression on MSC-EVs for their effective uptake by primary human 
monocytes and alveolar epithelial cells(171). Researchers are now investigating the 
potential of using EVs therapeutically, instead of whole cell therapies(175, 322, 494). 
 
MSC-EVs are known to contain KGF mRNA, which is partly responsible for their 
therapeutic effects in lung injury models(317). Microarrays have shown that these EVs 
also contain a multitude of miRNAs which could regulate a host of other processes. 
Intriguingly, the miRNA content of MSCs and their EVs differ considerably, 
suggesting that there is active sequestration of specific miRNAs into these exosomal 
compartments(291). These MSC-derived miRNAs were found to exert anti-
inflammatory effects on macrophages via the downregulation of TLR signalling. 
Indeed, MSC-EV miRNAs have been demonstrated to mediate a number of their 
regulatory functions. miR-133b found in MSC-EVs stimulates neurite growth and 
miR-31 was able to promote angiogenesis in endothelial cells by targeting and 
inhibiting factor-inhibiting HIF-1(320, 321). Perhaps most impressively, MSC-EVs can 
also contain functional mitochondria which are transferrable to recipient cells, 
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evidenced by Phinney et al, where they studied mitochondrial transfer to 
macrophages(291). Mitochondrial transfer has also been reported through contact-
dependent mechanisms such as tunnelling nanotubules and gap junction-assisted EV 
transfer(116, 318). This exchange of mitochondria can have a number of effects on the 
recipient cell; these studies have reported enhancement in cellular ATP levels as well 
as promoting phagocytic activity. The acquisition of functional mitochondria, 
particularly from another cell type, could have more substantial effects on cellular 
homeostasis than those already reported. It is unsurprising that there is a resultant 
increase in ATP production in alveolar epithelial cells receiving MSC-derived 
mitochondria, given they are the powerhouses of the cell. Mitochondria, however, play 
key roles in other important cellular processes. They may initiate programmed cell 
death through the intrinsic pathway and mitochondrial ROS generation is important 
for bactericidal function of phagocytes(359, 363). In fact, there is more and more 
emerging evidence showcasing the involvement of mitochondria in innate immune 
functions. Mitochondria play a pivotal role in anti-viral responses mediated by the 
RIG-1/MDA-5/MAVS signalling pathway leading to type I IFN production and both 
IRF3 and NF-κB activation(370). They are capable of NLRP3 inflammasome activation 
through ROS production(371). Mitochondria facilitate so many central functions that it 
seems feasible that mitochondrial transfer has consequences more complex than 
simply increasing cellular metabolic capacity. 
 
Macrophage polarisation and metabolism are integrally linked. The metabolism of 
iron and arginine is indicative of macrophage activation state(248, 253, 255). M1 
macrophages activated by LPS or IFNγ utilise primarily glycolysis, whereas M2 
macrophages are characterised by a switch to fatty acid oxidation and mitochondrial 
respiration(239, 240). Vats et al showed that alternative activation of murine macrophages 
induced by IL-4 was dependent on mitochondrial respiration(240). The inhibition of 
mitochondrial respiration using either oligomycin or FCCP resulted in perturbed IL-
4-dependent M2 activation measured by reduced arginase activity. Furthermore, these 
inhibitors also sustained TNFα, IL-6 and IL-12p40 production in response to 
LPS/IFNγ, blocking the anti-inflammatory effects of additional IL-4 treatment. The 
mitochondria’s pivotal role in regulating metabolic activity as well as the strong 
association between macrophage activation and glycolysis/oxidative phosphorylation 
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balance, leads to the hypothesis that mitochondrial transfer influences macrophage 
polarisation. 
 
5.2 Aims  
In Chapter 3, the hMDM phenotype that is promoted by hMSCs was characterised in 
vitro. In the current chapter there were three main aims:  
 Investigate the role of hMSC-EVs in hMDM phenotype modulation 
 Determine the importance of hMSC-EV modulation of macrophages in vivo 
 Investigate the roles of EV-derived miRNAs and mitochondria in the hMSC 
effect on macrophage phenotype 
 
5.3 hMSC-derived EVs are present in hMSC-CM and are characterised by high 
expression of CD44 on their surface 
To test the hypothesis that hMSC-EVs play a role in the modulation of macrophage 
phenotype by hMSCs, it was important to confirm that EVs are present in these hMSC-
CM preparations. Firstly, to provide some indication of the size of hMSC-EVs, hMSC-
CM was centrifuged to remove cell debris and then analysed by flow cytometry 
alongside latex beads which have a diameter of 4μm. Latex beads alone were first 
gated for by FSC vs SSC. Latex beads were then added to hMSC-CM and analysed at 
the same settings. The EV population was situated below the latex beads on the FSC 
vs SSC plot indicating that EVs are considerably smaller (Fig 5.1 A). hMSCs were 
grown to confluence before being stained with a fluorescent anti-CD44 antibody (or 
isotype control) and a general cell membrane stain (cell mask). hMSCs were also 
stained with propidium iodide and annexin V to determine the amount of necrotic or 
apoptotic cell bodies respectively. hMSCs were washed and CM was generated for 24 
hours in the presence of LPS stimulation. Cell debris was removed by centrifugation 
before proceeding to flow cytometry of EVs within the CM. To identify the EV 
population, the following gating strategy was used: FSC vs SSC showed a dense 
population of EVs at the limits of sensitivity of the cytometer. Of all events 96.1% 
were cell mask positive and were therefore cell membrane-derived. Propidium iodide 
and annexin V stains showed that there was small contamination with necrotic (2.4%) 
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and apoptotic (9.1%) debris in this EV population. Events which were propidium 
iodide and annexin V negative were gated for. The gate for CD44 staining was 
adjusted according to the isotype control and 94.8% of EVs were found to express 











Fig 5.1 hMSC-derived EVs express CD44 on their surface (continued overleaf) 
hMSC-CM-derived EVs were analysed by flow cytometry alongside latex beads of 
known size to provide a reference point (A). FSC and SSC voltage settings were 
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Fig 5.1 hMSC-derived EVs express CD44 on their surface 
MSCs were pre-stained with propidium iodide, annexin V, cell mask and anti-CD44 
antibody or isotype control before generating CM. CM was centrifuged to remove cell 
debris and was then analysed by flow cytometry. EVs were selected by FSC vs SSC 
(i), cell mask positive events were gated for (ii), apoptosis contamination was 
accounted for (annexin V, Ann V) (iii), then necrosis (propidium iodide, PI) was ruled 
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5.4 hMSC-derived CD44-expressing EVs are partially responsible for 
suppression of LPS-induced TNFα secretion by hMDMs 
To determine if these CD44-expressing EVs were important for hMSC effects, CM 
from hMSCs was prepared as before and pre-incubated with a neutralising antibody 
for CD44 or isotype control. hMDMs were then stimulated with LPS and hMSC-CM 
with or without antibody pre-treatment. hMDMs treated with LPS and antibody, but 
not hMSC-CM, were included as a control for the effects of the antibodies on hMDMs. 
Supernatants were lifted and TNFα production was determined by ELISA. Treatment 
of hMDMs with anti-CD44 had no effect on TNFα levels and isotype had no effect in 
LPS or LPS + hMSC-CM-treated hMDMs. Consistent with previous data, hMSC-CM 
significantly reduced LPS-induced production of TNFα by macrophages 
(1312.0±229.4 vs 389.6±255.7 pg/mL) (p<0.05). Pre-incubation of hMSC-CM with 
anti-CD44 resulted in partial abrogation of this effect, suggesting that CD44 
expressing EVs present in the hMSC-CM are at least partially responsible for the MSC 
effect (Fig 5.2). 
 
5.5 hMSC-derived CD44-expressing EVs are critical for enhancement of hMDMs 
phagocytic activity 
Next the importance of CD44-expressing EVs in the enhancement of hMDM 
phagocytosis was investigated. Using the same conditions, for 24 hours of stimulation, 
supernatants were aspirated and the hMDMs were washed before adding E. coli 
bioparticles to assess phagocytic activity. hMSC-CM increased the proportion of 
phagocytic hMDMs by 28.1% (p<0.01), and produced a 9-fold increase in MFI (360.8 
vs 3249.8) (p<0.01), in the presence of LPS. Pre-incubation of hMSC-CM with anti-
CD44 completely reversed the enhancement in phagocytosis by both percentage 
(80.4±4.8 vs 61.1±7.6 %) (p<0.05) and MFI (3249.8±2240.2 vs 753.8±529.8). Isotype 


























Fig 5.2 hMSC-derived CD44-expressing EVs are partially responsible for 
suppression of LPS-induced TNFα secretion by hMDMs 
hMDMs were treated with LPS for 24 hours with hMSC-CM which had been pre-
incubated with or without anti-CD44 (or isotype). Supernatants were taken for analysis 
of TNFα production. Error bars represent SD (n=4 all groups) (Kruskal Wallis with 












































Fig 5.3 hMSC-derived CD44-expressing EVs are critical for the enhancement of 
hMDMs phagocytic activity 
hMDMs were treated with LPS for 24 hours with hMSC-CM which had been pre-
incubated with or without anti-CD44 (or isotype). E. coli bioparticles were used to 
determine phagocytic activity and is presented as percentage phagocytic cells (A) and 
MFI (B). Error bars represent SD (n=5 all groups) (Kruskal Wallis with Dunn’s post 
hoc test, *p<0.05, **p<0.01). 
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5.6 AMs are the cellular mediators of hMSC-EVs beneficial effects in E. coli 
endotoxin-induced lung injury in vivo  
After establishing that EVs were primarily responsible for the paracrine mechanism 
of hMSC modulation of macrophage phenotype in vitro, it was necessary to test the 
importance of hMSC-educated macrophages in lung injury in vivo. C57BL/6 male 
mice at eight weeks of age were culled for BAL to isolate AMs. EVs were isolated 
from hMSC-CM and these were added to the murine AMs ex vivo. AMs cultured ex 
vivo without hMSC-EVs were included as a control. Mice were injured with LPS or 
PBS and four hours later treated with AMs which had received EV treatment, AMs 
without treatment or PBS. 24 hours after injury, mice were culled for BAL. BALF was 
processed for total cell counts, neutrophil counts and protein content. The experiment 
was performed twice; once treating mice with untreated AM and the other treating 
mice with AM that had been cultured with hMSC-EVs. These experiments were 
performed separately due to the difficulty in isolating sufficient numbers of AM from 
mice by BAL for ex vivo culture. Cytospins prepared from the BALF of these mice 
were imaged at 20x magnification (Fig 5.4 A). In the first experiment LPS 
administration produced a substantial influx of inflammatory cells into the airspaces 
compared to PBS-treated mice (0.29±0.10 vs 1.18±0.34 x106 total cells/mL) which 
included a large proportion of neutrophils (<0.01 vs 0.38±0.18 x106 neutrophils/mL). 
Untreated AMs did not influence these cell numbers (1.18±0.34 vs 1.14±0.22 x106 
cells/mL) (0.38±0.18 vs 0.48±0.10 x106 neutrophils/mL) (Fig 5.4 B). Consistent with 
inflammatory cell infiltration, LPS treatment resulted in an increase in BALF protein 
levels compared to the PBS group (295.87±27.45 vs 569.04±324.19 μg/mL). This 
indicates protein rich oedema formation due to impairment of epithelial-endothelial 
barrier integrity. Untreated AMs were unable to reduce protein content in the BALF 
compared to LPS-injured mice receiving PBS (569.04±324.19 vs 593.67±85.17 
μg/mL) (Fig 5.4 C). In the second experiment LPS produced a more robust 
inflammatory response, evidenced by higher total cell counts as well as absolute 
neutrophil counts in the BALF (0.29±0.10 vs 1.95±0.26 x106 cells/mL) (<0.01 vs 
1.41±0.39 x106 neutrophils/mL). EV-treated AMs significantly reduced both total cell 
counts and neutrophilia in the BALF (1.95±0.26 vs 1.08±0.25 x106 cells/mL) (p<0.01) 
(1.41±0.39 vs 0.54±0.14 x106 neutrophils/mL) (p<0.05) (Fig 5.4 D). LPS instillation 
induced lung injury as indicated by an increase in BALF protein levels compared to 
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uninjured controls (295.87±27.45 vs 674.41±64.22 μg/mL). Importantly, EV-treated 
AMs were able to prevent this lung injury, reducing BALF protein to levels 
comparable to the uninjured mice (674.41±64.22 vs 326.13±38.70 μg/mL) (p<0.001) 
(Fig 5.4 E). This study demonstrates that hMSC-EVs are capable of macrophage 
modulation that is critical in providing protection from lung injury in vivo and also 
























Fig 5.4 AMs are the cellular mediators of hMSC-EVs beneficial effects in E. coli 
endotoxin-induced lung injury in vivo (continued overleaf) 
Mice were injured with LPS administration and treated with PBS, or AMs which 
themselves were untreated or cultured with hMSC-EVs. 24 hours after injury, mouse 
lungs were lavaged. Cytospins were prepared from the BALF, cells were stained and 
imaged by brightfield microscopy (20x magnification). Representative images for 
each group are shown (A). 
A PBS + PBS LPS + PBS 
LPS + unt AM LPS + EV-AM 
100μm 





















Fig 5.4 (continued) AMs are the cellular mediators of hMSC-EVs beneficial 
effects in E. coli endotoxin-induced lung injury in vivo (continued overleaf) 
Prior to cytospin preparation, aliquots were taken from BALF samples and total cell 
counts performed. Differential counts of cytospin images were performed to quantify 
neutrophils (B). Protein content of cell-free BALF supernatant was quantified by BCA 
(C). Results from the untreated AM-treated mice are shown. Error bars represent SD 
(n=4 all groups but untreated AM group which is n=5) (One way ANOVA with 
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Fig 5.4 (continued) AMs are the cellular mediators of hMSC-EVs beneficial 
effects in E. coli endotoxin-induced lung injury in vivo 
Prior to cytospin preparation, aliquots were taken from BALF samples and total cell 
counts performed. Differential counts of cytospin images were performed to quantify 
neutrophils (D). Protein content of cell-free BALF supernatant was quantified by BCA 
(E). Results from the EV-treated AM-treated mice are shown. Error bars represent SD 
(n=4 PBS group, n=5 LPS group, n=3 EV AM group) (One way ANOVA with 
Bonferroni’s post hoc test, *p<0.05, **p<0.01, ***p<0.001).  
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5.7 Investigation of the role of hMSC-EV-derived miRNAs in the mechanisms 
underpinning the hMSC-EV effect on hMDMs 
Having established the important role of hMSC-EVs in mediating hMSC modulation 
of macrophage function, the next step was to begin investigation of the EV contents 
responsible for the effect. Phinney et al were the first to demonstrate that miRNA-
containing MSC-EVs had an anti-inflammatory effect on macrophages; it was 
observed that the removal of miRNA from the MSC-EV compartment by inhibiting 
DICER abrogated their ability to modulate TLR expression. Therefore it was 
hypothesised that the anti-inflammatory effects of hMSC-EVs in the present study are 
mediated by miRNAs. Phinney et al have performed a miRNA screen on both MSCs 
and their EVs to determine their content(291), they did not however investigate the roles 
of individual miRNAs. Microarray data have been deposited in the GEO NCBI 
database (accession code GSE71241); analysis of these data identified several specific 
miRNAs as promising candidates to be tested for their involvement in the hMSC-EV 
effect on macrophages in the present study. As reported by Phinney et al miR-125b 
was amongst those present in both MSCs and their EVs; this miRNA has a number of 
roles in regulating myeloid cell function. miR-125b targets TNFα mRNA transcripts 
in macrophages inhibiting its translation(495). This miRNA also stabilises κB-Ras2, an 
inhibitor of NF-κB, thereby inhibiting pro-inflammatory cytokine secretion(496). miR-
125a is produced by MSCs and acts to suppress M1 macrophage M1 activation while 
promoting M2 activation(497, 498). Another candidate for the hMSC effect is miR-223 
which also dampens pro-inflammatory activity in macrophages by targeting 
Pknox1(347, 499). I sought to determine whether miR-125a, miR-125b or miR-223 were 
responsible for the hMSC effect on hMDMs. miRNA was extracted from hMSCs and 
qPCR was performed to determine whether these miRNAs were present. qPCR 
confirmed the presence of miR-125a and miR-125b and while miR-223 was detected 
the CT values were very high (Fig 5.5 A). Next miRNA was extracted from hMSCs-
EVs and the experiment repeated. miR-125b was the only miRNA present in 
considerable abundance based on CT values although the gradient of the amplification 
plots for miR-125a and miR-223 suggest some inhibition of the PCR reaction (Fig 5.5 
B). In order to investigate the functional importance of miR-125a and miR-125b, 
hMSCs were transfected with anti-miRNA inhibitors for these targets using 
oligofectamine (Thermo Fisher Scientific). A non-specific negative control inhibitor 
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was included as a control for the transfection process. The efficacy of the inhibitors 
was first confirmed by qPCR; use of anti-miR-125b completely abolished miR-125b 
expression in hMSCs and it was no longer detectable. Similarly anti-miR-125a 
completely blocked miR-125a expression, however there appeared to be some non-
specific inhibition of miR-125a with the anti-miR-125b inhibitor and vice versa (Fig 
5.5 C). hMSCs used in stimulation experiments were treated with the anti-miR-125b 
inhibitor but considered to have ablated miR-125a and miR-125b expression. CM 
from transfected hMSCs was taken and added to hMDMs treated with LPS for 24 
hours. Supernatants were analysed by ELISA for TNFα production. LPS produced a 
robust TNFα response which was reduced by CM from hMSCs that had been 
transfected with either negative control or anti-miR-125b inhibitors. This suggests that 
miR-125b is not responsible for the anti-inflammatory effect of hMSC-CM (Fig 5.5 
D). hMDMs were washed after isolating the supernatants and E. coli bioparticles were 
added to evaluate phagocytosis. hMSC-CM from negative control inhibitor transfected 
cells produced a consistent increase in phagocytosis by both percentage of phagocytic 
hMDMs and MFI, however the use of specific anti-miR-125b inhibitor did not affect 
this, again suggesting that miR-125b is not involved in hMSC-CM enhancement of 
































Fig 5.5 hMSC-EV-derived miR-125a and miR-125b are not responsible for the 
hMSC effect on hMDMs (continued overleaf) 
miRNA from hMSCs and their EVs were analysed by qPCR for detection of miR-
125a, miR-125b and miR-223 (A and B respectively) (n=1). Efficacy of miR-125a and 
miR-125b inhibition using transfection was determined by qPCR (C) (n=1). qPCR 



























































Fig 5.5 (continued) hMSC-EV-derived miR-125a and miR-125b are not 
responsible for the hMSC effect on hMDMs 
CM from hMSCs which had been transfected with the negative control and miR-
125a/b inhibitors were added to LPS-treated hMDMs; their supernatants were tested 
for TNFα by ELISA (D) and E. coli bioparticles were used to quantify phagocytosis 
(E). Percentage phagocytic hMDMs and MFI for phagocytic index are presented. 
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5.8 hMSC-EVs contain mitochondria which are transferred to hMDMs 
Our group has recently published a paper showing that hMSCs can donate their 
mitochondria to hMDMs through tunnelling nanotubules which mediates the 
enhancement of macrophage phagocytosis(116). MSC-EVs are known to contain 
mitochondria which is another means of transferring these organelles to other cell 
types(291, 318). I hypothesised that transfer of mitochondria via EVs is responsible for 
the hMSC effect on hMDMs. To test this hypothesis it was important to first confirm 
that mitochondria-containing EVs are present in these hMSC-CM preparations. When 
preparing the hMSCs for flow cytometry as described in Section 5.3, they were also 
pre-stained with MitoTracker Red; a highly specific dye for functional 
mitochondria(500, 501). Using the same gating strategy outlined in Section 5.3, the 
amount of EVs containing mitochondria was quantified. The proportion of total EVs 
containing mitochondria was 25.2% (Fig 5.6 A). To test for EV-mediated 
mitochondrial transfer, hMDMs were cultured on chamber slides and pre-stained with 
MitoTracker Green and Hoechst nuclear stain (blue). hMSCs were pre-stained with 
MitoTracker Red and CM was produced after extensive washing for 24 hours. hMSC-
CM was added to the pre-stained hMDMs and cultured for a further 24 hours. Uptake 
of hMSC mitochondria into hMDMs was visualised by fluorescence microscopy (x40 
magnification). Evidence of mitochondria-containing EV adhesion to hMDMs is 
evident with red hMSC mitochondria visible on the green hMDM mitochondria (white 
arrows). Integration of hMSC mitochondria into the hMDM mitochondrial network is 
apparent where the red and green fluorescence co-localise to give a yellow hue (yellow 
arrow) (Fig 5.6 B). Finally, MitoTracker Red pre-stained hMSCs in non-contact co-
culture or their CM was added to unstained hMDMs in the presence of LPS. The 
hMDMs were processed by flow cytometry to determine whether they acquired 
MitoTracker Red fluorescence. 21.7% of hMDMs in non-contact co-culture with 
hMSCs acquired hMSC mitochondria and this was further increased to 55.1% with 
the use of hMSC-CM (p<0.01) (Fig 5.6 C). NB: Fig 5.6 C data features in Figure 7 
of our group’s recently published paper (Jackson et al, 2016)(116).  
 
























Fig 5.6 hMSC-EVs contain mitochondria which are transferred to hMDMs 
(continued overleaf) 
hMSCs were pre-stained with MitoTracker Red and EVs were selected using the 
gating strategy described in Section 5.3. hMSC-CM was taken and analysed by flow 
cytometry to determine mitochondrial content (A). hMDMs were stained with 
MitoTracker Green and Hoechst nuclear stain. CM from MitoTracker Red stained 
hMSCs was added to hMDMs and mitochondrial transfer was visualised by 
fluorescence microscopy at 20x magnification (B).  
A 
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Fig 5.6 (continued) hMSC-EVs contain mitochondria which are transferred to 
hMDMs 
MitoTracker Red pre-stained hMSCs or their CM was added to hMDMs with LPS for 
24 hours. hMDMs were washed and analysed by flow cytometry to determine the 
extent of hMSC mitochondrial transfer (C). Error bars represent SD (n=3-5 per group) 
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5.9 Mitochondrial transfer via hMSC-EVs mediates their effects on hMDMs 
Having confirmed that EV-mediated mitochondrial transfer is taking place, I next 
determined whether this phenomenon was facilitating the hMSC effects on hMDM 
function. MitoTracker Red pre-stained hMSCs were co-cultured with hMDMs for 24 
hours in the presence of LPS then washed before performing an E. coli bioparticle 
phagocytosis assay. Selective gating was performed to examine the phagocytic 
indexes of hMDMs which had received hMSC mitochondria and those which had not 
(determined by positivity for MitoTracker Red). hMDMs which had internalised 
hMSC mitochondria demonstrated a higher phagocytic index measured by MFI 
(p<0.05) showing an association between mitochondrial transfer and phagocytic 
enhancement (Fig 5.7 A). NB: Fig 5.7 A data also appears in Figure 7 of our 
group’s recently published paper (Jackson et al, 2016)(116). To elucidate whether 
these mitochondria were functionally responsible for the hMSC effects on hMDMs, 
dysfunctional mitochondria were prepared using rhodamine 6G. Rhodamine 6G has 
been used previously to irreversibly inhibit mitochondrial function in MSCs, which it 
achieves through binding to the inner membrane of mitochondria and blocking 
adenine nucleotide translocase(399, 502). hMSCs were grown to confluence and treated 
with rhodamine 6G for 48 hours. The cells were then washed and CM was prepared 
in LPS. To validate the efficacy of rhodamine 6G in preventing mitochondrial 
respiration, hMSCs with or without rhodamine 6G pre-treatment were assayed using 
the Seahorse XF Cell Mito Stress Test Kit (Agilent Technologies). This kit measures 
oxygen consumption rate (OCR) as an indication of mitochondrial respiration and 
allows calculation of parameters such as ATP turnover and maximal respiration 
capacity using oligomycin, FCCP and an antimycin A/rotenone cocktail to modulate 
mitochondrial activity. hMSCs pre-treated with rhodamine 6G had greatly diminished 
mitochondrial respiration and ATP turnover with a compensatory switch to glycolysis, 
evidenced by a dramatic increase in non-mitochondrial respiration (Fig 5.7 B). To 
assess the effect of rhodamine 6G pre-treatment on hMSC paracrine factor secretion, 
IL-8 and Ang-1 production was quantified by ELISA after LPS treatment for 24 hours. 
Rhodamine 6G pre-treated hMSCs produced less Ang-1 (919.3 vs 1403.6 pg/mL) and 
IL-8 (873.6 vs 1714.9 pg/mL) compared to the untreated controls (Fig 5.7 C). hMSC-
CM was added to hMDMs along with LPS for 24 hours and both TNFα production 
and phagocytosis assays were carried out. Once again, LPS induced a TNFα response 
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which was suppressed by hMSC-CM (4727.0±812.6 vs 2162.4±860.5 pg/mL) 
(p<0.05). Use of CM from rhodamine 6G pre-treated hMSCs abrogated this effect and 
hMSCs were no longer able to significantly suppress TNFα secretion (4727.0±812.6 
vs 3792.9±1366.4 pg/mL) consistent with the effect observed with anti-CD44 
treatment (Fig 5.7 D). Phagocytic capacity was enhanced by hMSC-CM measured by 
the proportion of phagocytic hMDMs (51.1±13.0 vs 79.8±7.15 %) and MFI 
(651.8±629.9 vs 3169.2±1137.7) (p<0.05). Rhodamine 6G completely reversed the 
enhancement in phagocytic capacity determined by MFI (651.8±629.9 vs 
1284.8±762.6) although interestingly did not have any effect on the proportion of 
phagocytic hMDMs (Fig 5.7 E). These data suggest that mitochondrial transfer 
through hMSC-EVs is at least partially responsible for the suppression of 




Fig 5.7 Mitochondrial transfer via hMSC-EVs mediates their effects on hMDMs 
(continued overleaf) 
hMDMs were treated with hMSC-CM from MitoTracker Red pre-stained hMSCs and 
E. coli bioparticles were added for phagocytosis analysis. hMDMs were gated based 
on the presence or absence of hMSC mitochondria and phagocytic indexes were 
compared (A). Error bars represent SD (n=5 each group) (Student’s t-test, *p<0.05). 
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Fig 5.7 (continued) Mitochondrial transfer via hMSC-EVs mediates their effects 
on hMDMs (continued overleaf) 
hMSCs were treated with rhodamine 6G for 48 hours, washed and mitochondrial 
function was assessed using the Mito Stress Test (Bi) (n=1). The measurements 
produced by the Mito Stress Test and the hMDM oxygen consumption rate (OCR) raw 
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Fig 5.7 (continued) Mitochondrial transfer via hMSC-EVs mediates their effects 
on hMDMs (continued overleaf) 
Calculations performed by the Mito Stress Test (n=1); maximal mitochondrial 
respiration (Bii), mitochondrial ATP turnover (iii) and non-mitochondrial respiration 















































































Fig 5.7 (continued) Mitochondrial transfer via hMSC-EVs mediates their effects 
on hMDMs (continued overleaf) 
hMSCs pre-treated with rhodamine 6G were stimulated with LPS for 24 hours and 
their Ang-1 and IL-8 production were measured by ELISA (C) (n=1). Showing 



























































Fig 5.7 (continued) Mitochondrial transfer via hMSC-EVs mediates their effects 
on hMDMs 
hMSCs were treated with rhodamine 6G to produce dysfunctional mitochondria and 
their effects on hMDM TNFα secretion (D) and phagocytosis (E) were assessed. Error 
bars represent SD (n=4 all groups) (Kruskal Wallis with Dunn’s post hoc test, 
*p<0.05). 
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5.10 Mitochondria containing hMSC-EV modulate hMDM function via 
enhanced oxidative phosphorylation 
I hypothesised that the transfer of mitochondria from hMSCs to hMDMs produced the 
effects on hMDM function by modulating their metabolic activity through promoting 
oxidative phosphorylation. As proof of concept, the ATP synthase inhibitor 
oligomycin was used(503). hMDMs were stimulated with LPS and oligomycin was 
added simultaneously to determine whether blocking oxidative phosphorylation 
influenced TNFα production and phagocytosis. DMSO was added as a vehicle control. 
LPS-induced TNFα production by hMDMs was amplified with the addition of 
oligomycin (3788.6±2199.5 vs 14385.0± 3290.9 pg/mL) (p<0.05). Oligomycin also 
prevented hMSC-CM suppression of TNFα production (1108.8±914.6 vs 
9415.9±6590.9 pg/mL) (p<0.05) and in fact increased it beyond the levels produced 
by LPS-stimulated hMDMs, albeit non-significantly (3788.6±2199.502 vs 
9415.9±6590.8 pg/mL) (Fig 5.8 A). Oligomycin produced a trend towards decreasing 
phagocytic capacity of hMDMs stimulated with LPS by both percentage phagocytic 
hMDMs (54.3±15.0 vs 33.6±16.7 %) and MFI (1359.9±1916.8 vs 349.6). Oligomycin 
significantly diminished phagocytic activity of hMDMs in the presence of hMSC-CM 
by both percentage (80.1±5.6 vs 31.9±21.7 %) (p<0.001) and MFI (4261.6±2493.2 vs 
378.5±439.6) (p<0.01) (Fig 5.8 B). Thus, the effect of hMSC-CM was dependent on 
their enhancement of oxidative phosphorylation. Next, in order to determine whether 
hMSC-CM enhanced mitochondrial respiration directly, I used the Mito Stress Test 
once again. hMDMs were treated with LPS, as well as hMSC-CM from untreated or 
rhodamine 6G-treated hMSCs and the Mito Stress Test was carried out. Only two 
donors were obtained to perform this experiment and so there was no statistical 
analysis performed. The raw data plots for OCR are shown along with the calculations 
used to determine mitochondrial activity parameters (Fig 5.8 C). Basal mitochondrial 
respiration rate was enhanced by hMSC-CM in the presence of LPS (8.3±1.1 vs 
13.62±0.3 pmol/min). Maximal mitochondrial respiration rate was also increased 
(40.7±4.6 vs 52.3±5.7 pmol/min) (Fig 5.8 D). Additionally, ATP turnover was 
trending upwards with addition of hMSC-CM (6.9±2.1 vs 9.2±0.2 pmol/min) (Fig 5.8 
E). The pre-treatment of hMSCs with rhodamine 6G to generate dysfunctional 
mitochondria, abrogated the apparent increase in basal respiration rate (8.3±1.1 vs 
10.54±1.23 pmol/min), maximal respiration rate (40.7±4.6 vs 43.0±1.1 pmol/min) and 
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ATP turnover (6.9±2.1 vs 7.4±0.8 pmol/min) that was present with untreated hMSC-



















Fig 5.8 The effect of hMSCs on hMDM function is dependent on oxidative 
phosphorylation (continued overleaf) 
hMDMs were stimulated with LPS with or without oligomycin as well as hMSC-CM. 
Supernatants were lifted after 24 hours for TNFα measurement (A) (n=4 for DMSO 
group, n=5 for remaining groups). E. coli bioparticles were added to assess 
phagocytosis, presented as a percentage and by MFI (B) (n=7 all groups). Error bars 
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Fig 5.8 (continued) The effect of hMSCs on hMDM function is associated with 
enhanced oxidative phosphorylation (continued overleaf) 
hMDMs were stimulated with LPS and CM from hMSCs with or without rhodamine 
6G pre-treatment and mitochondrial respiration was evaluated. The measurements 
produced by the Mito Stress Test and the hMDM OCR raw data is presented 
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Fig 5.8 (continued) The effect of hMSCs on hMDM function is associated with 
enhanced oxidative phosphorylation 
Calculations of mitochondrial function were produced using the Mito Stress Test. 
Basal and maximal mitochondrial respiration rates (D), as well as ATP turnover rate 
































































After unsuccessful attempts to identify soluble mediators responsible for the paracrine 
effects of hMSCs, EVs were hypothesised to be responsible for the macrophage 
modulating effects of hMSC-CM. Monsel et al have already shown that MSC-EVs 
were protective in the in vivo model of E. coli pneumonia and demonstrated that CD44 
expression on the EV surface was required for uptake by recipient cells(171). The CD44 
family are transmembrane glycoproteins known for their roles in ECM and cellular 
adhesion, cell migration, immune cell activation and limb development(504-508). CD44 
has also been implicated in MSC migration through the ECM and in trafficking to sites 
of injury after intravenous injection(509, 510). Before testing the potential role of hMSC-
EVs in the hMSC effect, the EVs were first characterised by flow cytometry. hMSC-
CM was analysed alongside latex beads of known size to provide an indication of the 
size of these EVs. FSC vs SSC plots demonstrate that these EVs are smaller than the 
latex beads (4μm) which is consistent with the literature showing that the larger 
microvesicle component of EVs can range from 0.4 to 1 μm in diameter. It was 
important to rule out potential contaminating apoptotic and necrotic bodies in these 
preparations. This was achieved by staining with annexin V, which has a high affinity 
for phosphatidylserine; this phospholipid is only present on the exterior face of the 
plasma membrane during apoptosis(511). Propidium iodide staining was used to rule 
out necrotic cell debris. Additionally, using flow cytometry allows for protein 
aggregates, which commonly contaminate ultracentrifuged EV isolations, to be ruled 
out using a cell membrane stain(512). The limitation of this method is that conventional 
flow cytometers are not sensitive enough to detect smaller EVs (exosomes) and so it 
is likely that these were not accounted for. Dedicated flow cytometers with increased 
sensitivity are available for EV flow cytometry but conventional cytometers may be 
used and can reportedly detect vesicles ranging from 270-600nm in diameter(513-515). 
Phinney et al used electron microscopy to visualise MSC-EVs and observed exosomes 
below 100nm in diameter, mitochondria-containing EVs and multivesicular bodies 
with diameters beyond 400nm(291). Flow cytometry for the present study demonstrated 
that nearly all of the EVs that the cytometer could detect were positive for CD44 and 
25.2% of these EVs contained mitochondria. 
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The importance of CD44-expressing EVs was assessed by antibody-based 
neutralisation experiments. It was necessary to add anti-CD44 antibody to hMDMs 
without hMSC-CM. The purpose of the antibody is to bind the CD44 present on the 
EV membranes that reside within the hMSC-CM so that it cannot be taken up by the 
hMDMs. It is known that macrophages also express CD44 which plays a number of 
functional roles; CD44 is an important mediator in the resolution of inflammation 
through facilitating apoptotic neutrophil clearance and contributing to the activation 
of TGFβ(516, 517); CD44 can even suppress TLR2 signalling in macrophages leading to 
reduced NFκB activation(518). Furthermore, the hyaluronan receptor (CD44) is integral 
to the ingestion of M. tuberculosis by macrophages(372). As expected, hMSC-CM 
resulted in the suppression of TNFα secretion and the enhancement in phagocytosis. 
Notably, the enhancement in phagocytosis with CM is much more pronounced than 
occured with hMSC co-culture in Chapter 3 (Fig 3.4), specifically determined by 
MFI (phagocytic index). One explanation for this is that using CM produced for 24 
hours by hMSCs will contain paracrine factors including EVs which are presented to 
the hMDMs immediately. hMSCs in non-contact co-culture are added at the time of 
LPS stimulation and have to then produce these factors anew which will take 24 hours 
to reach the levels present in the CM. Therefore, hMDMs treated with hMSC-CM are 
being influenced with these regulatory factors at this higher concentration for what is 
effectively a longer time. Moreover, the increased phagocytic augmentation in CM-
treated hMDMs may be explained by the nature of the co-culture system used. hMSCs 
were cultured on transwell inserts containing 0.4μm pores, these pores are too small 
for the largest EVs to move across and reach the hMDMs. That means that the contents 
of these larger EVs will not be accounted for in the paracrine effect on hMDMs in the 
non-contact co-culture experiments. Naturally isotype control antibody was also 
included and was added to hMDMs with or without hMSC-CM. This is of importance 
to rule out non-specific effects of antibody binding but especially important in this 
experiment given the body of literature suggesting the influential role of immune 
complexes on macrophage phenotype and function. For example, interactions with the 
FcγR of the macrophage result in an M2 phenotypic shift, evidenced by their induction 
of Th2 lymphocyte responses(519).  
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Treatment of hMDMs with isotype antibody or anti-CD44 alone trended towards 
suppressing TNFα production. hMSC-CM significantly reduced TNFα secretion by 
hMDMs and anti-CD44 treatment partially abrogated this effect indicating that CD44-
expressing EVs are at least partially responsible for the hMSC-CM effect on TNFα 
secretion. A number of explanations could be proposed for the absence of significance 
here. Firstly, the trend towards inhibiting TNFα secretion with anti-CD44 treatment 
of hMDMs without hMSC-CM suggests that the potential reversal in TNFα 
suppression by blocking EV uptake was masked by the additional suppression 
afforded by anti-CD44 interactions with hMDMs directly. Another explanation is that 
hMSCs produce multiple immunoregulatory paracrine factors; PGE2, IDO and IL-1ra 
to name a few(520). It is unlikely that blocking just one such factor would completely 
reverse the anti-inflammatory effect of hMSCs on hMDMs given that so many other 
elements of the MSC regulatory repertoire are still active. Furthermore, it is likely that 
flow cytometry could not characterise the smaller exosomal component of the EVs 
which may have lacked CD44 expression and still have been capable of exerting some 
anti-inflammatory effects. Anti-CD44 did however significantly reverse the 
phagocytic enhancement seen with hMSC-CM. Isotype and anti-CD44 antibody 
treatment of hMDMs without hMSC-CM had no effect on phagocytosis. Reversal of 
phagocytic enhancement by blocking CD44 in hMSC-CM suggests that CD44-
expressing EVs found in this CM are mediating the effect.  
 
All of the results thus far have been based on in vitro experiments.  To demonstrate 
the importance of EV transfer to macrophages in the protective effect of hMSCs in 
lung injury, an adoptive transfer experiment was conducted where murine AMs were 
treated ex vivo with hMSC-EVs and then administered to E. coli endotoxin-injured 
mice. Results showed that treatment of LPS-injured mice with EV-treated AMs 
mitigated lung injury as determined by inflammatory cellular infiltrates and the 
amount of protein present in the BALF. Importantly, AMs cultured ex vivo without 
EV treatment were unable to reduce the extent of lung injury. Inflammatory cellular 
infiltration is a key feature of ARDS; neutrophils and monocytes are recruited from 
the periphery and damage the alveolar epithelium through the release of pro-apoptotic 
factors(20, 22, 23, 273, 521). Total cell counts in the BALF were measured and the various 
cell types present are shown by brightfield microscopy. In non-injured, PBS-treated 
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mice there are primarily myeloid type cells and a few epithelial cells present. With 
LPS injury there is a large influx of neutrophils, macrophages and erythrocytes into 
the BALF. EV-treated-AM-treated mice demonstrated a lower total cell count and 
absolute neutrophil cell count compared to the LPS group indicating reduced 
inflammation. Decrease in absolute neutrophil counts is of special importance since 
neutrophil infiltration is a hallmark of ARDS(20, 522, 523). Myeloid cell numbers, in this 
case, would have been confounded by the administration of ex vivo-cultured AMs. 
Reduced inflammation was associated with decreased protein in the BALF, indicating 
greater alveolar epithelial-endothelial integrity in these mice. This demonstrates that 
EVs represent an essential component of the hMSC secretory profile capable of 
recapitulating the beneficial effects of hMSCs through reduction of inflammation and 
lung injury. This finding also supports the concept that AMs are key cellular mediators 
of the hMSC-EV protective effect in lung injury. Indeed, a number of groups are 
investigating the potential of macrophage adoptive transfer as a therapy. Andreesen et 
al tested the safety and efficacy of peripheral blood MDMs, primed with IFNγ given 
IV and IP to cancer patients. They observed some side effects and disappearance of 
malignancies in a small proportion of patients(524). Leung et al demonstrated the 
potential of adoptive transfer of macrophages in an experimental colitis model. 
Treatment with alternatively activated bone marrow-derived macrophages resulted in 
reduced histopathological severity(525). The crucial importance of AMs in mediating 
the hMSC effect in lung injury is consistent with our group’s previously published 
work investigating the effect of macrophage depletion in E. coli-induced pneumonia. 
Treatment with hMSCs no longer resulted in reduced bacterial load, neutrophilia or 
protein in the BALF after clodronate depletion of AMs(116). The AM-dependent nature 
of the hMSC effect further highlights the importance of AM in driving the 
inflammatory response in lung injury and identifies AMs as an ideal target for therapy.  
 
The mild model of lung injury using a relatively low dose of endotoxin (20μg per 
mouse) was chosen to maximise the chances for hMSC-EV-educated AMs to achieve 
therapeutic effect. The results should be considered as a proof of concept that 
macrophages are key cellular mediators of the MSC effect in ARDS, the next step 
would be to extend these studies to a more relevant model, such as live E. coli or 
sepsis-induced lung injury. The major technical obstacles in performing these 
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experiments were isolating substantial numbers of AMs for ex vivo culture and 
isolating sufficient yields of EVs from hMSC-CM to treat them. For that reason it was 
decided to treat each mouse with 2.5x105 AMs. The results so far suggest that hMSC-
EVs influence macrophage function and that these educated macrophages are 
protective in lung injury. The next step was to determine the contents of these EVs 
that are specifically facilitating these effects. Given that MSC-EVs are known to 
contain miRNAs and that these miRNAs have been shown to downregulate TLR 
signalling, it was hypothesised that miRNAs within hMSC-EVs were responsible for 
inhibiting TNFα secretion(291). Reviewing the literature, three potential candidates 
were identified; miR-125a, miR-125b and miR-223 which are known to modulate 
macrophage function (291, 347, 399, 497, 498). These candidates were all detected within 
hMSCs and their EVs. miR-125b was the most abundant and so was investigated 
further. Inhibitor validation tests demonstrated some non-specific effects; anti-miR-
125b inhibitor also suppressed miR-125a and vice versa. Therefore subsequent 
inhibition experiments with anti-miR-125b were effectively testing whether miR-125a 
or miR-125b played a role in the hMSC effect. The results suggest that this is not the 
case. It cannot be ruled out that miR-125a and miR-125b may have had divergent and 
opposite influences on these hMDMs effectively masking the effects of inhibiting one 
or the other. This seems improbable however, based on reports of their functions in 
macrophages and the nature of their homology. Phinney et al show that MSC-EV 
miRNAs do play a role in modulating TLR signalling but the specific miRNA/s 
responsible remain elusive(291).  
 
Given that mitochondria are contained in CD44-expressing vesicles and our group’s 
findings that contact-dependent mitochondrial transfer augments macrophage 
phagocytic capacity(116), it was hypothesised that EV-dependent mitochondrial 
transfer was responsible for the hMSC effect on macrophage modulation. So far, these 
results have shown that hMSC-EVs contain mitochondria but their effective transfer 
to hMDMs was yet to be confirmed. The adherence of hMSC-EVs containing 
mitochondria to hMDMs was observed by fluorescence microscopy. Internalisation 
and integration into the hMDM mitochondrial network is apparent through co-
localisation of fluorescent staining. Interestingly, the co-localisation is distinctly 
localised rather than assuming a more diffuse distribution. Our group’s previous paper 
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studying non-contact co-culture shows much more diffuse mitochondrial transfer(116). 
Tunnelling nanotubules likely represent a more efficient means of donating 
mitochondria allowing greater numbers to integrate into the macrophage network. 
Phinney et al were investigating mitophagy and EV-mediated transport and also 
observed more substantial mitochondrial transfer than my results show(291). 
Importantly however those cultures were also with MSC-macrophage contact and so 
the rate of EV-mediated transfer would be much higher. Mitochondrial transfer to 
hMDMs via EVs was further supported by flow cytometry; hMSCs cultured on 
transwell inserts donated mitochondria to 21.7% of hMDMs which was increased to 
55.1% using hMSC-CM. Gating for hMDMs which had received hMSC mitochondria 
and those which had not demonstrated an association between mitochondrial transfer 
and phagocytic capacity but not causation. 
 
To test whether hMSC mitochondria were functionally responsible, dysfunctional 
mitochondria were generated using rhodamine 6G which irreversibly inhibits adenine 
nucleotide translocase function(502). CM from hMSCs pre-treated with rhodamine 6G 
was unable to reduce TNFα secretion in hMDMs stimulated with LPS, nor was it able 
to promote phagocytic activity measured by MFI. This loss-of-function experiment 
suggests that functional mitochondria transfer to hMDMs is required for both TNFα 
suppression and phagocytic enhancement by hMSCs. Regarding phagocytosis, this 
causation correlates with the association already seen between mitochondrial transfer 
and phagocytic activity. One concern about this loss-of-function experiment is that 
producing dysfunctional mitochondria and inducing glycolytic metabolism could 
somehow affect other hMSC functions such as paracrine factor production. To address 
this, rhodamine 6G pre-treated hMSCs were treated with LPS and their production of 
Ang-1 and IL-8 was compared to that of untreated hMSCs. There was a 
downregulation of production but importantly the levels after rhodamine 6G treatment 
were still substantial. Rhodamine 6G pre-treatment does not drastically ablate 
paracrine factor production but it did completely inhibit mitochondrial function and 
so the effects observed can be attributed to the absence of functional mitochondria. It 
is also worth considering the results from the oligomycin experiments when 
considering the reliability of the rhodamine 6G experiment. hMDMs that were given 
hMSC-CM produced less TNFα and adding oligomycin not only prevented this but 
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actually increased production further than the LPS alone group (non-significantly). In 
the CM and oligomycin-treated group hMDMs would have been exposed to hMSC 
mitochondria and all paracrine factors that they secrete; in spite of this, TNFα was no 
longer reduced. The same was true of the enhancement in phagocytosis; oligomycin 
completely reversed the phagocytosis enhancing effect of hMSC-CM. Oligomycin 
could only possibly block the function of mitochondria, certainly of either hMSC or 
hMDM origin, but importantly other paracrine factors could interact with the hMDMs 
unabated. This supports the hypothesis that it is the transfer of functional mitochondria 
and not only soluble mediators that are responsible for the hMSC effects. Secondly, it 
highlights the importance of mitochondrial respiration in modulating macrophage 
functions. Promotion of mitochondrial respiration using oxidative phosphorylation 
seems to dampen inflammatory responses, whereas LPS-activated M1 macrophages 
will preferentially employ glycolysis(240, 526). Oligomycin forces hMDMs down the 
glycolytic pathway amplifying the metabolic effects of LPS alone, promoting a more 
pronounced M1 macrophage phenotype. This corresponds to increased pro-
inflammatory cytokine secretion and even further reduced phagocytosis which is 
observed in response to LPS alone in the current study. In order to confirm the 
hypothesis that EV-mediated mitochondrial transfer is responsible for hMSC effects 
in vivo, rhodamine pre-treated hMSC-derived EVs could be used in an adoptive 
transfer experiment. A limitation of this in vivo model however is that without using 
live bacteria, the antimicrobial effects of EV-treated AMs cannot be assessed. 
 
So far in this chapter, these results suggest that mitochondria-containing EVs produced 
by hMSCs are actively taken up by hMDMs and that this transfer is entirely 
responsible for their enhancement in phagocytosis but only partially responsible for 
the suppression of TNFα production. In order to investigate this mechanism in more 
depth, the extent of mitochondrial respiration in hMDMs treated with LPS, LPS + 
hMSC-CM and LPS + rhodamine 6G pre-treated-hMSC-CM was assessed. It was 
hypothesised that the transfer of hMSC mitochondria would increase the rate of 
oxidative phosphorylation and mitochondrial ATP production which could explain the 
dampened inflammatory response and enhanced phagocytosis of hMDMs. These 
experiments were performed on two donor’s hMDMs and so the results are 
inconclusive. The trends were in agreement with the hypothesis; an increase in basal 
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and maximal mitochondrial respiration as well as ATP turnover was observed with 
hMSC-CM treatment. This finding is in keeping with previous reports showing that 
mitochondrial transfer from MSCs results in enhanced bioenergetics of macrophages 
and alveolar epithelial cells(116, 291, 318). Interestingly, when hMSCs were pre-treated 
with rhodamine 6G, their CM no longer improved hMDM bioenergetics suggesting 
that it was the hMSC-derived mitochondria responsible for this effect. The loss of 
hMSC effect with rhodamine 6G pre-treatment or with addition of oligomycin, 
suggests that hMSCs are able to influence hMDM phenotype and function by donating 
mitochondria and promoting oxidative phosphorylation. This study has not however 
tested whether there is any influence of hMSCs on the extent of hMDM glycolysis. It 
would be interesting to determine if there is a reciprocal downregulation of glycolysis 
and if that plays a role in mediating hMSC modulation of hMDM phenotype.  
 
5.12 Summary and conclusions 
The key findings from these studies are: 
 CD44-expressing EVs are primarily responsible for the paracrine effects of 
hMSCs on hMDM modulation   
 hMSC-EVs are essential for AM modulation in vivo 
 hMSCs modulate hMDM TNFα secretion and enhance their phagocytic 
capacity through the release of mitochondria-containing EVs  
 hMSC modulation of hMDM function depends on oxidative phosphorylation 
 Preliminary data suggests that the transfer of mitochondria to hMDMs may 
promote oxidative phosphorylation, producing the phenotypic shift 
attributable to hMSCs.  
 
Collectively these studies reveal a new mechanism of hMSC paracrine effect, 
highlights the role of AMs as cellular mediators of the MSC effect in ARDS in vivo 
and provide evidence that promotes further development of MSC-derived EVs and 
MSC-educated macrophages as potential therapeutic approaches for the treatment of 
ARDS.  



















Final conclusions and future directions 





6.1 Final conclusions 
ARDS is a highly prevalent clinical disorder in ICUs worldwide which is associated 
with unacceptably high mortality rates and significant morbidity in survivors(5, 527-529). 
Due to improvements in quality of care, primarily through the use of low-volume 
mechanical ventilation, mortality rates have declined modestly with time(4, 530). As yet 
however, there is no pharmacologically effective treatment available. MSCs have 
piqued the interest of basic scientists and clinicians as a potential therapy for ARDS 
with a growing body of literature supporting this notion through pre-clinical studies(77, 
81, 93, 318). Indeed, MSCs have proved safe and feasible for their administration to 
ARDS patients in phase I clinical trials(130, 131) and a larger phase II clinical trial is 
underway (ClinicalTrials.gov identifier: NCT02097641). The mechanisms by which 
MSCs exert their therapeutic effects in models of lung injury are not fully elucidated. 
A fuller understanding of their mechanisms will allow the rational development of 
MSC-based therapy through generation of disease specific MSC potency assays. 
Moreover it may identify novel biomarkers to test MSC efficacy in clinical samples. 
For example, patient BALF may be processed by flow cytometry to assess macrophage 
expression of CD206 which could serve as a biomarker for the efficacy of MSC 
treatment. Potency assays will be crucial for batch testing of MSCs to determine which 
preparations will be consistent and effective clinical-grade cell therapies. Furthermore, 
discovering new mechanisms of MSC effect may highlight new therapeutic strategies 
or targets for treatment of patients with ARDS. 
 
MSCs are renowned for their immunomodulatory capacity, including their interactions 
with macrophages(289, 404, 468). The AM is the resident innate immune cell of the distal 
lung which is implicated in the initiation and resolution of inflammation in lung 
injury(273, 390). Modulation of AM phenotype and function, therefore, may prove 
beneficial in treatment of ARDS and could represent one mechanism by which MSCs 
have proven successful in preclinical models of lung injury. The major aims of this 
project were to investigate the effects of hMSCs on human macrophage phenotype 
and function in in vitro models of ARDS and to elucidate the mechanism(s) of these 
effects. hMSCs were shown to induce an unconventional M2-like hMDM phenotype 
in E. coli LPS or ARDS BALF-induced inflammation. This phenotype was consistent 
across both in vitro models and was defined by a dampened inflammatory cytokine 





profile, increased expression of the CD206 M2 macrophage marker and enhanced 
phagocytic capacity. This macrophage phenotype could feasibly reduce inflammation 
and injury in ARDS whilst maintaining bacterial clearance in infected patients. The 
macrophage phenotype described in this study corroborates the findings of other 
groups studying the influence of MSCs on macrophage phenotype. Deng et al reported 
induction of CD206 expression in mouse macrophages with increased phagocytic 
capacity in systemic lupus erythematosus(439). Kim and Hematti similarly showed 
increased expression of CD206, reduced TNFα production and accelerated 
phagocytosis in hMDMs cultured with hMSCs(287). MSC promotion of alternatively 
activated macrophages is also evident in in vivo models; Nemeth et al showed 
increased IL-10 production by macrophages which was necessary for the beneficial 
effects observed in MSC-treated septic mice(85); AMs treated with MSCs in a model 
of asthma also adopt and M2 macrophage phenotype resulting in reduced airway 
hyperresponsiveness(531). Where these studies differ from the current study is in the 
effects seen on anti-inflammatory cytokine production. Many of these groups have 
reported increased production of IL-10 in the presence of MSCs. This discrepancy 
could be explained by differences in the source of macrophages or their culture 
conditions. Variations in differentiation protocols and inflammatory stimuli can 
influence macrophage phenotype(411, 417). Moreover, the methods used in these studies 
differ from those employed here; Kim and Hematti tested intracellular IL-10 
expression by flow cytometry after treatment with 1μg/mL of LPS; Nemeth et al 
studied mouse MSCs and mouse macrophages. This is not the first study to report a 
lack of IL-10 production by human macrophages expressing an otherwise M2-like 
phenotype; Vogel et al reported that IL-10 production in human macrophages was 
negligibly low after a variety of M1 and M2 polarising stimuli(411). To our knowledge, 
this is the first study to test the influence of hMSCs on human macrophage polarisation 
in the presence of ARDS patient BALF. These results suggest that hMSCs are capable 
of inducing the same M2-like phenotype in ARDS BALF as they are with LPS 
treatment. This may provide valuable insight into the interactions that would occur 
between administered hMSCs and the AMs of ARDS patients and may represent a 
mechanism of their effect.  
 





The second aim of this project was to determine the mechanism(s) of hMSC effects 
on hMDM phenotype and function. EVs produced by hMSCs have previously been 
shown to mediate many of their effects in lung injury and CD44 expression on the 
surface of these EVs was important for their uptake(171, 317). In the current study, anti-
CD44 antibody pre-treatment of hMSC-CM prevented their enhancement of hMDM 
phagocytosis and partially blocked the suppression of TNFα production. These results 
suggest that hMSC CD44-expressing EVs are important for hMSC modulation of 
hMDM function. Similarly, Monsel et al showed that hMSC-EVs enhance human 
monocyte phagocytosis and mitigate the TNFα response to E. coli in vitro(171). The 
importance of hMSC-EV modulation of AMs was confirmed in an endotoxin-induced 
lung injury mouse model where adoptive transfer of hMSC-EV-treated AMs conferred 
protection. EV-treated AMs were able to reduce inflammatory cell recruitment and 
rescue alveolar epithelial barrier permeability. These data highlight the AM as an 
important cellular mediator of the hMSC therapeutic effect in lung injury. These 
results consolidate findings by our group previously, where depletion of AMs using 
clodronate-containing lysosomes prevented the beneficial effects of hMSCs in E. coli-
induced lung injury(116). Nemeth et al also showed that depleting macrophages 
systemically abrogated the MSC effect in a murine sepsis model(85). There are 
limitations to the lung injury model chosen here. This is a model of mild endotoxin-
induced lung injury which is of limited relevance to ARDS. The purpose of this 
experiment was not to test the capacity of hMSC-EV-treated AMs as a treatment for 
lung injury; it was to show proof-of-concept that AMs help facilitate the protective 
effects of hMSCs in lung injury. Some groups have investigated the feasibility and 
efficacy of macrophage adoptive transfer as a treatment modality in cancer and renal 
fibrosis in vivo(524, 532). Leung et al were able to reduce the severity of experimental 
colitis with the adoptive transfer of bone marrow-derived alternatively activated 
macrophages(525). Careau and Bissonnette demonstrate that adoptive transfer of 
allergy-resistant rats AMs to allergy-sensitive rats mitigated airway 
hyperresponsiveness(533). However further study is required before it may be 
considered in the context of lung injury.  
 
 





Mitochondrial transfer from MSCs through the use of TNTs, gap junctions or EVs to 
a number of cell types including macrophages has been reported(115, 116, 291, 318). This 
exchange has been associated with protective effects in lung injury through the 
enhancement in alveolar epithelial cell bioenergetics(318). Our group previously 
reported macrophages receiving MSC mitochondria via TNTs demonstrate enhanced 
phagocytosis(116). Mitochondria are responsible for oxidative metabolism which is 
known to play a role in modulating macrophage function. Vats et al demonstrate that 
IL-4 induces fatty acid oxidation in macrophages which was required for enhancement 
of arginase activity (M2 marker) and suppression of LPS-induced TNFα 
production(240). In the current study, EV-mediated mitochondrial transfer from hMSCs 
to hMDMs was demonstrated by flow cytometry and fluorescence imaging. 
Preliminary data suggests an increase in hMDM mitochondrial respiration with 
hMSC-CM which was prevented with the use of hMSCs with dysfunctional 
mitochondria. Inhibiting oxidative phosphorylation in hMDMs or generating 
dysfunctional hMSC mitochondria both prevented the enhancement of phagocytosis 
and the suppression of TNFα secretion normally seen with hMSC-CM treatment. 
Taken together these results indicate that hMSC mitochondrial transfer to hMDMs is 
required to produce these effects. These findings are also in keeping with the study 
produced by Vats et al demonstrating the link between oxidative respiration and 
macrophage alternative activation. The next step for this line of research would be to 
confirm that it is mitochondrial transfer to AMs that is responsible for the protective 
effects of hMSC-EVs in lung injury in vivo. 
 
Collectively, the results obtained from this study show for the first time that hMSCs 
produce an M2-like human macrophage phenotype in the presence of ARDS patient 
BALF which is defined by decreased inflammatory cytokine secretion and enhanced 
phagocytic capacity. Mechanistic experiments indicate that hMSC-EV-mediated 
transfer of mitochondria is responsible for the modulation of human macrophage 
phenotype through promotion of mitochondrial oxidative phosphorylation.





6.2 Future directions 
The current work has provided further insight into the complex mechanisms of effect 
of hMSCs in lung injury, specifically through their interactions with macrophages. 
Further study into understanding the mechanism of hMSC modulation of human 
macrophages could focus on uncovering the pathways involved in induction of the 
M2-like macrophage phenotype in response to mitochondrial transfer. As discussed 
earlier, the literature has already made clear the association between metabolism and 
macrophage polarisation(242, 534). Vats et al show the importance of oxidative 
phosphorylation in the acquisition of an IL-4-induced M2 macrophage phenotype(240). 
They demonstrate that IL-4 signals through STAT6 and PGC-1β to promote fatty acid 
oxidation which was important for modulating macrophage function. The current 
study supports this finding and suggests that mitochondrial transfer from hMSCs to 
the hMDMs promotes this phenotypic shift through promotion of oxidative 
phosphorylation. It is possible that the donation of hMSC mitochondria to the hMDMs 
could represent a more direct way of modulating metabolic activity and macrophage 
function. It would be worthwhile investigating the effects of hMSC-EVs on STAT6 
signalling and activation of PGC-1β to determine if the signalling pathways involved 
in the hMSC-induced phenotype and the IL-4 induced phenotype are similar. It would 
be interesting to investigate these mechanisms further in vivo. The results demonstrate 
that treatment of lung injury with hMSC-EV-treated AMs is protective but they do not 
show that it is mitochondrial transfer through these EVs that is responsible. Treatment 
of AMs with rhodamine 6G pre-treated hMSC-EVs would provide evidence that it is 
the mitochondria-containing EVs that are conferring these protective effects to the 
AMs.  
 
Another question that remains is exactly how hMSC-EV treated AMs are protective 
in this lung injury model. Characterisation of the secretory profiles of the hMDMs in 
vitro showed a general downregulation of both pro and anti-inflammatory mediators. 
Presumably, the induction of an M2-like phenotype in these AMs would potentially 
dampen inflammation by influencing host AMs to reduce their inflammatory cytokine 
secretion or even adopt a similar M2-like profile. The cytokines produced by the EV-
treated AMs were not investigated and the in vitro experiments in hMDMs would 





suggest that neither IL-10 nor IL-1ra are responsible for the anti-inflammatory effects 
of these AMs. Investigation of the secretory profile of hMSC-EV-treated macrophages 
may uncover the mediator responsible and uncover a new therapeutic candidate for 
the treatment of lung injury. The findings in the present study add to the accumulating 
evidence that hMSC-EVs can mediate many of the therapeutic effects of the whole 
cell therapy itself. Recently there is an increasing interest in the use of MSC-EVs as a 
treatment itself for a number of conditions including lung injury, pulmonary 
hypertension, kidney injury and stroke(113, 171, 535, 536). Certainly, EV preparations have 
been investigated in clinical trial and appears to be a feasible prospect(322). hMSC-EVs 
may be able to overcome a number of the hurdles associated with hMSC therapy; EVs 
avoid the risk of transformation that is associated with stem cell therapies; EVs have 
very low expression of MHC class I and II on their surfaces meaning minimal 
immunogenicity, an emerging concern with hMSCs as a cell therapy(48). One potential 
disadvantage however is that EVs will not be able to actively respond to their 
environment in the way that MSCs do, although there is evidence that they may not 
need to. Certainly, studies reporting the efficacy of hMSC-EVs often use preparations 
which are constitutively produced by MSCs with no pre-conditioning of any kind(112, 
171, 537). This is not to suggest that the cells could not be stimulated in vitro to modulate 
their EV production in order to optimise their therapeutic effect in vivo. Serum 
starvation is reported to enhance MSC-EV production(538). Bustos et al showed that 
hMSCs which were pre-conditioned with ARDS patient serum were more protective 
than unconditioned hMSCs in endotoxin-induced lung injury(137). It is possible that 
such pre-conditioning regimens could influence EV production and contents 
enhancing their effects. hMSC-EVs are a promising candidate to replace hMSCs as a 
therapy for ARDS but our understanding of this cell product and their mechanisms is 
limited.  
 
Reliable potency assays which may be used to inform the release of MSCs for use in 
clinical trials remain elusive. Bloom et al tested the robustness and feasibility of 
testing MSC suppression of mixed lymphocyte reactions as a potency assay(539). The 
observation that AMs are cellular mediators of their therapeutic effects proposes that 
the capacity of hMSCs to modulate macrophage phenotype could be assessed and 
serve as a potency assay. In this study CD206 was upregulated by hMDMs in ARDS 





BALF which was associated with reduced TNFα secretion and enhanced 
phagocytosis. It may be worth testing whether MSC enhancement of macrophage 
expression of CD206 correlates with their ability to dampen macrophage 
inflammatory cytokine secretion or enhance phagocytic activity. If so, assessment of 
CD206 expression in hMSC-cultured monocytes or macrophages could serve as a 
potency assay for the selection of MSC donors for use in clinical trials in ARDS as 
well as a biomarker to assess their efficacy after treatment.
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